WO2014050412A1 - Absorbent article - Google Patents

Absorbent article Download PDF

Info

Publication number
WO2014050412A1
WO2014050412A1 PCT/JP2013/072905 JP2013072905W WO2014050412A1 WO 2014050412 A1 WO2014050412 A1 WO 2014050412A1 JP 2013072905 W JP2013072905 W JP 2013072905W WO 2014050412 A1 WO2014050412 A1 WO 2014050412A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
top sheet
hydrocarbon moiety
group
chain hydrocarbon
Prior art date
Application number
PCT/JP2013/072905
Other languages
French (fr)
Japanese (ja)
Inventor
竜也 田村
野田 祐樹
央 橋野
鈴木 裕一
卓 小野塚
裕和 目黒
Original Assignee
ユニ・チャーム株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニ・チャーム株式会社 filed Critical ユニ・チャーム株式会社
Publication of WO2014050412A1 publication Critical patent/WO2014050412A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/15Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/45Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
    • A61F13/47Sanitary towels, incontinence pads or napkins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/15Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers
    • A61F13/511Topsheet, i.e. the permeable cover or layer facing the skin
    • A61F13/51104Topsheet, i.e. the permeable cover or layer facing the skin the top sheet having a three-dimensional cross-section, e.g. corrugations, embossments, recesses or projections
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/15Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers
    • A61F13/511Topsheet, i.e. the permeable cover or layer facing the skin
    • A61F13/512Topsheet, i.e. the permeable cover or layer facing the skin characterised by its apertures, e.g. perforations
    • A61F13/5121Topsheet, i.e. the permeable cover or layer facing the skin characterised by its apertures, e.g. perforations characterised by the vertical shape of the apertures, e.g. three dimensional apertures, e.g. macro-apertures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/15Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers
    • A61F13/511Topsheet, i.e. the permeable cover or layer facing the skin
    • A61F13/512Topsheet, i.e. the permeable cover or layer facing the skin characterised by its apertures, e.g. perforations
    • A61F13/5123Topsheet, i.e. the permeable cover or layer facing the skin characterised by its apertures, e.g. perforations the apertures being formed on a multilayer top sheet
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/15Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/53Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
    • A61F13/534Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad
    • A61F13/535Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad inhomogeneous in the plane of the pad, e.g. core absorbent layers being of different sizes
    • A61F13/536Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad inhomogeneous in the plane of the pad, e.g. core absorbent layers being of different sizes having discontinuous areas of compression

Definitions

  • the present invention relates to an absorbent article.
  • Patent Document 1 an absorbent article in which a plurality of recesses are formed from the surface layer to the absorbent layer is known (for example, Patent Document 1).
  • an object of this invention is to provide the absorbent article which can prevent the exposure of the liquid absorbed by the absorber.
  • the present invention provides a liquid-permeable top sheet having a skin contact surface, a liquid-impermeable back sheet having a non-skin contact surface, and the top sheet and the back sheet.
  • An absorbent article comprising: an absorbent body provided between, wherein the top sheet is provided with a plurality of cutting openings penetrating the top sheet at least on an excretory opening contact region of the skin contact surface.
  • Said absorber has an absorber recess leading to each of said plurality of cutting openings, and a top sheet fragment produced in forming said cutting openings covers the bottom of said absorber recess The absorbent article.
  • an absorbent article which can prevent the exposure of the liquid absorbed by the absorbent.
  • FIG. 1 is a partially broken plan view of a sanitary napkin according to an embodiment of the absorbent article of the present invention.
  • 2 (a) is a cross section taken along line AA of FIG. 1
  • FIG. 2 (b) is a partially enlarged view of FIG.
  • FIG. 3 is a figure for demonstrating an example of the method of forming a cutting opening part in a top sheet, and forming a recessed part in an absorber.
  • FIG. 4A and FIG. 4B are diagrams for explaining an example of embossing.
  • FIG. 5 is an electron micrograph of the laminate (top sheet and absorber) after embossing.
  • FIG. 6 is an electron micrograph of the skin contact surface of the top sheet in the sanitary napkin in which the top sheet contains avian C2L oil fatty acid glyceride.
  • FIG. 7 is a photomicrograph of menstrual blood with or without a blood slipping agent.
  • FIG. 8 is a diagram for explaining a method of measuring surface tension.
  • the absorbent article according to aspect 1A is provided between a liquid-permeable top sheet having a skin contact surface, a liquid-impermeable back sheet having a non-skin contact surface, and the top sheet and the back sheet.
  • the absorber has an absorber recess leading to each of the plurality of cutting openings, and a top sheet fragment produced in forming the cutting openings covers the bottom of the absorber recess. It is the said absorbent article.
  • the peripheral portion of the cutting opening in the top sheet is densified.
  • the top sheet is composed of a plurality of layers, and the plurality of layers are crimped to each other at peripheral portions of the cutting opening.
  • the absorbent material contained in the absorber is exposed from the side portion of the absorber recess.
  • the top sheet fragment is crimped to the bottom of the absorber recess.
  • the kinematic viscosity at 40 ° C. is 0.01 to 80 mm at least in the peripheral portion of the cutting opening contact region.
  • a blood slipping agent having a water-retaining rate of 0.01 to 4.0% by mass and a weight average molecular weight of less than 1,000 is applied.
  • the IOB of the blood slipping agent is an IOB of 0.00 to 0.60.
  • the blood slipping agent is any one of the following (i) to (iii): (I) Hydrocarbons, (Ii) from a carbonyl group (-CO-) and an oxy group (-O-) inserted between (ii-1) a hydrocarbon moiety and (ii-2) a C-C single bond of the hydrocarbon moiety
  • the blood slipping agent is selected from the following (i ′) to (iii ′): (I ') hydrocarbons, (Ii ') (ii'-1) a hydrocarbon moiety, and (ii'-2) a carbonyl bond (-CO-), an ester bond (-COO) inserted between a C-C single bond of the hydrocarbon moiety -), A compound having one or more same or different bonds selected from the group consisting of carbonate bond (-OCOO-) and ether bond (-O-), and (iii ') (iii'-) 1) A carbonyl bond (-CO-), an ester bond (-COO-), a carbonate bond (-OCOO) inserted between a hydrocarbon moiety and (iii'-2) a C-C single bond of the hydrocarbon moiety -), And one or more same or different bonds selected from the group
  • the blood slipping agent is any one of the following (A) to (F): (A) A compound having (A1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms of the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and the chain Ester with a compound having one carboxyl group replacing the hydrogen atom of the cyclic hydrocarbon moiety, (B) a compound having (B1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the chain Ether with a compound having one hydroxyl group replacing the hydrogen atom of the cyclic hydrocarbon moiety, (C) a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing a (C1) linear hydrocarbon moiety and 2 to 4 carboxyl
  • the blood slipping agent is an ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid, (a 2 ) Ester of linear hydrocarbon triol and at least one fatty acid, ester of (a 3 ) linear hydrocarbon diol and at least one fatty acid, (b 1 ) linear hydrocarbon tetraol and at least one aliphatic Ether with monohydric alcohol, ether of (b 2 ) chain hydrocarbon triol and at least one aliphatic monohydric alcohol, ether of (b 3 ) chain hydrocarbon diol and at least one aliphatic monohydric alcohol , (c 1) chain hydrocarbon tetracarboxylic acids having 4 carboxyl groups, hydroxy acid, alkoxy acid or oxo acid, at least one aliphatic Esters of an alcohol, (c 2) a chain hydrocarbon tricarbox
  • the blood slipping agent has a vapor pressure of 0.00 to 0.01 Pa at 1 atmospheric pressure and 40 ° C.
  • the manufacturing method according to aspect 1B is a manufacturing method of an absorbent article, including a step of embossing a laminate of a top sheet and an absorbent to form a recess penetrating the top sheet to reach the absorbent. Said manufacturing method comprising the steps of: forming the cutting opening in the top sheet; and pressing the top sheet fragment generated in forming the cutting opening onto the bottom of the recess. It is.
  • a protrusion roll having an outer peripheral surface provided with a plurality of protrusions and a plain roll having a smooth outer peripheral surface are used for the embossing.
  • the shearing force of the projection forms the cutting opening in the top sheet, and the projection is pressed into the absorber by the bottom of the recess.
  • the top sheet fragments are crimped onto the
  • the type and use of the absorbent article of the present invention are not particularly limited.
  • the absorbent articles include sanitary products and sanitary products such as sanitary napkins and panty liners, which may be humans or non-human animals such as pets.
  • the liquid to be absorbed by the absorbent article is not particularly limited, but is mainly liquid excrement such as menstrual blood.
  • a sanitary napkin as an example, an embodiment of the absorbent article of the present invention will be described based on the drawings.
  • a sanitary napkin 1 according to one embodiment of the absorbent article of the present invention is, as shown in FIGS. 1 and 2, a liquid-permeable top sheet 2, a liquid-impermeable back sheet 3, and a top sheet 2. And an absorbent body 4 provided between the back sheet 3 and a recess 5 penetrating the top sheet 2 to reach the absorbent body 4.
  • the X axis direction corresponds to the width direction of the sanitary napkin 1
  • the Y axis direction corresponds to the longitudinal direction of the sanitary napkin 1
  • the direction of the plane spreading in the X axis Y axis direction corresponds to the plane direction of the sanitary napkin 1.
  • the sanitary napkin 1 is worn for the purpose of absorbing liquid excrement such as menstrual blood.
  • the top sheet 2 is worn on the skin side of the wearer and the back sheet 3 is located on the clothes (underwear) side of the wearer.
  • Liquid excrement such as menstrual blood passes through the top sheet 2 to reach the absorber 4, and is absorbed and held by the absorber 4. Leakage of liquid excrement absorbed and held by the absorber 4 is prevented by the back sheet 3.
  • the top sheet 2 and the back sheet 3 have their longitudinal ends joined by the sealing portions 11a and 11b to form the main body 6, and the widthwise ends have the sealing portions 12a. , 12b to form substantially rectangular wing portions 7a, 7b extending in the width direction from the main body portion 6.
  • the shape of the main body portion 6 can be appropriately adjusted within a range that suits the wearer's body, underwear and the like, and the shape of the main body portion 6 includes, for example, a substantially rectangular shape, a substantially elliptical shape, a substantially wedge shape or the like .
  • the longitudinal dimension of the main body portion 6 is usually 100 to 500 mm, preferably 150 to 350 mm, and the transverse dimension of the main body portion 6 is usually 30 to 200 mm, preferably 40 to 180 mm.
  • Examples of the bonding method by the seal portions 11a, 11b, 12a, 12b include embossing, ultrasonic waves, and a hot melt adhesive. In order to enhance the bonding strength, two or more bonding modes may be combined (for example, after bonding with a hot melt adhesive, embossing, etc.).
  • embossing for example, a method in which the top sheet 2 and the back sheet 3 are combined and passed between an embossing roll having a patterned convex portion and a flat roll (a method called a so-called round seal), etc. Can be mentioned. In this method, heating of the emboss roll and / or the flat roll softens the respective sheets, so that the seal portion tends to be clear.
  • an embossing pattern a lattice-like pattern, a zigzag pattern, a wavelike pattern etc. are mentioned, for example.
  • a hot melt adhesive for example, a rubber-based material such as styrene-ethylene-butadiene-styrene (SEBS), styrene-butadiene-styrene (SBS), styrene-isoprene-styrene (SIS) or the like, or linear Pressure-sensitive adhesives or thermosensitive adhesives mainly composed of olefins such as low density polyethylene; water-soluble polymers (eg, polyvinyl alcohol, carboxyl methyl cellulose, gelatin etc.) or water-swellable polymers (eg, polyvinyl acetate, poly And water-sensitive adhesives made of sodium acrylate etc.).
  • a coating method of an adhesive agent spiral coating, coater coating, curtain coater coating, summit gun coating etc. are mentioned, for example.
  • adhesive parts 13 a and 13 b are provided on the clothes side of the back sheet 3 forming the wing parts 7 a and 7 b, and on the clothes side of the back sheet 3 forming the main body part 6
  • the adhesion part 13c is provided.
  • the sanitary napkin 1 is made by sticking the adhesive portion 13c to the crotch portion of the undergarment, bending the wing portions 7a and 7b to the outer surface side of the undergarment, and sticking the adhesive portions 13a and 13b to the crotch portion of the undergarment. It is stably fixed to the underwear.
  • Examples of the adhesive contained in the adhesive portions 13a, 13b and 13c include styrene-ethylene-butylene-styrene block copolymer, styrene-butylene polymer, styrene-butylene-styrene block copolymer, styrene-isobutylene- Styrene polymers such as styrene copolymer; C5 petroleum resin, C9 petroleum resin, dicyclopentadiene petroleum resin, rosin petroleum resin, polyterpene resin, tackifier such as terpene phenol resin, etc .; Monomer plasticizers such as dibutyl and dioctyl phthalate; and polymer plasticizers such as vinyl polymers and polyesters.
  • the top sheet 2 has the 1st layer 21 provided in the skin contacting surface side, and the 2nd layer 22 provided in the non-skin-contacting surface side.
  • the first layer 21 and the second layer 22 each have liquid permeability.
  • the top sheet 2 has liquid permeability as a whole, and can permeate liquid excrement such as menstrual blood.
  • the first layer 21 is a skin contact surface.
  • the second layer 22 is laminated on the other surface of the first layer 21, and the top sheet 2 has a two-layer structure.
  • the top sheet 2 may have one or more third layers in addition to the first layer 21 and the second layer 22.
  • the position at which the third layer is provided is not particularly limited.
  • one or more third layers may be provided between the first layer 21 and the second layer 22, or one or more on the surface of the second layer 22 opposite to the first layer 21 side.
  • the first layer 21 and the second layer 22 are not particularly limited as long as liquid excrement such as menstrual blood can be permeated.
  • Examples of the first layer 21 and the second layer 22 include nonwoven fabrics, synthetic resin films in which liquid permeation holes are formed, and laminates of synthetic resin films and nonwoven fabrics, and the like, with preference given to nonwoven fabrics.
  • the top sheet 2 includes one or more third layers in addition to the first layer 21 and the second layer 22, similar ones may be mentioned as specific examples of the third layer.
  • non-woven fabric examples include an air through non-woven fabric, a heat-bonded non-woven fabric, a spun-bonded non-woven fabric, a melt-blown non-woven fabric, a spun lace non-woven fabric, and a needle punched non-woven fabric.
  • fibers constituting the non-woven fabric include natural fibers (such as wool and cotton), regenerated fibers (such as rayon and acetate), inorganic fibers (such as glass fibers and carbon fibers), and synthetic resin fibers (such as polyethylene, polypropylene, polybutylene, and ethylene).
  • Polyolefins such as vinyl acetate copolymer, ethylene-ethyl acrylate copolymer, ethylene-acrylic acid copolymer, ionomer resin, etc .
  • Polyester such as polyethylene terephthalate, polybutylene terephthalate, polytrimethylene terephthalate, polylactic acid, etc.
  • polyamides such as nylon).
  • the form of the fibers constituting the non-woven fabric is, for example, composite fibers such as core-sheath type fibers, side-by-side type fibers, island / sea type fibers; hollow type fibers; flat type, Y type, C type etc Atypical fibers; three-dimensional crimped fibers of latent crimp or manifest crimp; split fibers divided by physical load such as water flow, heat, embossing, etc. may be mentioned.
  • the fineness of the fibers constituting the non-woven fabric is preferably 1 to 20 dtex, more preferably 1.5 to 4 dtex.
  • the thickness, basis weight and the like of the first layer 21 and the second layer 22 can be appropriately adjusted in consideration of the formability of the recess 5 and the like.
  • the thickness is usually 0.1 to 5 mm, preferably 0.5 to 2 mm, and the basis weight is usually 10 to 50 g / m 2 , preferably 20 to 40 g / m 2 .
  • the density of the second layer 22 is preferably larger than the density of the first layer 21. Thereby, menstrual blood transferability from the first layer 21 to the second layer 22 can be improved.
  • the first layer 21 and / or the second layer 22 may contain an inorganic filler such as titanium oxide, barium sulfate, calcium carbonate or the like from the viewpoint of enhancing the hiding power of the top sheet 2.
  • an inorganic filler such as titanium oxide, barium sulfate, calcium carbonate or the like from the viewpoint of enhancing the hiding power of the top sheet 2.
  • the first layer 21 and / or the second layer 22 be subjected to a hydrophilization treatment.
  • a hydrophilization treatment for example, the surface coating of the first layer 21 and / or the second layer 22 with a hydrophilic agent, the addition of the hydrophilic agent to the component of the first layer 21 and / or the second layer 22, corona treatment, Plasma processing etc. are mentioned.
  • the hydrophilization treatment for example, the surface coating of the first layer 21 and / or the second layer 22 with a hydrophilic agent, the addition of the hydrophilic agent to the component of the first layer 21 and / or the second layer 22, corona treatment, Plasma processing etc. are mentioned.
  • the lipophilic region derived from the blood slipping agent and the hydrophilic region derived from the hydrophilic agent coexist in the top sheet 2 sparsely. Menstrual blood slips from the opening of the recess 5 (the cutting opening 51 formed in the top sheet 2) to the inside of the recess 5 (the absorber recess 52 formed in the absorber
  • the back sheet 3 is liquid impermeable. Since liquid excrement such as menstrual blood can not permeate the back sheet 3, the back sheet 3 prevents leakage of the liquid excrement absorbed by the absorber 4.
  • One surface of the back sheet is a non-skin contact surface (in the present embodiment, a surface on which a wearer's clothing (underwear) contacts).
  • the back sheet 3 preferably has moisture permeability in addition to liquid impermeability in order to reduce stuffiness when worn.
  • the back sheet 3 may be, for example, a non-woven fabric waterproofed, a synthetic resin (for example, polyethylene, polypropylene, polyethylene terephthalate etc.) film, a composite sheet of non-woven fabric and a synthetic resin film (for example non-woven fabric such as spunbond or spunlace) And a composite film in which a breathable synthetic resin film is joined, an SMS non-woven fabric in which a highly water-resistant meltblown non-woven fabric is sandwiched by a strong spunbond non-woven fabric, and the like.
  • a synthetic resin for example, polyethylene, polypropylene, polyethylene terephthalate etc.
  • a composite sheet of non-woven fabric and a synthetic resin film for example non-woven fabric such as spunbond or spunlace
  • a composite film in which a breathable synthetic resin film is joined an SMS non-woven fabric in which a highly water-resistant meltblown non-woven fabric is sandwiched by a strong spunbond non-woven fabric, and the like.
  • the absorber 4 contains the absorptive material which absorbs liquid excretion, such as menstrual blood.
  • the absorbent material contained in the absorber 4 is not particularly limited as long as it can absorb and retain liquid excrement such as menstrual blood.
  • Examples of the absorbent material include water-absorbent fibers and highly water-absorbent materials (for example, highly water-absorbent resin, highly water-absorbent fibers, etc.).
  • Absorber 4 is an additive such as an antioxidant, a light stabilizer, an ultraviolet light absorber, a neutralizer, a nucleating agent, an epoxy stabilizer, a lubricant, an antibacterial agent, a flame retardant, an antistatic agent, a pigment, and a plasticizer You may contain as needed.
  • water-absorbent fibers include wood pulps obtained from softwood or hardwood as raw materials (for example, mechanical pulps such as ground pulp, refiner ground pulp, thermomechanical pulp, chemithermomechanical pulp, etc .; kraft pulp, sulfide pulp, alkaline pulp, etc. Semi-chemical pulp, etc.); mercerized pulp obtained by subjecting wood pulp to chemical treatment or crosslinked pulp; non-wood pulp such as bagasse, kenaf, bamboo, hemp, cotton (eg cotton linters); rayon, fibril Regenerated celluloses such as rayon; semi-synthetic celluloses such as acetate and triacetate may, for example, be mentioned, but ground pulp is preferred from the viewpoint of low cost and ease of molding.
  • mechanical pulps such as ground pulp, refiner ground pulp, thermomechanical pulp, chemithermomechanical pulp, etc .
  • kraft pulp, sulfide pulp alkaline pulp, etc.
  • Semi-chemical pulp, etc. mercerized pulp obtained by subjecting wood pulp to chemical treatment
  • the superabsorbent material examples include starch-based, cellulose-based, synthetic polymer-based superabsorbent materials.
  • starch-based or cellulose-based superabsorbent materials include starch-acrylic acid (salt) graft copolymers, saponified starch-acrylonitrile copolymers, crosslinked products of sodium carboxymethylcellulose, etc.
  • Synthetic polymers examples include polyacrylates, polysulfonates, anhydrides maleates, polyacrylamides, polyvinyl alcohols, polyethylene oxides, polyaspartates and polyglutamates.
  • Superabsorbent Polymers SAP
  • SAP polyalginate-based, starch-based, and cellulose-based superabsorbent polymers
  • polyacrylate-based especially, sodium polyacrylate-based
  • SAP superabsorbent Polymers
  • the shape of the superabsorbent material include particles, fibers, scaly and the like, and in the case of particles, the particle size is preferably 50 to 1000 ⁇ m, more preferably 100 to 600 ⁇ m. .
  • the absorbent body 4 contains a highly water-absorptive material (for example, highly water-absorptive resin, highly water-absorptive fiber, etc.), the content of the highly water-absorptive material is usually 5 to 80% by mass, preferably 10 of the absorbent body 4 It is at most 60% by mass, more preferably 20 to 40% by mass.
  • a highly water-absorptive material for example, highly water-absorptive resin, highly water-absorptive fiber, etc.
  • the absorber 4 may contain silver, copper, zinc, silica, activated carbon, an aluminosilicate compound, zeolite or the like. Thereby, functions, such as deodorizing property, antibacterial property, an endothermic effect, can be provided to an absorber.
  • the thickness, fabric weight and the like of the absorber 4 can be appropriately adjusted in accordance with the characteristics (for example, absorbability, strength, lightness, and the like) that the sanitary napkin 1 should have.
  • the thickness of the absorber 4 is usually 0.1 to 15 mm, preferably 1 to 10 mm, more preferably 2 to 5 mm, and the basis weight is usually 20 to 1000 g / m 2 , preferably 50 to 800 g / m 2 , Preferably it is 100 to 500 g / m 2 .
  • the thickness of a absorber 4, a fabric weight, etc. may be constant over the absorber 4 whole, and may differ partially.
  • Absorbent body 4 may have a core containing an absorptive material, and a core wrap which covers a core.
  • the core wrap is not particularly limited as long as it has liquid permeability and absorber retention.
  • core wraps include nonwoven fabrics, woven fabrics, synthetic resin films having liquid permeation holes, and net-like sheets having a mesh.
  • a wet method is mainly used with crushed pulp. Tissues molded with are preferred.
  • the sanitary napkin 1 is formed with a plurality of recesses 5. As shown in FIG. 2, the recess 5 penetrates the top sheet 2, extends in the thickness direction of the sanitary napkin 1, and reaches the inside of the absorbent body 4.
  • the concave portion 5 is formed in the excretory opening contact area 20 of the skin contact surface of the top sheet 2.
  • the recess 5 may be formed on substantially the entire absorbent placement area including the discharge opening contact area 20 in the skin contact surface of the top sheet 2.
  • region projects the absorber 4 on the top sheet 2, it is an area
  • the excretory opening contact area 20 is an area where the wearer's excretory opening (for example, the minor labia, the labia majora, etc.) abuts when the sanitary napkin 1 is worn. As shown in FIG. 1, the excretion opening contact area 20 is set at substantially the center of the absorber placement area. The position, area, and the like of the discharge port contact region 20 can be appropriately adjusted.
  • the discharge opening contact region 20 may be set as a region substantially identical to the region to which the discharge opening actually contacts, or may be set to a region larger than that, but the liquid discharge such as menstrual blood In order to prevent the leakage to the outside, it is preferable to set as a region larger than the region where the discharge port actually abuts.
  • the length of the discharge port contact area 20 is usually 50 to 200 mm, preferably 70 to 150 mm, and the width is usually 10 to 80 mm, preferably 20 to 50 mm.
  • the excretory opening contact area 20 is set as a virtual area, but may be set as a visually recognizable area.
  • Visual recognition can be made, for example, by coloring the excretory opening contact area 20, forming a recess in the periphery of the excretory opening contact area 20 (for example, an embossed section formed by heat embossing), or the like.
  • the recess 5 is a cutting opening 51 passing through the top sheet 2, and an absorber recess 52 that opens in the surface of the absorber 4 on the top sheet 2 side and extends in the thickness direction of the absorber 4. And.
  • the recess 5 is a flow path for guiding the liquid from the cutting opening 51 to the absorber recess 52, and menstrual blood excreted from the wearer is transferred to the absorber recess 52 through the cutting opening 51, and the absorber recess is Absorbed from the side 521 and bottom 522 of 52.
  • the formation of the cutting opening 51 improves menstrual transferability from the top sheet 2 to the absorber 4, and the formation of the absorber recess 52 increases the surface area of the surface of the absorber 4 on the top sheet 2 side. Along with this, the menstrual blood absorbability of the absorber 4 is improved.
  • the recess 5 is a perforated portion formed by the perforation of the top sheet 2 and the absorber 4, and the cutting opening 51 and the absorber recess 52 are integrally formed. Therefore, as shown in FIG. 2, the absorber recess 52 is provided at a position corresponding to the position of the cutting opening 51 and is in communication with the cutting opening 51. That is, in the recess 5, the opening end of the cutting opening 51 and the opening end of the absorber recess 52 are continuous, and the opening diameter of the cutting opening 51 substantially matches the opening diameter of the absorber recess 52. ing.
  • the number of recesses 5 per 1 cm 2 of the discharge port contact area 20 is preferably 0.5 to 5, and more preferably Are one to three. If the number of concave portions 5 per 1 cm 2 of the excretion opening contact area 20 is smaller than 0.5, there is a possibility that the improvement effect of menstrual blood transferability and menstrual blood absorbability by the formation of the concave portions 5 does not sufficiently appear.
  • the absorber 4 is specified
  • the concentration of menstrual blood in the area of (4) may cause rewet (relapse of menstrual blood once absorbed).
  • the opening diameter of the recess 5 (the opening diameter of the cutting opening 51, the opening diameter of the absorber recess 52) is preferably 0.3 to 6 mm, more preferably 0.6 to 3 mm. In addition, when opening shape is not circular, let the diameter of a circumscribed circle be opening diameter. When the opening diameter of the recess 5 is smaller than 0.3 mm, there is a possibility that menstrual transferability from the cutting opening 51 to the absorber recess 52 may be reduced, while if the opening diameter of the recess 5 is larger than 6 mm, the recess 5 The decrease in rigidity of the portion provided with is significantly reduced, and there is a possibility that the deflection is likely to occur when the sanitary napkin 1 is attached.
  • the cutting opening 51 is formed by cutting a predetermined portion of the top sheet 2 (the first layer 21 and the second layer 22). By forming the cutting opening 51, the contact area between the top sheet 2 and the skin of the wearer can be reduced, and accordingly, the friction between the top sheet 2 and the skin of the wearer can be reduced. .
  • the top sheet fragments 9 separated from the top sheet 2 result.
  • the top sheet fragments 9 formed during the formation of the cutting openings 51 cover the bottom 522 of the absorber recess 52.
  • the top sheet fragment 9 may cover a part of the side surface 521 of the absorber recess 52 in addition to the bottom 522 of the absorber recess 52.
  • the top sheet fragment 9 is preferably crimped to the bottom 522 of the absorber recess 52.
  • the top sheet fragment 9 is consolidated integrally with the bottom 522 of the absorber recess 52, and the rigidity of the bottom 522 of the absorber recess 52 is increased, so that the recess 5 may occur when the sanitary napkin 1 is attached. And the reduction in menstrual blood transferability from the top sheet 2 to the absorber 4 due to the blockage.
  • the first layer 21 and the second layer 22 are preferably crimped to each other at the peripheral portion of the cutting opening 51.
  • the peripheral portion of the cutting opening 51 is densified, and the rigidity of the peripheral portion of the cutting opening 51 is increased, so that closing of the cutting opening 51 that may occur when the sanitary napkin 1 is attached, the first layer It is possible to suppress the separation of the first and second layers 22 and the decrease in menstrual transferability from the top sheet 2 to the absorber 4 due to these.
  • menstrual blood excreted from the wearer is likely to be collected at the peripheral portion of the cutting opening 51, and the menstrual blood from the cutting opening 51 to the absorbent recess 52 Migration is improved.
  • the top sheet 2 When forming the cutting opening 51, the top sheet 2 is compressed along with the part to be cut (the part to be the top sheet fragment 9 after cutting) and its surrounding part. By this compression, crimping of the first layer 21 and the second layer 22 in the peripheral portion of the cutting opening 51 is possible. Further, by pressure bonding the first layer 21 and the second layer 22 in the peripheral portion of the cutting opening 51, the density of the peripheral portion of the cutting opening 51 can be increased. In particular, in the case where the first layer 21 and the second layer 22 are non-woven fabrics, the first layer 21 and the second layer 22 are easily crimped to each other at the peripheral portion of the cutting opening 51. It is easy to densify the
  • the absorber 4 can expand in the vicinity of the bottom 522 of the absorber recess 52, and the absorber 4 can absorb and hold menstrual blood also in the vicinity of the bottom 522 of the absorber recess 52.
  • the kinematic viscosity at 40 ° C. is 0.01 to 80 mm 2 / s, the water retention rate is 0.01 to 4.0 mass%, and the weight average molecular weight is less than 1,000 in the discharge opening contact area 20 of the top sheet 2
  • the blood slipping agent which is In addition, in FIG. 1, the hatched part in the excretion opening
  • the blood slipping agent will be described in detail in a separate item.
  • the blood slipping agent is coated on substantially the whole of the excretory opening contact region 20, but the blood slipping agent is the peripheral portion of the cutting opening 51 in the excretory opening contact region 20. It should just be coated by. As long as the blood slipping agent is coated on the periphery of the cutting opening 51 in the drainage opening abutting region 20, the blood slip imparting agent is coated on other than the periphery of the cutting opening 51 on the drainage opening abutting region 20. It may be coated, and may be applied to a region of the skin contact surface other than the discharge opening contact region 20 (for example, a peripheral region of the discharge opening contact region 20). For example, the blood slipping agent can be applied to substantially the entire skin contact surface or substantially the entire absorbent placement area.
  • the blood slipping agent By coating the blood slipping agent on at least the peripheral portion of the cutting opening 51 in the excretory opening contact region 20, the following effects are exhibited.
  • the sanitary napkin 1 When the menstrual blood excreted from the wearer reaches the excretory opening contact area 20, it slides down into the recess 5 together with the blood slipping agent present in the peripheral portion of the cutting opening 51 (ie, the absorber through the cutting opening 51) Transition to the recess 52). Therefore, the sanitary napkin 1 has an improved menstrual blood transferability from the top sheet 2 to the absorbent body 4, and the menstrual blood remaining in the top sheet 2 can be reduced. For this reason, the sticky feeling of the skin contact surface of the top sheet 2 is prevented, and a smooth feeling is maintained. The action and effect of such a blood slipping agent is exhibited regardless of the change in menstrual blood discharge during menstruation (that is, whether the amount of menstrual blood discharged at one time is large or small) .
  • the recess 5 exists in the excretion opening contact region 20 and the portion where the recess 5 does not exist is relatively a protrusion, the function and effect of the blood slipping agent are effectively exhibited. Ru.
  • the action and effect of the blood slipping agent is also applied to the inner surface of the recess 5 (for example, the inner peripheral surface of the cutting opening 51, the inner surface of the absorber recess 52). It can be enhanced by coating.
  • the blood slipping agent also acts as a lubricant and reduces the friction between the fibers, the flexibility of the entire top sheet 2 can be improved.
  • the sanitary napkin 1 does not require components such as an emollient and a fixing agent, and the blood slipping agent alone is a top It can be applied to the sheet 2.
  • the basis weight of the blood slipping agent is usually about 1 to 30 g / m 2 , preferably about 2 to 20 g / m 2 , and more preferably about 3 to 10 g / m 2 .
  • the basis weight of the blood slipping agent is less than about 1 g / m 2 , menstrual blood tends to remain on the top sheet 2 while when the basis weight of the blood slipping agent exceeds about 30 g / m 2 , Sticky feeling is likely to increase during wearing.
  • the basis weight of the blood slipping agent can be measured, for example, as follows. (1) A sample is obtained by cutting out the range to be measured of the top sheet using a sharp blade, for example, a replaceable blade of a cutter so as not to change its thickness as much as possible. (2) Measure the area of the sample: SA (m 2 ) and the mass: SM 0 (g). (3) The sample is stirred in a solvent capable of dissolving the blood slipping agent such as ethanol, acetone or the like for at least 3 minutes to dissolve the blood slipping agent in the solvent. (4) The sample is filtered on the weighed filter paper, and the sample is thoroughly washed with the solvent on the filter paper. The sample on filter paper is dried in an oven at 60 ° C.
  • the mass of the filter paper and the sample is measured, and the mass of the filter paper is reduced therefrom to calculate the mass of the sample after drying: SM 1 (g).
  • BBS (g / m 2 ) [SM 0 (g) -SM 1 (g)] / SA (m 2 )
  • the blood slipping agent be applied so as not to close the space between the fibers of the top sheet 2.
  • the blood slipping agent adheres to the surface of the fibers of the top sheet 2 in the form of droplets or particles, or covers the surface of the fibers.
  • the blood slipping agent is preferably applied so as to increase the surface area.
  • the contact area between the blood slipping agent and the menstrual blood increases, and the blood slipping agent tends to slip off with the menstrual blood.
  • the surface area can be increased by decreasing the particle size.
  • a coating method of the blood slipping agent for example, a method using a coating apparatus (for example, non-contact coater such as spiral coater, curtain coater, spray coater, dip coater, contact coater, etc.) may be mentioned.
  • the preferred coating apparatus is a noncontact coater.
  • the blood slipping agent can be optionally coated as a coating solution containing a volatile solvent such as an alcohol solvent, an ester solvent, an aromatic solvent and the like.
  • a volatile solvent such as an alcohol solvent, an ester solvent, an aromatic solvent and the like.
  • the blood slipping agent is heated at room temperature as it is, or heated to lower its viscosity, and heated at room temperature so as to liquefy in the case of a solid, to control seam HMA (Hot Melt Adhesive ) Can be coated by gun.
  • a particulate blood slipping agent can be applied by increasing the air pressure of the control seam HMA gun.
  • the application amount of the blood slipping agent can be adjusted, for example, by increasing or decreasing the amount of application from the control seam HMA gun.
  • the blood slipping agent may be applied when producing the top sheet 2 or may be applied in the production line of the sanitary napkin 1. From the viewpoint of suppressing equipment investment, it is preferable to apply a blood slipping agent on the manufacturing line of the sanitary napkin 1, and furthermore, the blood slipping agent is prevented from dropping off and contaminating the line. For this purpose, it is preferable to apply a blood slipping agent immediately downstream of the production line, specifically, immediately before enclosing the product in an individual package.
  • the sanitary napkin 1 may include a second sheet disposed between the top sheet 2 and the absorbent body 4 in addition to the top sheet 2 as a liquid-permeable layer.
  • the blood slipping agent may be applied to the second sheet.
  • the second sheet is not particularly limited as long as liquid excrement such as menstrual blood can be permeated, and the thickness, basis weight, density, etc. of the second sheet are appropriately adjusted in the range in which liquid excrement such as menstrual blood can permeate. be able to.
  • Non-woven fabrics include, for example, air-through non-woven fabrics, spun-bonded non-woven fabrics, point-bonded non-woven fabrics, spun-laced non-woven fabrics, needle-punched non-woven fabrics, melt-blown non-woven fabrics, and combinations thereof (for example, SMS etc.) etc.
  • natural fibers wool, cotton, etc.
  • regenerated fibers rayon, acetate, etc.
  • inorganic fibers glass fibers, carbon fibers, etc.
  • synthetic resin fibers polyethylene, polypropylene, polybutylene, ethylene-vinyl acetate copolymer, Polyolefins such as ethylene-ethyl acrylate copolymer, ethylene-acrylic acid copolymer, ionomer resin; polyesters such as polyethylene terephthalate, polybutylene terephthalate, polytrimethylene terephthalate, polylactic acid; De), and the like.
  • Non-woven fabrics include core / sheath fibers, side-by-side fibers, composite fibers such as island / sea fibers; hollow fibers; flat fibers, irregular fibers such as Y-type and C-type; latent crimp or overt presence A crimped three-dimensional crimped fiber; split fibers divided by physical load such as water flow, heat, embossing, etc. may be mixed.
  • the first layer 21 unwound from the roll 120 is supplied onto the carrier sheet 110 advancing in the transport direction MD. Then, the supplied second layer 22 unrolled from the roll 130 is laminated on the first layer 21.
  • Recesses 144 are formed on the circumferential surface of the suction drum 140 rotating in the transport direction MD at a required pitch in the circumferential direction as a mold for packing the absorber material 142.
  • the suction portion 146 acts on the concave portion 144, and the absorber material 142 supplied from the material supply portion 141 is vacuum suctioned to the concave portion 144.
  • the material supply unit 141 is formed to cover the suction drum 140, and the material supply unit 141 supplies the absorber material 142 to the recess 144 by air conveyance, and the absorber 4 is formed in the recess 144. Ru.
  • the absorber 4 formed in the concave portion 144 is transferred onto the carrier sheet 110 advancing in the transport direction MD.
  • a laminate 152 in which the absorber 4, the second layer 22 and the first layer 21 are laminated in order is formed.
  • the carrier sheet 110 supports the laminate 152 with two belts extending on both sides in the transport direction MD. That is, of the surface on the carrier sheet side (the lower surface in FIG. 3) of the laminate 152, both side portions extending on both sides in the conveying direction MD are supported by the carrier sheet 110, but a central portion extending in the conveying direction MD Are not supported by the carrier sheet 110 and are exposed from between the two belts of the carrier sheet 110. This exposed portion is processed in the embossing process 160 in the next step. Therefore, the layered product 152 is processed by the embossing treatment 160 in the next step while being placed on the carrier sheet 110.
  • This embodiment may be modified to end the support of the laminate 152 by the carrier sheet 110 before processing by the embossing procedure 160.
  • the laminate 152 is not processed on the carrier sheet 110 but processed by the embossing treatment 160 in a state supported by the tension of the first layer 21 and the second layer 22.
  • the laminate 152 may be placed on the carrier sheet 110 and conveyed again after being processed by the embossing treatment 160.
  • Embossing device 160 includes a projecting roll 161 having a plurality of projections 161a having a needle shape, a cylindrical shape, a conical shape, and the like on the outer peripheral surface, and a plain roll 162 having a smooth surface on the outer peripheral.
  • the projection 161 a of the projecting roll 161 forms a predetermined portion of the first layer 21 and the second layer 22 in the thickness direction , And shear the pressed portion to form the cutting opening 51. Then, the top sheet fragment 9 divided from the cutting opening 51 is pressed into the absorber 4 to form the absorber recess 52, and the top sheet fragment 9 is crimped to the bottom 522 of the absorber recess 5.
  • FIGS. 4A and 4B are diagrams for explaining an example of embossing.
  • the tip end of the protrusion 161 a of the protrusion roll 161 abuts on the top sheet 2. Then, the shear force of the protrusion 161 a generated when the protrusion 161 a compresses the top sheet 2 cuts the end portion (the portion represented by reference numeral 10 b) of the contact area of the protrusion 161 a. The top sheet 2 is cut by the shear force of the projections 161 a to form the top sheet fragment 9.
  • the height of the protrusion 161a is preferably as high as possible. Further, it is preferable that the angle of the line connecting the tip of the protrusion 161a and the root of the protrusion 161a be closer to perpendicular. That is, the angle between the side surface of the protrusion 161 a and the outer peripheral surface of the protrusion roll 161 is preferably close to 90 °.
  • the height of the protrusion 161 a is larger than one-third the thickness of the absorber 4 before the recess 5 is formed, and ten times the thickness of the absorber 4 before the recess 5 is formed.
  • Is preferably smaller than half the thickness of the absorber 4 before the recess 5 is formed, and is five times the thickness of the absorber 4 before the recess 5 is formed. It is further preferred that it be smaller than When the height of the protrusion 161a is smaller than 1/3 of the thickness of the absorber 4 before the recess 5 is formed, the absorber 4 is compressed in the thickness direction even in the portion where the recess 5 is not formed. The whole of the absorber 4 may become rigid. When the height of the protrusion 161a is larger than 10 times the thickness of the absorber 4 before the recess 5 is formed, the protrusion 161a may be broken.
  • the tip angle of the protrusion 161a is preferably 20 to 45 °. If the tip angle of the protrusion 161 a is smaller than 20 °, the durability of the protrusion 161 a may be reduced. If the tip angle of the protrusion 161 a is larger than 45 °, the shearing force by the protrusion 161 a may be reduced.
  • the protrusions 161 a of the protrusion roll 161 are pressed into the absorber 4.
  • the top sheet piece 9 is crimped to the bottom 522 of the absorber recess 52, and is consolidated and densified integrally. Since the top sheet fragments 9 are completely separated from the main body of the top sheet 2, even if the top sheet fragments 9 receive stress from the protrusions 161a, the stress to which the top sheet 2 is subjected is weak.
  • the absorber 4 is suppressed from being compressed in the thickness direction in the peripheral portion of the absorber recess 52.
  • the electron micrograph of the laminated body 152 after embossing is shown in FIG.
  • the top sheet 2 is provided with a cutting opening 51. Since the edge (cut portion) 10 b of the cutting opening 51 of the top sheet 2 does not extend to the side surface 521 of the absorber recess 52, the cutting opening 51 corresponds to the top sheet 2 (first layer 21 and second layer). It can be seen that it was formed by cutting the layer 22) at the cutting portion 10b. In addition, at the bottom 522 of the absorber recess 52, the compressed top sheet fragment 9 is present. In the surface opposite to the surface on which the absorber recess 52 is formed, the recess 50 is formed in a portion facing the bottom of the absorber recess 52.
  • the side sheet 8 shown in FIG. 1 prevents menstrual blood from leaking outward in the width direction of the sanitary napkin 1 through the top sheet 2.
  • the side sheets 8 preferably have hydrophobicity or water repellency.
  • a spunbond nonwoven fabric, an SMS nonwoven fabric, or the like is used for the side sheet 8.
  • the air through nonwoven fabric which can reduce rubbing irritation to skin as the side sheet 8.
  • the side sheet 8 may be omitted.
  • the blood slipping agent has a kinematic viscosity of about 0.01 to about 80 mm 2 / s at 40 ° C., a water retention of about 0.05 to about 4.0% by mass, and a weight average molecular weight of about 1 Less than 1,000.
  • the kinematic viscosity of the blood slipping agent at 40 ° C. can be appropriately adjusted in the range of about 0 to about 80 mm 2 / s, preferably about 1 to about 70 mm 2 / s, more preferably about 3 to about 3 60 mm 2 / s, still more preferably about 5 to about 50 mm 2 / s, still more preferably about 7 to about 45 mm 2 / s.
  • the kinematic viscosity at 40 ° C. may be simply referred to as “kinetic viscosity”.
  • the kinematic viscosity is a) as the molecular weight of the blood slipping agent is increased, b) polar groups such as carbonyl bond (-CO-), ether bond (-O-), carboxyl group (-COOH), hydroxyl group
  • polar groups such as carbonyl bond (-CO-), ether bond (-O-), carboxyl group (-COOH), hydroxyl group
  • the melting point of the blood slipping agent is preferably 45 ° C. or less.
  • the kinematic viscosity tends to be high.
  • the kinematic viscosity in the blood slipping agent exceeds about 80 mm 2 / s, the viscosity of the blood slipping agent is high, and the menstrual blood reached the skin contact surface of the top sheet At the same time, it tends to be difficult to slide from the convex portion to the concave portion and then to move into the inside of the absorber.
  • the kinematic viscosity can be measured at a test temperature of 40 ° C. using a Canon Fentzberg reverse flow viscometer according to “5. Dynamic viscosity test method” of JIS K 2283: 2000.
  • the water retention rate of the blood slipping agent can be appropriately adjusted in the range of about 0.01 to about 4.0% by mass, preferably about 0.02 to about 3.5% by mass, and more preferably It is about 0.03 to about 3.0% by weight, still more preferably about 0.04 to about 2.5% by weight, and still more preferably about 0.05 to about 2.0% by weight.
  • water-retaining rate means the proportion (mass) of water that a substance can hold, and can be measured as follows. (1) In a temperature-controlled room at 40 ° C., leave a 20 mL test tube, rubber stopper, substance to be measured and deionized water overnight. (2) In a temperature-controlled room, 5.0 g of a substance to be measured and 5.0 g of deionized water are put into a test tube. (3) In a temperature-controlled room, put a rubber stopper on the mouth of the test tube, rotate the test tube once, and leave it for 5 minutes.
  • the water retention rate is a) as the molecular weight of the blood slipping agent decreases, and b) polar groups such as carbonyl bond (-CO-), ether bond (-O-), carboxyl group (-COOH), hydroxyl
  • polar groups such as carbonyl bond (-CO-), ether bond (-O-), carboxyl group (-COOH), hydroxyl
  • the water retention rate tends to increase as the IOB increases, that is, as the inorganic value increases and as the organic value decreases. It is because a blood slipping agent will have more hydrophilicity.
  • menstrual blood excreted from the wearer When menstrual blood excreted from the wearer reaches the excretory opening contact area, it contacts the blood slipping agent present in the convex part, slides along with it into the concave part, passes through the top sheet, and transfers to the absorber .
  • a blood slipping agent having a kinematic viscosity of about 0.01 to about 80 mm 2 / s at 40 ° C. has a very low viscosity near the wearer's body temperature and has constant affinity with menstrual blood It is thought that menstrual blood passes through the top sheet and can be rapidly transferred to the absorbent body by using the force of sliding when the menstrual blood slides down from the convex part to the concave part and has a sliding effect.
  • the blood slipping agent present in the convex portion has a water retention rate of about 0.01 to about 4.0% by mass, it is mainly compatible with hydrophilic components (such as plasma) in the blood. It is thought that menstrual blood does not easily remain on the top sheet.
  • the blood slipping agent slips along with menstrual blood from the convex part to the concave part and draws menstrual blood into the interior of the top sheet and then withdraws into the absorbent body, thereby rapidly transferring the menstrual blood to the absorbent body be able to.
  • the blood slipping agent has a weight average molecular weight of less than about 1,000 and preferably has a weight average molecular weight of less than about 900.
  • the weight-average molecular weight is about 1,000 or more, the blood slipping agent itself is tacky, which tends to make the wearer uncomfortable.
  • the weight average molecular weight is high, the viscosity of the blood slipping agent tends to be high, so it is difficult to lower the viscosity of the blood slipping agent to a viscosity suitable for coating by heating. As a result, the blood slipping agent may occur if it has to be diluted with a solvent.
  • the blood slipping agent preferably has a weight average molecular weight of about 100 or more, and more preferably about 200 or more. If the weight-average molecular weight is decreased, the vapor pressure of the blood slipping agent may be increased to be vaporized during storage, which may cause problems such as a decrease in amount and an odor when worn.
  • the weight average molecular weight means a value in terms of polystyrene, which is determined by gel permeation chromatography (GPC).
  • GPC measurement conditions include the following. Model: High-performance liquid chromatogram Lachrom Elite manufactured by Hitachi High-Technologies Corporation Column: Showa Denko KK SHODEX KF-801, KF-803 and KF-804 Eluent: THF Flow rate: 1.0 mL / min Implanted volume: 100 ⁇ L Detection: RI (differential refractometer)
  • the weight average molecular weight described in the Example of this specification is measured based on the said conditions.
  • the blood slipping agent can have an IOB of about 0.00 to about 0.60.
  • IOB Inorganic Organic Balance
  • the IOB is preferably about 0.00 to about 0.60, more preferably about 0.00 to about 0.50, and about 0.00 to about 0.40. More preferably, it is about 0.00 to about 0.30.
  • the hydrostatic capacity and the kinematic viscosity tend to satisfy the above-mentioned requirements.
  • the blood slipping agent preferably has a melting point of 45 ° C. or less, more preferably 40 ° C. or less.
  • the blood slipping agent tends to have a kinematic viscosity in the range described above.
  • the "melting point” means the peak top temperature of an endothermic peak when changing from solid state to liquid state when measured at a temperature rising rate of 10 ° C./min in a differential scanning calorimeter.
  • the melting point can be measured, for example, using a DSC-60 type DSC measurement apparatus manufactured by Shimadzu Corporation.
  • the blood slipping agent may be liquid or solid at room temperature (about 25 ° C.) as long as it has a melting point of about 45 ° C. or less, ie, even if the melting point is about 25 ° C. or higher, or It may be less than about 25.degree. C. and may have a melting point such as, for example, about -5.degree. C., about -20.degree.
  • the melting point of the blood slipping agent there is no lower limit to the melting point of the blood slipping agent, but its vapor pressure is preferably low.
  • the vapor pressure of the blood slipping agent is preferably about 0 to about 200 Pa at 25 ° C. (1 atm), more preferably about 0 to about 100 Pa, and further preferably about 0 to about 10 Pa Preferably, it is still more preferably about 0 to about 1 Pa, and even more preferably about 0.0 to about 0.1 Pa.
  • the vapor pressure is preferably about 0 to about 700 Pa and about 0 to about 100 Pa at 40 ° C. (1 atm). Is more preferably about 0 to about 10 Pa, still more preferably about 0 to about 1 Pa, and still more preferably about 0.0 to about 0.1 Pa. If the vapor pressure of the blood slipping agent is high, it may be vaporized during storage, which may cause problems such as reduction of the amount and odor when worn.
  • the melting point of the blood slipping agent can be selected according to the weather, the length of wearing time, and the like. For example, in areas where the average temperature is about 10 ° C. or less, menstrual blood may be excreted and then cooled by the ambient temperature by employing a blood slipping agent having a melting point of about 10 ° C. or less. Also, it is considered that the blood slipping agent is easy to function.
  • the melting point of the blood slipping agent is preferably higher in the range of about 45 ° C. or less. It is because it is hard to be influenced by sweat, friction at the time of wearing, etc., and even when it is worn for a long time, the blood slipping agent is hardly biased.
  • the skin contact surface of the top sheet is coated with a surfactant for the purpose of changing the surface tension of menstrual blood and the like to rapidly absorb menstrual blood.
  • the surfactant-coated top sheet has high affinity with hydrophilic components (blood plasma etc.) in the blood, and tends to attract them and rather keep menstrual blood remaining on the top sheet.
  • the blood slipping agent has low affinity with menstrual blood, and can be rapidly transferred to the absorber without leaving menstrual blood on the top sheet.
  • the blood slipping agent is preferably selected from the following (i) to (iii), (I) Hydrocarbons, (Ii) consisting of (ii-1) hydrocarbon moiety and (ii-2) carbonyl group (-CO-) and oxy group (-O-) inserted between C-C single bonds of hydrocarbon moiety A compound having one or more same or different groups selected from the group, and (iii) (iii-1) between a hydrocarbon moiety and a CC single bond of (iii-2) hydrocarbon moiety And one or more identical or different groups selected from the group consisting of a carbonyl group (-CO-) and an oxy group (-O-) inserted, and (iii-3) a hydrogen atom of a hydrocarbon moiety A compound having one or more same or different groups selected from the group consisting of carboxyl group (—COOH) and hydroxyl group (—OH) to be substituted, And any combination thereof.
  • hydrocarbon means a compound consisting of carbon and hydrogen, and is a chain hydrocarbon, for example, paraffinic hydrocarbon (also referred to as alkane not containing double bond and triple bond) Olefinic hydrocarbons (containing one double bond, also referred to as alkenes), acetylenic hydrocarbons (containing one triple bond, also called alkynes), and a group consisting of double bonds and triple bonds And hydrocarbons containing two or more bonds selected from the following, as well as cyclic hydrocarbons such as aromatic hydrocarbons and alicyclic hydrocarbons.
  • paraffinic hydrocarbon also referred to as alkane not containing double bond and triple bond
  • Olefinic hydrocarbons containing one double bond, also referred to as alkenes
  • acetylenic hydrocarbons containing one triple bond, also called alkynes
  • hydrocarbons containing two or more bonds selected from the following, as well as cyclic hydrocarbons such as aromatic hydrocarbons and alicyclic hydrocarbons.
  • the hydrocarbon is preferably a chain hydrocarbon and an alicyclic hydrocarbon, more preferably a chain hydrocarbon, paraffin hydrocarbon, olefin hydrocarbon, and two or more double bonds. More preferably, they are hydrocarbons containing (without triple bonds), and more preferably paraffinic hydrocarbons.
  • the chain hydrocarbon includes straight chain hydrocarbon and branched chain hydrocarbon.
  • each oxy group (—O—) is not adjacent. Accordingly, the compounds (ii) and (iii) do not include compounds having a continuous oxy group (so-called peroxides).
  • At least one hydrogen atom of the hydrocarbon moiety is more hydroxyl group (-OH than a compound in which at least one hydrogen atom of the hydrocarbon moiety is substituted with a carboxyl group (—COOH) Compounds substituted with) are preferred. This is because the carboxyl group is bonded to a metal or the like in blood, and the water retention rate of the blood slipping agent is increased to exceed the predetermined range in some cases. This is also true from the point of view of the IOB.
  • the carboxyl group binds to metals and the like in the blood, and the inorganic value greatly increases from 150 to 400 or more, the blood slipping agent having the carboxyl group is used Occasionally, the value of IOB may exceed about 0.60.
  • the blood slipping agent is selected from the following (i ') to (iii'), (I ') hydrocarbons, (Ii ') Carbonyl bond (-CO-), ester bond (-COO-) inserted between (ii'-1) hydrocarbon moiety and C-C single bond of (ii'-2) hydrocarbon moiety
  • the blood slipping agent has about 1.8 or less carbonyl bond (-CO-) and 2 or less ester bond (-COO-) per 10 carbon atoms in the hydrocarbon moiety, carbonate About 1.5 or less bonds (-OCOO-), about 6 or less ether bonds (-O-), about 0.8 or less carboxyl groups (-COOH), and / or hydroxyl groups (-OH) Or less.
  • the blood slipping agent is any one of the following (A) to (F), (A) A compound having (A1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms of the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and a chain hydrocarbon An ester with a compound having one carboxyl group replacing the hydrogen atom of the hydrogen moiety, (B) A compound having (B1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and a chain hydrocarbon An ether with a compound having one hydroxyl group replacing the hydrogen atom of the hydrogen moiety, (C) a carboxylic acid, hydroxy acid, alkoxy acid or oxo acid containing (C1) a chain hydrocarbon moiety and 2 to 4 carboxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (C2 And d) an ester of a compound having a chain hydrocarbon
  • the ester with a compound having one carboxyl group replacing the hydrogen atom of the hydrogen portion (hereinafter sometimes referred to as “compound (A)”) has the above-mentioned kinematic viscosity, water retention rate and weight average molecular weight As long as it has, not all hydroxyl groups may be esterified.
  • Examples of the compound (A1) having a chain hydrocarbon portion and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon portion include
  • linear hydrocarbon tetraols such as alkanetetraols such as pentaerythritol
  • linear hydrocarbon triols such as alkanetriols such as glycerin
  • linear hydrocarbon diols such as alkanediols such as glycol Can be mentioned.
  • (A2) As a compound having a chain hydrocarbon portion and one carboxyl group replacing a hydrogen atom of the chain hydrocarbon portion, for example, one hydrogen atom on a hydrocarbon is one carboxyl group ( And -COOH) substituted compounds such as fatty acids.
  • the compound (A) include an ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid, an ester of (a 2 ) chain hydrocarbon triol and at least one fatty acid, and (a 3 And esters of linear hydrocarbon diols and at least one fatty acid.
  • Ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid As an ester of a chain hydrocarbon tetraol and at least one fatty acid, for example, the following formula (1): Tetraester of pentaerythritol with fatty acid, the following formula (2): Triester of pentaerythritol with fatty acid, the following formula (3): A diester of pentaerythritol with fatty acid, the following formula (4): And monoesters of fatty acid with pentaerythritol. (Wherein, R 1 to R 4 are each a chain hydrocarbon)
  • esters of pentaerythritol and fatty acids have kinematic viscosity, water retention and weight average
  • saturated fatty acids such as C 2 -C 30 saturated fatty acids such as acetic acid (C 2 ) (C 2 represents a carbon number
  • R 1 is not particularly limited as long as it satisfies the molecular weight requirements.
  • propanoic acid C 3
  • butanoic acid C 4
  • isomers thereof for example, 2-methylpropanoic acid ( C 4 ), pentanoic acid (C 5 ) and its isomers, such as 2-methylbutanoic acid (C 5 ), 2,2-dimethylpropanoic acid (C 5 ), hexanoic acid (C 6 ), heptanoic acid (C 7) ), octanoic acid (C 8) Beauty isomers thereof, e.g., 2-ethylhexanoic acid (C 8), nonanoic acid (C 9), decanoic acid (C 10), dodecanoic acid (C 12), tetradecanoic acid (C 14), hexadecanoic acid (C 16) , Heptadecanoic acid (C 17 ), octa
  • the fatty acids can also be unsaturated fatty acids.
  • unsaturated fatty acids include C 3 -C 20 unsaturated fatty acids, such as monounsaturated fatty acids such as crotonic acid (C 4 ), myristoleic acid (C 14 ), palmitoleic acid (C 16 ), olein Acid (C 18 ), elaidic acid (C 18 ), vacenic acid (C 18 ), gadeuric acid (C 20 ), eicosenic acid (C 20 ), etc., diunsaturated fatty acids such as linoleic acid (C 18 ), eicosadiene Acid (C 20 ), etc., triunsaturated fatty acids such as linolenic acid, eg ⁇ -linolenic acid (C 18 ) and ⁇ -linolenic acid (C 18 ), pinolenic acid (C 18 ), eleostearic acid, eg , ⁇ -eleostearic acid
  • Tetra-unsaturated fatty acids eg, stear Don acid (C 20), arachidonic acid (C 20), eicosatetraenoic acid (C 20), etc., penta unsaturated fatty acids, for example, bosseopentaenoic acid (C 18), such as eicosapentaenoic acid (C 20), as well as their Partially hydrogenated adducts of
  • An ester of pentaerythritol and a fatty acid is preferably an ester of pentaerythritol and a fatty acid derived from a saturated fatty acid, that is, an ester of pentaerythritol and a saturated fatty acid, considering the possibility of modification by oxidation etc. .
  • ester of pentaerythritol and fatty acid it is preferable that it is diester, triester or tetraester from the viewpoint of reducing the value of water retention rate, and it is more preferable that it is triester or tetraester, and tetraester More preferably, it is an ester.
  • the total carbon number of fatty acids constituting the tetraester of pentaerythritol and fatty acid ie, the above formula In (1), the total carbon number of the R 1 C, R 2 C, R 3 C and R 4 C moieties is preferably about 15 (when the total carbon number is 15, the IOB is 0. It becomes 60).
  • Examples of tetra-esters of pentaerythritol and fatty acid include pentaerythritol, hexanoic acid (C 6 ), heptanoic acid (C 7 ), octanoic acid (C 8 ), such as 2-ethylhexanoic acid (C 8 ), nonane Acid (C 9 ), decanoic acid (C 10 ) and / or tetraester with dodecanoic acid (C 12 ) are mentioned.
  • the total carbon number of fatty acids constituting the triester of pentaerythritol and fatty acid ie, the above formula In (2), the total carbon number of the R 1 C, R 2 C and R 3 C moieties is preferably about 19 or more (when the total carbon number is 19, the IOB is 0.58) ).
  • the total carbon number of fatty acids constituting the diester of pentaerythritol and fatty acid ie, the above formula (3)
  • the total carbon number of the R 1 C and R 2 C moieties is about 22 or more (when the total carbon number is 22, the IOB is 0.59).
  • the carbon number of the fatty acid constituting the monoester of pentaerythritol and fatty acid that is, the above formula (4)
  • the carbon number of the R 1 C moiety is about 25 or more (when the carbon number is 25, the IOB is 0.60).
  • the effects of double bond, triple bond, iso branch, and tert branch are not considered (the same applies hereinafter).
  • esters of pentaerythritol and fatty acid examples include Unistar H-408 BRS, H-2408 BRS-22 (mixed product) and the like (all manufactured by NOF Corporation).
  • Ester of (a 2 ) chain hydrocarbon triol and at least one fatty acid As an ester of a linear hydrocarbon triol and at least one fatty acid, for example, the following formula (5): Triester of glycerin and fatty acid, the following formula (6): And a diester of fatty acid with glycerin and the following formula (7): (Wherein, each of R 5 to R 7 is a chain hydrocarbon) And monoesters of glycerin and fatty acids.
  • esters of glycerin and fatty acids satisfy the requirements of dynamic viscosity, water retention and weight average molecular weight
  • examples thereof include fatty acids listed in “ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid”, that is, saturated fatty acids and unsaturated fatty acids, oxidation, etc.
  • it is preferable to use an ester of glycerin and a fatty acid derived from a saturated fatty acid that is, an ester of glycerin and a saturated fatty acid.
  • ester of glycerol and a fatty acid it is preferable that it is a diester or a triester from a viewpoint of making the value of water retention rate small, and it is more preferable that it is a triester.
  • the triester of glycerin and fatty acid is also referred to as triglyceride, for example, triester of glycerin and octanoic acid (C 8 ), triester of glycerin and decanoic acid (C 10 ), glycerin and dodecanoic acid (C 12 ) And triesters of glycerin and two or three fatty acids, and mixtures thereof.
  • triesters of glycerin and two or more fatty acids include triesters of glycerin with octanoic acid (C 8 ) and decanoic acid (C 10 ), glycerin, octanoic acid (C 8 ), decanoic acid Triester with (C 10 ) and dodecanoic acid (C 12 ), glycerin and octanoic acid (C 8 ), decanoic acid (C 10 ), dodecanoic acid (C 12 ), tetradecanoic acid (C 14 ), hexadecanoic acid (C 10 ) Examples thereof include triesters with C 16 ) and octadecanoic acid (C 18 ).
  • the triester of glycerin and a fatty acid is the total carbon number of fatty acids constituting the triester of glycerin and a fatty acid, that is, in the formula (5), R 5 C
  • the sum of the carbon numbers of the R 6 C and R 7 C moieties is about 40 or less.
  • the total carbon number of fatty acids constituting the triester of glycerin and fatty acid ie, the formula (5)
  • the total carbon number of the R 5 C, R 6 C, and R 7 C moieties is about 12 or more (when the total carbon number is 12, the IOB is 0.60).
  • Triester of glycerin and a fatty acid is a so-called fat and is a component that can constitute the human body, and thus is preferable from the viewpoint of safety.
  • triester of glycerin and fatty acid include tricotic oil fatty acid glyceride, NA36, panaseto 800, panaseto 800B and panaceto 810S, and tri C2L oil fatty acid glyceride and tri CL oil fatty acid glyceride (manufactured by NOF Corporation) Etc.
  • the diester of glycerin and fatty acid is also referred to as diglyceride, for example, a diester of glycerin and decanoic acid (C 10 ), a diester of glycerin and dodecanoic acid (C 12 ), a diester of glycerin and hexadecanoic acid (C 16 ) And diesters of glycerin with two fatty acids, and mixtures thereof.
  • the total carbon number of fatty acids constituting the diester of glycerin and fatty acid that is, in the formula (6), the total carbon number of the R 5 C and R 6 C moieties is preferably about 16 or more (when the total carbon number is 16, the IOB is 0.58).
  • the monoester of glycerin and fatty acid is also referred to as monoglyceride, and examples thereof include octadecanoic acid (C 18 ) monoester of glycerin, docosanoic acid (C 22 ) monoester of glycerin and the like.
  • the carbon number of the fatty acid constituting the monoester of glycerin and fatty acid that is, in the formula (7), the carbon number of the R 5 C portion is preferably about 19 or more (when the carbon number is 19, the IOB is 0.59).
  • Ester of (a 3 ) chain hydrocarbon diol and at least one fatty acid for example, a C 2 to C 6 linear hydrocarbon diol, for example, a C 2 to C 6 glycol, such as ethylene glycol, propylene glycol, butylene glycol And mono- or diesters of pentylene glycol or hexylene glycol with a fatty acid.
  • a linear hydrocarbon diol and at least one fatty acid for example, a C 2 to C 6 linear hydrocarbon diol, for example, a C 2 to C 6 glycol, such as ethylene glycol, propylene glycol, butylene glycol And mono- or diesters of pentylene glycol or hexylene glycol with a fatty acid.
  • R 8 COOC k H 2k OCOR 9 (8) (Wherein k is an integer of 2 to 6 and R 8 and R 9 are each a chain hydrocarbon) And a diester of a C 2 -C 6 glycol and a fatty acid, and the following formula (9): R 8 COOC k H 2k OH (9) (Wherein k is an integer of 2 to 6 and R 8 is a chain hydrocarbon) And monoesters of fatty acid with C 2 -C 6 glycol.
  • Examples of the fatty acid to be esterified in the ester of C 2 -C 6 glycol and fatty acid include C 2 -C 6 glycol and The ester with fatty acid is not particularly limited as long as it satisfies the requirements of dynamic viscosity, water content and weight average molecular weight, for example, “(a 1 ) chain hydrocarbon tetraol and at least one fatty acid
  • the fatty acids listed in "Ester" that is, saturated fatty acids and unsaturated fatty acids are mentioned, and considering the possibility of modification by oxidation etc., saturated fatty acids are preferred.
  • the carbon number of the R 8 C and R 9 C moiety is Is preferably about 6 or more (when the total carbon number is 6, the IOB is 0.60).
  • the carbon number of the R 8 C moiety is about It is preferable that it is 12 or more (when the carbon number is 12, the IOB is 0.57).
  • esters of C 2 ⁇ C 6 glycols and fatty acid in view of the potential for degradation by oxidation and the like, derived from saturated fatty acids, esters of C 2 ⁇ C 6 glycols and fatty acid, Nachi Suwa, C 2 ⁇ It is preferably an ester of C 6 glycol and a saturated fatty acid.
  • esters of C 2 -C 6 glycols and fatty acids esters of glycols and fatty acids derived from glycols having a large number of carbon atoms, for example, butylene glycol, pentylene, from the viewpoint of reducing the water retention rate. It is preferable that it is ester of glycol and fatty acid derived from glycol or hexylene glycol. Furthermore, as the ester of C 2 -C 6 glycol and fatty acid, a diester is preferable from the viewpoint of reducing the water retention rate. Examples of commercially available esters of C 2 -C 6 glycol and fatty acid include Commol BL, Commol BS (all manufactured by NOF Corporation) and the like.
  • (B) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, a chain Ether with compound having one hydroxyl group replacing hydrogen atom of hydrocarbon moiety
  • (B) A compound having (B1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and a chain hydrocarbon
  • An ether with a compound having one hydroxyl group replacing a hydrogen atom of a hydrogen portion (hereinafter sometimes referred to as “compound (B)”) has the above-mentioned kinematic viscosity, water retention rate and weight average molecular weight As long as it has, not all hydroxyl groups may be etherified.
  • compound (B1) a compound having a chain hydrocarbon portion and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon portion (hereinafter, may be referred to as “compound (B1)”), Those listed as the compound (A1) in the “compound (A)” include, for example, pentaerythritol, glycerin and glycol.
  • Examples of (B2) a compound having a chain hydrocarbon portion and one hydroxyl group replacing a hydrogen atom of the chain hydrocarbon portion include, for example, Compounds in which one hydrogen atom of hydrocarbon is substituted with one hydroxyl group (—OH), for example, aliphatic monohydric alcohols such as saturated aliphatic monohydric alcohols and unsaturated aliphatic monohydric alcohols It can be mentioned.
  • a saturated aliphatic monohydric alcohol for example, a C 1 to C 20 saturated aliphatic monohydric alcohol, for example, methyl alcohol (C 1 ) (C 1 represents a carbon number, the same applies hereinafter), ethyl alcohol (C 2 ), propyl alcohol (C 3 ) and its isomers such as isopropyl alcohol (C 3 ), butyl alcohol (C 4 ) and its isomers such as sec-butyl alcohol (C 4 ) and tert-butyl alcohol ( C 4 ), pentyl alcohol (C 5 ), hexyl alcohol (C 6 ), heptyl alcohol (C 7 ), octyl alcohol (C 8 ) and isomers thereof, such as 2-ethylhexyl alcohol (C 8 ), nonyl alcohol ( C 9), decyl alcohol (C 10), dodecyl alcohol (C 12), tetradecyl alcohol (C 14), hexyl Decyl alcohol (
  • an ether of (b 1 ) chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol for example, monoether, diether, triether and tetraether, preferably diether, triether Ethers and tetraethers, more preferably triethers and tetraethers, and still more preferably tetraethers, ethers of (b 2 ) chain hydrocarbon triol and at least one aliphatic monohydric alcohol, such as monoethers, diethers and the like Triethers, preferably diethers and triethers, and more preferably triethers, and ethers of (b 3 ) chain hydrocarbon diol and at least one aliphatic monohydric alcohol, such as monoethers and diethers, and preferably Diether It is below.
  • ether of a chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol for example, the following formulas (10) to (13): (Wherein, each of R 10 to R 13 is a chain hydrocarbon). And tetraethers of pentaerythritol and aliphatic monohydric alcohols, triethers, diethers and monoethers.
  • ethers of chain hydrocarbon triol and at least one aliphatic monohydric alcohol include the following formulas (14) to (16): (Wherein, R 14 to R 16 are each a chain hydrocarbon). And triethers of glycerin and aliphatic monohydric alcohols, diethers and monoethers.
  • R 17 OC n H 2n OR 18 (Wherein n is an integer of 2 to 6 and R 17 and R 18 are each a chain hydrocarbon) Diethers of C 2 -C 6 glycols and aliphatic monohydric alcohols, and the following formula (18): R 17 OC n H 2n OH (18) (Wherein n is an integer of 2 to 6 and R 17 is a chain hydrocarbon) And monoethers of C 2 -C 6 glycols and aliphatic monohydric alcohols.
  • an aliphatic 1 constituting a tetraether of pentaerythritol and aliphatic monohydric alcohol is used.
  • the total carbon number of the polyhydric alcohol that is, the total of the carbon numbers of the R 10 , R 11 , R 12 and R 13 moieties in the above formula (10) is preferably about 4 or more (the total carbon number is In the case of 4, the IOB is 0.44).
  • an aliphatic 1 constituting the triether of pentaerythritol and aliphatic monohydric alcohol is used.
  • the sum of carbon number of the polyhydric alcohol that is, the sum of carbon numbers of R 10 , R 11 and R 12 in the above formula (11) is preferably about 9 or more (when the total carbon number is 9) ,
  • the IOB is 0.57).
  • an aliphatic monohydric alcohol constituting a diether of pentaerythritol and aliphatic monohydric alcohol.
  • the sum of the carbon numbers of R 10 and R 11 in the above formula (12) is preferably about 15 or more (when the total carbon number is 15, IOB is 0 It becomes .60).
  • aliphatic 1 constituting the monoether of pentaerythritol and aliphatic monohydric alcohol
  • the carbon number of the polyhydric alcohol is preferably about 22 or more (when the carbon number is 22, the IOB is 0.59).
  • an aliphatic 1 constituting the triether of glycerin and aliphatic monohydric alcohol is about 3 or more (when the total carbon number is 3) , IOB is 0.50).
  • an aliphatic monohydric alcohol constituting a monoether of glycerin and aliphatic monohydric alcohol
  • the carbon number of R 14 in the formula (16) is preferably about 16 or more (when the carbon number is 16, the IOB is 0.58).
  • the compound (B) can be produced by dehydration condensation of the compound (B1) and the compound (B2) in the presence of an acid catalyst.
  • (C1) a linear hydrocarbon moiety and a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing 2 to 4 carboxyl groups replacing the hydrogen atom of the linear hydrocarbon moiety (hereinafter referred to as “compound (C1 ))
  • a linear hydrocarbon carboxylic acid having 2 to 4 carboxyl groups such as a linear hydrocarbon dicarboxylic acid, such as an alkane dicarboxylic acid, such as ethanedioic acid, Propanedioic acid, butanedioic acid, pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid, nonanedioic acid and decanedioic acid, linear hydrocarbon tricarboxylic acids such as alkanetricarboxylic acids such as propane triacid Butane triacid, pentane
  • a linear hydrocarbon hydroxy acid having 2 to 4 carboxyl groups for example, a linear chain having 2 to 4 carboxyl groups, such as malic acid, tartaric acid, citric acid, isocitric acid, etc.
  • Hydrocarbon alkoxy acids such as O-acetylcitric acid, and linear hydrocarbon oxoacids with 2 to 4 carboxyl groups are included.
  • Examples of the compound having (C2) a chain hydrocarbon portion and one hydroxyl group replacing a hydrogen atom of the chain hydrocarbon portion include those listed in the “compound (B)”, for example, fat And monohydric monohydric alcohols.
  • an ester of (c 1 ) chain hydrocarbon tetracarboxylic acid having 4 carboxyl groups, a hydroxy acid, an alkoxy acid or an oxo acid, and at least one aliphatic monohydric alcohol for example, Mono-, di-, tri- and tetra-esters, preferably diesters, tri- and tetra-esters, more preferably tri- and tetra-esters, and still more preferably tetra-esters, chained with 3 (c 2 ) carboxyl groups
  • Esters of hydrocarbon tricarboxylic acids, hydroxy acids, alkoxy acids or oxo acids with at least one aliphatic monohydric alcohol such as monoesters, diesters and triesters, preferably diesters and triesters, and more preferably triesters ,
  • an ether As an aliphatic monohydric alcohol constituting an ether (corresponding to R 19 OH and R 20 OH in the formula (19)), an ether satisfying the above-mentioned requirements for the kinematic viscosity, water content and weight average molecular weight It is not particularly limited, and examples thereof include aliphatic monohydric alcohols listed in the section "Compound (B)".
  • dialkyl ketone As the dialkyl ketone, the following formula (20): R 21 COR 22 (20) (Wherein, each of R 21 and R 22 is an alkyl group) And compounds having the formula:
  • the dialkyl ketone is commercially available and can be obtained by a known method, for example, by oxidizing a secondary alcohol with chromic acid or the like.
  • Examples of the fatty acid constituting the ester include, for example, fatty acids listed in “ester of (a 1 ) chain hydrocarbon tetraol and fatty acid”, ie, Saturated fatty acids or unsaturated fatty acids are mentioned, and in consideration of the possibility of modification by oxidation etc., saturated fatty acids are preferred.
  • Examples of the aliphatic monohydric alcohol constituting the ester include, for example, the aliphatic monohydric alcohols listed in the “compound (B)” section.
  • esters of fatty acids and aliphatic monohydric alcohols include, for example, esters of dodecanoic acid (C 12 ), dodecyl alcohol (C 12 ), tetradecanoic acid (C 14 ), and dodecyl alcohol (C 12 )
  • esters of fatty acid and aliphatic monohydric alcohol include Electol WE20 and Electol WE40 (all manufactured by NOF Corporation).
  • dialkyl carbonates can be synthesized by the reaction of phosgene with alcohol, the reaction of formic acid chloride with alcohol or alcoholate, and the reaction of silver carbonate with alkyl iodide.
  • the weight average molecular weight is preferably about 100 or more, and more preferably about 200 or more.
  • the total carbon number is about 8, for example, 5-nonanone
  • the melting point is about ⁇ 50 ° C.
  • the vapor pressure is about 230 Pa at 20 ° C.
  • Examples of (E) polyoxy C 3 -C 6 alkylene glycol, or an alkyl ester or alkyl ether thereof include (e 1 ) polyoxy C 3 -C 6 alkylene glycol, (e 2 ) Esters of polyoxy C 3 -C 6 alkylene glycol and at least one fatty acid, and (e 3 ) ethers of polyoxy C 3 -C 6 alkylene glycol and at least one aliphatic monohydric alcohol. This will be described below.
  • the polyoxy C 3 -C 6 alkylene glycol has the following formula (23): HO- (C m H 2m O) n -H (23) (In the formula, m is an integer of 3 to 6) Is represented by
  • poly C 3 -C 6 alkylene glycols include, for example, Uniol (trademark) PB-500 and PB-700 (manufactured by NOF Corporation).
  • ester of (e 2 ) polyoxy C 3 -C 6 alkylene glycol with at least one fatty acid As ester of polyoxy C 3 -C 6 alkylene glycol and at least one fatty acid, OH terminal of polyoxy C 3 -C 6 alkylene glycol described in the section “(e 1 ) polyoxy C 3 -C 6 alkylene glycol” One or both may be esterified with fatty acids, ie, monoesters and diesters.
  • the fatty acid to be esterified is, for example, listed in “ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid”.
  • Fatty acids that is, saturated fatty acids or unsaturated fatty acids, and in view of the possibility of modification by oxidation etc., saturated fatty acids are preferred.
  • aliphatic monohydric alcohol in the ether of polyoxy C 3 -C 6 alkylene glycol and at least one aliphatic monohydric alcohol, as aliphatic monohydric alcohol to be etherified, for example, aliphatic listed in the “compound (B)” section Monohydric alcohol is mentioned.
  • the chain hydrocarbon includes, for example, (f 1 ) chain alkanes, such as straight chain alkanes and branched alkanes.
  • Linear alkanes have a carbon number of about 22 or less when the melting point is about 45 ° C. or less, and a carbon number of about 13 when the vapor pressure is about 0.01 Pa or less at 1 atmosphere and 25 ° C. It becomes above.
  • Branched alkanes tend to have lower melting points at the same carbon number than linear alkanes.
  • branched alkanes can also contain those having 22 or more carbons, even when the melting point is about 45 ° C. or less.
  • a blood slipping agent may be coated alone on at least the convex portion 8 in the discharge port abutting region 20, or contains the blood slipping agent and at least one other component.
  • the blood slipping agent-containing composition may be coated.
  • the blood slipping agent-containing composition contains the above-described blood slipping agent and at least one other component.
  • the other components are not particularly limited as long as they do not inhibit the action and effect of the blood slipping agent, and materials conventionally applied to absorbent articles, particularly top sheets in the art can be used. .
  • silicone oil silicone oil, silicone, silicone resin etc. are mentioned, for example.
  • antioxidants such as BHT (2,6-di-t-butyl-p-cresol), BHA (butylated hydroxyanisole), propyl gallate and the like.
  • vitamins such as natural or synthetic vitamins.
  • vitamins for example, water-soluble vitamins, such as vitamin B group, such as vitamin B 1, vitamin B 2, vitamin B 3, vitamin B 5, vitamin B 6, vitamin B 7, vitamin B 9, Vitamin B 12, etc.
  • vitamin C for example, water-soluble vitamins, such as vitamin B group, such as vitamin B 1, vitamin B 2, vitamin B 3, vitamin B 5, vitamin B 6, vitamin B 7, vitamin B 9, Vitamin B 12, etc.
  • vitamins examples include fat-soluble vitamins such as vitamin A group, vitamin D group, vitamin E group, and vitamin K group. Vitamins also include their derivatives.
  • amino acids such as, for example, alanine, arginine, lysine, histidine, proline, hydroxyproline and the like, as well as peptides.
  • zeolites such as natural zeolites, such as, for example, chabazite, chabazite, fluorite, natrolite, sodalite and somsonite, as well as synthetic zeolites.
  • Other components include, for example, cholesterol, hyaluronic acid, lecithin, ceramide and the like.
  • Other components include, for example, drugs such as skin astringent agents, anti-acne agents, anti-wrinkle agents, anti-cellulite agents, skin-whitening agents, antibacterial agents, antifungal agents and the like.
  • drugs such as skin astringent agents, anti-acne agents, anti-wrinkle agents, anti-cellulite agents, skin-whitening agents, antibacterial agents, antifungal agents and the like.
  • Examples of the skin astringent agent include oil-soluble skin astringent agents such as zinc oxide, aluminum sulfate, tannic acid and the like, for example, oil-soluble polyphenols.
  • oil-soluble polyphenols include natural oil-soluble polyphenols, such as, for example, ginseng extract, hypericillium extract, prickly pear extract, kamomira extract, burdock extract, salvia extract, linden extract, bromeliad extract, birch extract, cedar extract, sage extract, salvia extract, Teuchichumimi extract, hibiscus extract, loquat leaf extract, bodaiji extract, hop extract, marronier extract, yokinin extract and the like.
  • anti-acne agent examples include salicylic acid, benzoyl peroxide, resorcinol, sulfur, erythromycin, zinc and the like.
  • anti-wrinkle agents examples include lactic acid, salicylic acid, salicylic acid derivatives, glycolic acid, phytic acid, lipoic acid and lysophosphatidic acid.
  • anti-cellulite agents examples include xanthine compounds such as aminophylline, caffeine, theophylline, theobromine and the like.
  • Examples of the skin lightening agent include niacinamide, kojic acid, arbutin, glucosamine and derivatives, phytosterol derivatives, ascorbic acid and its derivatives, and mulberry extract and placenta extract.
  • Other components include, for example, anti-inflammatory ingredients, pH adjusters, antibacterial agents, moisturizers, perfumes, dyes, dyes, pigments, plant extracts and the like.
  • anti-inflammatory component examples include naturally-occurring anti-inflammatory agents such as, for example, button, gogon, hyperglossia, chamomile, licorice, peach tree, sage extract, etc .
  • pH adjusters include those for keeping the skin weakly acidic, such as malic acid, succinic acid, citric acid, tartaric acid, lactic acid and the like.
  • a titanium oxide is mentioned, for example.
  • the blood slipping agent-containing composition preferably comprises about 50 to about 99% by weight and about 1 to about 50% by weight, more preferably about 60% by weight of the blood slipping agent and at least one other component, respectively.
  • By weight still more preferably about 90 to 99% by weight and about 1 to about 10% by weight, still more preferably about 95 to 99% by weight and about 1 to about 5% by weight. It is from the viewpoint of the effect of the blood slipping agent and other components.
  • the blood slipping agent-containing composition preferably contains a surfactant in an amount equal to or less than the amount derived from the hydrophilization treatment of the top sheet or the second sheet. More specifically, the blood slipping agent-containing composition preferably contains a surfactant, preferably about 0.0 to about 1.0 g / m 2 , more preferably about 0.0 to about 0.8 g / m 2 2 , more preferably in the range of a basis weight of about 0.1 to about 0.5 g / m 2 , still more preferably about 0.1 to about 0.3 g / m 2 .
  • the blood slipping agent-containing composition preferably contains water, preferably about 0.0 to about 1.0 g / m 2 , more preferably about 0.0 to about 0.8 g / m 2 , still more preferably about 0.
  • a basis weight ranging from 1 to about 0.5 g / m 2 , even more preferably from about 0.1 to about 0.3 g / m 2 is included. Water is preferably low to reduce the absorption performance of the absorbent article.
  • the blood slipping agent-containing composition like the blood slipping agent, preferably has a kinematic viscosity of about 0 to about 80 mm 2 / s at 40 ° C. as a composition, and about 1 to about 70 mm 2. It is more preferred to have a kinematic viscosity of 1 / s, even more preferred to have a kinematic viscosity of about 3 to about 60 mm 2 / s, and even more preferred to have a kinematic viscosity of about 5 to about 50 mm 2 / s, Even more preferably, they have a kinematic viscosity of 7 to about 45 mm 2 / s.
  • the kinematic viscosity of the blood slipping agent-containing composition exceeds about 80 mm 2 / s, the viscosity is high and the blood slipping agent composition is an absorbent article together with menstrual blood reaching the skin contact surface of the top sheet. Because it tends to be difficult to slip inside.
  • the other components preferably have a weight average molecular weight of less than about 1,000. Preferably, it has a weight average molecular weight of less than about 900.
  • the weight average molecular weight is about 1,000 or more, the blood slipping agent-containing composition itself is tacky and tends to cause discomfort to the wearer.
  • the weight average molecular weight is high, the viscosity of the blood slipping agent-containing composition tends to increase, so that the viscosity of the blood slipping agent composition is lowered to a viscosity suitable for application by heating. Can be difficult, and as a result, the blood slipping agent may occur if it has to be diluted with a solvent.
  • the blood slipping agent-containing composition has, as a composition, a water retention rate of about 0.01 to about 4.0% by weight, and a water retention rate of about 0.02 to about 3.5% by weight More preferably about 0.03 to about 3.0% by weight, more preferably about 0.04 to about 2.5% by weight, and more preferably about It is further preferred to have a water retention of 0.05 to about 2.0% by weight.
  • the affinity between the blood slipping agent composition and menstrual blood decreases, and menstrual blood that has reached the skin contact surface of the top sheet tends not to slip off inside the absorbent article. There is.
  • the blood slipping agent-containing composition contains a solid, it is preferable to remove them by filtration in the measurement of the kinematic viscosity and the water retention rate.
  • Triethylene CL oil fatty acid glycerides, manufactured by NOF Corporation C 8 fatty acid: fatty acid of C 12 is approximately included in a weight ratio of 44:56, triesters of glycerin and fatty acid, the weight average molecular weight: about 570
  • -Panaceto 800 B manufactured by NOF Corporation Triester of glycerin and fatty acid in which all fatty acids are 2-ethylhexanoic acid (C 8 ), weight average molecular weight: about 470 NA36, manufactured by NOF Corporation C 16 fatty acids: C 18 fatty acids: C 20 fatty acids (including both saturated fatty acids and unsaturated fatty acids) in a weight ratio of approximately 5: 92: 3, Triester of glycerin and fatty acid, weight average molecular weight: about 880
  • Tricot oil fatty acid glyceride manufactured by NOF Corporation C 8 fatty acid: C 10 fatty acid: C 12 fatty acid: C 14 fatty acid: C 16 fatty acid (including both saturated fatty acid and unsaturated fatty acid) is approximately 4 Triester of glycerin and fatty acid, contained in a weight ratio of 8: 60: 25: 3, weight average molecular weight: 670 ⁇ Caprylic diglyceride, manufactured by NOF Corporation Diester of glycerin and fatty acid wherein fatty acid is octanoic acid, weight average molecular weight: 340
  • Uniol PB500 polybutylene glycol manufactured by NOF Corporation, weight average molecular weight: about 500
  • Uniol PB700 manufactured by NOF Corporation, polyoxybutylene polyoxypropylene glycol, weight average molecular weight: about 700
  • weight average molecular weight about 880 (Caprylic acid / capric acid) monoglyceride, monoester of glycerin and fatty acid, which contains octanoic acid (C 8 ) and decanoic acid (C 10 ) manufactured by NOF Corporation at
  • Uniol D-400 a polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 400 Uniol D-700, a polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 700 Uniol D-1000, a polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1,000 Uniol D-1200, polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1,160
  • Uniol D-2000 a polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 2,030 Uniol D-3000, a polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 3,000 Uniol D-4000, polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 4,000
  • -PEG 1500 polyethylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1,500 to about 1,600 ⁇ Wilbright cp 9, a compound in which OH groups at both ends of polybutylene glycol manufactured by NOF Corporation were esterified with hexadecanoic acid (C 16 ), weight average molecular weight: about 1,150 ⁇ Unileub MS-70K, stearyl ether of polypropylene glycol manufactured by NOF Corporation, about 15 repeating units, weight average molecular weight: about 1,140
  • Nonion S-6 manufactured by NOF Corporation, polyoxyethylene monostearate, repeating unit of about 7 weight average molecular weight: about 880 ⁇ Unileve 5TP-300KB Polyoxyethylene polyoxypropylene pentaerythritol ether, weight average molecular weight: 4,130, produced by adding 5 moles of ethylene oxide and 65 moles of propylene oxide to 1 mole of pentaerythritol.
  • UNIOL TG-1000 glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 16 repeating units, weight average molecular weight: about 1,000 ⁇ UNIOL TG-3000, glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 16 repeating units, weight average molecular weight: about 3,000 ⁇ UNIOL TG-4000, glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 16 repeating units, weight average molecular weight: about 4,000
  • Unirube DGP-700 a diglyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 9 repeating units, weight average molecular weight: about 700 -Uniox HC60, manufactured by NOF Co., Ltd. polyoxyethylene hydrogenated castor oil, weight average molecular weight: about 3,570 ⁇ Vaseline, Cognis Japan Ltd. Petroleum derived hydrocarbon, semi-solid
  • Test Example 2 [Persistence rate of menstrual blood when absorbing a large amount of blood A] An experiment was conducted to evaluate the absorbability when the sanitary napkin absorbs a large amount of blood at one time.
  • a top sheet formed of an air through non-woven fabric (composite fiber consisting of polyester and polyethylene terephthalate, basis weight: 35 g / m 2 ) treated with a hydrophilic agent, and an air through non-woven fabric (composite fiber consisting of polyester and polyethylene terephthalate, basis weight: 30 g) / M 2 ), pulp (basis weight: 150 to 450 g / m 2 , more in the central part), acrylic superabsorbent polymer (basis weight: 15 g / m 2 ) and tissue as core wrap An absorbent, a water repellent-treated side sheet, and a back sheet made of polyethylene film were prepared.
  • the top sheet is a top sheet having a ridged groove structure manufactured according to the method described in Japanese Patent Application Laid-Open No. 2008-2034.
  • the thickness of the ridge portion is about 1.5 mm, and the thickness of the groove portion is about 0. It had a diameter of 4 mm, a pitch of the weir structure (the width of the ridge + the width of the groove) of about 4 mm, and the groove had an opening with an opening ratio of about 15%.
  • H-408 BRS manufactured by NOF Corporation, tetraester of pentaerythritol and fatty acid
  • the skin contact surface of the top sheet ⁇ ⁇ ⁇
  • the groove surface was coated at a basis weight of 5.0 g / m 2 .
  • H-408 BRS was in the form of fine particles and adhered to the surface of the fiber.
  • the back sheet, the absorbent body, the second sheet, and the top sheet are sequentially stacked with the ridged surface up, sanitary napkin No. 1 It formed 1-1.
  • the blood slipping agent was changed from Unistar H-408 BRS to that shown in Table 2, and sanitary napkin No. 1-2 to No. 1-49 were manufactured. If the blood slipping agent is liquid at room temperature, heat as it is, and if the blood slipping agent is solid at room temperature, heat to a melting point + 20 ° C, and then use a control seam HMA gun. The blood slipping agent was atomized and applied to the skin contact surface of the top sheet so that the basis weight was approximately 5 g / m 2 . In addition, the blood slipping agent was applied to almost the entire surface of the skin contact surface of the top sheet, and to both the ridges and grooves.
  • Top sheet weight After measuring W 2 (g) (weight of top sheet before test), an acrylic plate with holes opened on the center of the absorbent article in the longitudinal direction and width direction and on the top sheet ( Place a 200 mm ⁇ 100 mm, 125 g, 40 mm ⁇ 10 mm hole in the center, and from the above hole, equine EDTA blood at 37 ⁇ 1 ° C. (to the blood of the horse, for prevention of coagulation ethylenediaminetetraacetic acid (In which "EDTA" was added) (4.0 g) was dropped using a pipette.
  • W 2 weight of top sheet before test
  • an acrylic plate with holes opened on the center of the absorbent article in the longitudinal direction and width direction and on the top sheet Place a 200 mm ⁇ 100 mm, 125 g, 40 mm ⁇ 10 mm hole in the center, and from the above hole, equine EDTA blood at 37 ⁇ 1 ° C. (to the blood of the horse, for prevention of coagulation
  • tackiness of the skin contact surface of the top sheet was measured at 35 ° C. according to the following criteria. ⁇ : no tackiness ⁇ : some tackiness ⁇ : tackiness
  • FIG. 6 shows an electron micrograph of the skin contact surface of the top sheet in the sanitary napkin in which the top sheet contains avian C2L oil fatty acid glyceride.
  • Sanitary napkin No. 1 having no blood slipping agent.
  • the surface residual rate A was 7.5% by mass
  • the sanitary napkin No. 1-1 to No. It is suggested that menstrual blood can be rapidly transferred from the top sheet to the absorber when a large amount of menstrual blood reaches the top sheet at one time.
  • a top sheet having a ridge and groove structure manufactured according to the method described in Japanese Patent Application Laid-Open No. 2008-2034 was used, but the blood slip property imparting agent is a ridge and groove structure manufactured by another method. Also in the case of using a top sheet having the same or when using a top sheet having a concavo-convex structure other than the groin structure, the blood slipping action is similarly exhibited, and menstrual blood can be rapidly transferred from the top sheet to the absorber. It is considered possible.
  • a top sheet (hereinafter sometimes referred to as "the top sheet having ridges") formed of an air through non-woven fabric (composite fiber made of polyester and polyethylene terephthalate, basis weight: 35 g / m 2 ) treated with a hydrophilic agent
  • a second sheet formed of an air through non-woven fabric (composite fiber made of polyester and polyethylene terephthalate, basis weight: 30 g / m 2 ), pulp (basis weight: 150 to 450 g / m 2 , more in the central part), acrylic type
  • An absorbent containing an absorbent polymer (basis weight: 15 g / m 2 ) and a tissue as a core wrap, a water repellent-treated side sheet, and a back sheet comprising a polyethylene film were prepared.
  • the top sheet is a top sheet having a ridged groove structure manufactured according to the method described in Japanese Patent Application Laid-Open No. 2008-2034.
  • the thickness of the ridge portion is about 1.5 mm, and the thickness of the groove portion is about 0. It had a diameter of 4 mm, a pitch of the weir structure (the width of the ridge + the width of the groove) of about 4 mm, and the groove had an opening with an opening ratio of about 15%.
  • H-408 BRS manufactured by NOF Corporation, tetraester of pentaerythritol and fatty acid
  • the skin contact surface of the top sheet ⁇ ⁇ ⁇
  • the groove surface was coated at a basis weight of 5.0 g / m 2 .
  • H-408 BRS was in the form of fine particles and adhered to the surface of the fiber.
  • the back sheet, the absorbent body, the second sheet, and the top sheet are sequentially stacked with the ridged surface up, sanitary napkin No. 1 Form 2-1 (i).
  • Top sheet (hereinafter referred to as "flat") formed of a flat, hydrophilic agent-treated non-woven air-through non-woven fabric (composite fiber made of polyester and polyethylene terephthalate, basis weight: 35 g / m 2 ) having no ridge and groove structure (Sometimes referred to as “top sheet”) except for the sanitary napkin No. In the same manner as 2-1 (i), sanitary napkin No. Form 2-1 (ii).
  • the blood slipping agent was changed from Unistar H-408 BRS to that shown in Table 3, and sanitary napkin No. 2-2 (i) to no. 2-11 (i) and no. 2-2 (ii) to no. 2-11 (ii) were manufactured. If the blood slipping agent is liquid at room temperature, heat as it is, and if the blood slipping agent is solid at room temperature, heat to a melting point + 20 ° C, and then use a control seam HMA gun. The blood slipping agent was atomized and applied to the skin contact surface of the top sheet so that the basis weight was approximately 5 g / m 2 . In addition, the blood slipping agent was applied to almost the entire surface of the skin contact surface of the top sheet, and in the case of the top sheet having the furrow structure, on both the groin and the groove.
  • Top sheet weight After measuring W 4 (g) (the weight of the top sheet before testing), 37 ⁇ 1 ° C. horse EDTA blood on the central top sheet in the longitudinal direction and width direction of the absorbent article About 0.25 g (2 drops) was dropped from the pipette. In the top sheet having a furrow, equine EDTA blood was dropped on the top of the buttocks.
  • a top sheet having a ridge and groove structure manufactured according to the method described in Japanese Patent Application Laid-Open No. 2008-2034 was used, but the blood slip property imparting agent is a ridge and groove structure manufactured by another method. Also in the case of using a top sheet having the same or when using a top sheet having a concavo-convex structure other than the groin structure, the blood slipping action is similarly exhibited, and menstrual blood can be rapidly transferred from the top sheet to the absorber. It is considered possible.
  • Example 4 [Viscosity of blood containing blood slipping agent]
  • the viscosity of the blood containing the blood slipping agent was measured using Rheometric Expansion System ARES (Rheometric Scientific, Inc). 2% by weight of Panaceto 810s was added to equine defibrinated blood, the mixture was lightly stirred to form a sample, the sample was loaded on a parallel plate of 50 mm in diameter, the gap was made 100 ⁇ m, and the viscosity was measured at 37 ⁇ 0.5 ° C. . Because of the parallel plate, the sample was not subjected to a uniform shear rate, but the average shear rate displayed on the instrument was 10 s ⁇ 1 .
  • the viscosity of equine defibrinated blood containing 2% by mass of Panaceto 810s was 5.9 mPa ⁇ s, while the viscosity of equine defibrillated blood containing no blood slipping agent was 50.4 mPa ⁇ s. Accordingly, it can be seen that equine defibrinated blood containing 2% by mass of Panaceto 810s reduces the viscosity by about 90% as compared to the case without the blood slipping agent.
  • Blood contains components such as blood cells and is known to have thixotropy properties, but the blood slipping agent of the present disclosure also has the effect of lowering the viscosity of blood such as menstrual blood in a low viscosity region. It is considered to have. By reducing the viscosity of blood, it is considered that absorbed menstrual blood is likely to be rapidly transferred from the top sheet to the absorber.
  • Example 5 [Micrograph of blood containing blood slipping agent] A healthy volunteer's menstrual blood is collected on a food protection wrap film, and a portion of it is Panaceto 810s dispersed in 10 times the mass of phosphate buffered saline, and the concentration of Panaceto 810s is 1% by mass. It added so that it might become. The menstrual blood was applied to a slide glass, covered with a cover glass, and the condition of red blood cells was observed with a light microscope. A photomicrograph of menstrual blood containing no blood slipping agent is shown in FIG. 7 (a), and a photomicrograph of menstrual blood containing PANACET 810s is shown in FIG. 7 (b).
  • red blood cells form a lump such as ritsusen, but in menstrual blood containing PANACET 810s, the red blood cells are dispersed stably. I understand that. Therefore, it is suggested that the blood slipping agent also has the function of stabilizing red blood cells in blood.
  • Test Example 6 Surface tension of blood containing blood slipping agent
  • the surface tension of blood containing a blood slipping agent was measured by a pendant drop method using a contact angle meter Drop Master 500 manufactured by Kyowa Interface Science.
  • the surface tension was measured after adding a predetermined amount of a blood slipping agent to sheep defibrinated blood and shaking sufficiently. The measurement is automatically performed by the device, but the surface tension ⁇ is obtained by the following equation (see FIG. 8).
  • the density ⁇ is 5 of “density test method and density / mass / volume conversion table” of JIS K 2249-1995. It was measured at the temperature shown in Table 4 below according to the vibrational density test method. For measurement, DA-505 of Kyoto Electronics Industries Ltd. was used. The results are shown in Table 4 below.
  • the blood slipping agent also has the effect of lowering the surface tension of blood.
  • the surface tension of the blood it is considered that the absorbed blood can be rapidly transferred to the absorber without being held between the fibers of the top sheet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Absorbent Articles And Supports Therefor (AREA)

Abstract

The present invention addresses the problem of providing an absorbent article wherein it is possible to prevent the exposure of liquid absorbed by an absorbent body. In order to solve said problem, the present invention provides a sanitary napkin (1) provided with a top sheet (2), a back sheet (3), and an absorbent body (4) disposed between the top sheet (2) and the back sheet (3), wherein: the top sheet (2) has multiple cut opening parts (51), which penetrate the top sheet (2), at least on an excretory orifice contact region (20) of a skin contact surface; the absorbent body (4) has absorbent concave parts (52) which lead to each cut opening part (51); and top sheet fragments created when forming the cut opening parts (51) cover the bottom parts (522) of the absorbent concave parts (52).

Description

吸収性物品Absorbent articles
 本発明は、吸収性物品に関する。 The present invention relates to an absorbent article.
 従来の吸収性物品として、表面層から吸収層にかけて複数の凹部が形成された吸収性物品が知られている(例えば、特許文献1)。 As a conventional absorbent article, an absorbent article in which a plurality of recesses are formed from the surface layer to the absorbent layer is known (for example, Patent Document 1).
特開2000-333992号公報JP 2000-333992 A
 しかしながら、特許文献1に記載の吸収性物品では、凹部の側部及び底部に表面層が存在しないため、吸収体に吸収された体液が凹部の底部から露出し、着用者に不快感を与える。 However, in the absorbent article described in Patent Document 1, since there is no surface layer on the side and bottom of the recess, the body fluid absorbed by the absorber is exposed from the bottom of the recess, causing discomfort to the wearer.
 そこで、本発明は、吸収体に吸収された液体の露出を防止することができる吸収性物品を提供することを目的とする。 Then, an object of this invention is to provide the absorbent article which can prevent the exposure of the liquid absorbed by the absorber.
 上記課題を解決するために、本発明は、肌当接面を有する液透過性のトップシートと、非肌当接面を有する液不透過性のバックシートと、前記トップシート及び前記バックシートの間に設けられた吸収体とを備えた吸収性物品であって、前記トップシートが、前記肌当接面のうち少なくとも排泄口当接領域に、前記トップシートを貫通する複数の切断開口部を有し、前記吸収体が、前記複数の切断開口部のそれぞれに通じる吸収体凹部を有し、前記切断開口部の形成の際に生じたトップシート断片が、前記吸収体凹部の底部を被覆している、前記吸収性物品である。 In order to solve the above problems, the present invention provides a liquid-permeable top sheet having a skin contact surface, a liquid-impermeable back sheet having a non-skin contact surface, and the top sheet and the back sheet. An absorbent article comprising: an absorbent body provided between, wherein the top sheet is provided with a plurality of cutting openings penetrating the top sheet at least on an excretory opening contact region of the skin contact surface. Said absorber has an absorber recess leading to each of said plurality of cutting openings, and a top sheet fragment produced in forming said cutting openings covers the bottom of said absorber recess The absorbent article.
 本発明によれば、吸収体に吸収された液体の露出を防止することができる吸収性物品が提供される。 According to the present invention, an absorbent article is provided which can prevent the exposure of the liquid absorbed by the absorbent.
図1は、本発明の吸収性物品の一実施形態に係る生理用ナプキンの部分破断平面図である。FIG. 1 is a partially broken plan view of a sanitary napkin according to an embodiment of the absorbent article of the present invention. 図2(a)は、図1のA-A線断面であり、図2(b)は、図1の一部拡大図である。2 (a) is a cross section taken along line AA of FIG. 1, and FIG. 2 (b) is a partially enlarged view of FIG. 図3は、トップシートに切断開口部を形成し、吸収体に凹部を形成する方法の一例を説明するための図である。FIG. 3: is a figure for demonstrating an example of the method of forming a cutting opening part in a top sheet, and forming a recessed part in an absorber. 図4(a)及び(b)はエンボス加工の一例を説明するための図である。FIG. 4A and FIG. 4B are diagrams for explaining an example of embossing. 図5は、エンボス加工後の積層体(トップシート及び吸収体)の電子顕微鏡写真である。FIG. 5 is an electron micrograph of the laminate (top sheet and absorber) after embossing. 図6は、トップシートがトリC2L油脂肪酸グリセリドを含む生理用ナプキンにおける、トップシートの肌当接面の電子顕微鏡写真である。FIG. 6 is an electron micrograph of the skin contact surface of the top sheet in the sanitary napkin in which the top sheet contains avian C2L oil fatty acid glyceride. 図7は、血液滑性付与剤を含む又は含まない経血の顕微鏡写真である。FIG. 7 is a photomicrograph of menstrual blood with or without a blood slipping agent. 図8は、表面張力の測定方法を説明するための図である。FIG. 8 is a diagram for explaining a method of measuring surface tension.
 以下、本発明について説明する。
 態様1Aに係る吸収性物品は、肌当接面を有する液透過性のトップシートと、非肌当接面を有する液不透過性のバックシートと、前記トップシート及び前記バックシートの間に設けられた吸収体とを備えた吸収性物品であって、前記トップシートが、前記肌当接面のうち少なくとも排泄口当接領域に、前記トップシートを貫通する複数の切断開口部を有し、前記吸収体が、前記複数の切断開口部のそれぞれに通じる吸収体凹部を有し、前記切断開口部の形成の際に生じたトップシート断片が、前記吸収体凹部の底部を被覆している、前記吸収性物品である。
Hereinafter, the present invention will be described.
The absorbent article according to aspect 1A is provided between a liquid-permeable top sheet having a skin contact surface, a liquid-impermeable back sheet having a non-skin contact surface, and the top sheet and the back sheet. An absorbent article, wherein the top sheet has a plurality of cutting openings penetrating the top sheet, at least in an excretory opening contact region of the skin contact surface, The absorber has an absorber recess leading to each of the plurality of cutting openings, and a top sheet fragment produced in forming the cutting openings covers the bottom of the absorber recess. It is the said absorbent article.
 態様1Aに係る吸収性物品の好ましい態様(態様2A)では、前記トップシートのうち、前記切断開口部の周囲部分が高密度化している。 In a preferred aspect (Aspect 2A) of the absorbent article according to Aspect 1A, the peripheral portion of the cutting opening in the top sheet is densified.
 態様1A又は2Aに係る吸収性物品の好ましい態様(態様3A)では、前記トップシートが複数の層からなり、前記複数の層が前記切断開口部の周囲部分で相互に圧着されている。 In a preferred embodiment (Aspect 3A) of the absorbent article according to Embodiment 1A or 2A, the top sheet is composed of a plurality of layers, and the plurality of layers are crimped to each other at peripheral portions of the cutting opening.
 態様1A~3Aのいずれかに係る吸収性物品の好ましい態様(態様4A)では、前記吸収体に含有される吸収性材料が、前記吸収体凹部の側部から露出している。 In a preferable aspect (Aspect 4A) of the absorbent article according to any one of the aspects 1A to 3A, the absorbent material contained in the absorber is exposed from the side portion of the absorber recess.
 態様1A~4Aのいずれかに係る吸収性物品の好ましい態様(態様5A)では、前記トップシート断片が、前記吸収体凹部の底部と圧着している。 In a preferred embodiment (Aspect 5A) of the absorbent article according to any of Embodiments 1A to 4A, the top sheet fragment is crimped to the bottom of the absorber recess.
 態様1A~5Aのいずれかに係る吸収性物品の好ましい態様(態様6A)では、前記排泄口当接領域のうち少なくとも前記切断開口部の周囲部分に、40℃における動粘度が0.01~80mm2/s、抱水率が0.01~4.0質量%、重量平均分子量が1,000未満である血液滑性付与剤が塗工されている。 In a preferred embodiment (Aspect 6A) of the absorbent article according to any one of Embodiments 1A to 5A, the kinematic viscosity at 40 ° C. is 0.01 to 80 mm at least in the peripheral portion of the cutting opening contact region. A blood slipping agent having a water-retaining rate of 0.01 to 4.0% by mass and a weight average molecular weight of less than 1,000 is applied.
 態様6Aに係る吸収性物品の好ましい態様(態様7A)では、前記血液滑性付与剤のIOBが、0.00~0.60のIOBである。 In a preferred embodiment (Aspect 7A) of the absorbent article according to Embodiment 6A, the IOB of the blood slipping agent is an IOB of 0.00 to 0.60.
 態様6A又は7Aに係る吸収性物品の好ましい態様(態様8A)では、前記血液滑性付与剤が、次の(i)~(iii):
 (i)炭化水素、
 (ii) (ii-1)炭化水素部分と、(ii-2)前記炭化水素部分のC-C単結合間に挿入された、カルボニル基(-CO-)及びオキシ基(-O-)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、及び
 (iii) (iii-1)炭化水素部分と、(iii-2)前記炭化水素部分のC-C単結合間に挿入された、カルボニル基(-CO-)及びオキシ基(-O-)から成る群から選択される、一又は複数の、同一又は異なる基と、(iii-3)前記炭化水素部分の水素原子を置換する、カルボキシル基(-COOH)及びヒドロキシル基(-OH)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、
 並びにそれらの任意の組み合わせから成る群から選択される(ここで、(ii)又は(iii)の化合物において、オキシ基が2つ以上挿入されている場合には、各オキシ基は隣接していない)。
In a preferred embodiment (Aspect 8A) of the absorbent article according to the embodiment 6A or 7A, the blood slipping agent is any one of the following (i) to (iii):
(I) Hydrocarbons,
(Ii) from a carbonyl group (-CO-) and an oxy group (-O-) inserted between (ii-1) a hydrocarbon moiety and (ii-2) a C-C single bond of the hydrocarbon moiety A compound having one or more same or different groups selected from the group consisting of: (iii) (iii-1) a hydrocarbon moiety, and (iii-2) a C—C single bond of the hydrocarbon moiety And one or more, same or different group (s) selected from the group consisting of carbonyl group (—CO—) and oxy group (—O—) inserted between (iii-3) A compound having one or more and the same or different groups selected from the group consisting of a carboxyl group (—COOH) and a hydroxyl group (—OH) which substitutes a hydrogen atom,
And any combination thereof (wherein in the compound of (ii) or (iii), when two or more oxy groups are inserted, each oxy group is not adjacent) ).
 態様6A~8Aのいずれかに係る吸収性物品の好ましい態様(態様9A)では、前記血液滑性付与剤が、次の(i’)~(iii’):
 (i’)炭化水素、
 (ii’) (ii’-1)炭化水素部分と、(ii’-2)前記炭化水素部分のC-C単結合間に挿入された、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)、及びエーテル結合(-O-)から成る群から選択される、一又は複数の、同一又は異なる結合とを有する化合物、及び
 (iii’) (iii’-1)炭化水素部分と、(iii’-2)前記炭化水素部分のC-C単結合間に挿入された、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)、及びエーテル結合(-O-)から成る群から選択される、一又は複数の、同一又は異なる結合と、(iii’-3)前記炭化水素部分の水素原子を置換する、カルボキシル基(-COOH)及びヒドロキシル基(-OH)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、
 並びにそれらの任意の組み合わせから成る群から選択される(ここで、(ii’)又は(iii’)の化合物において、2以上の同一又は異なる結合が挿入されている場合には、各結合は隣接していない)。
In a preferred embodiment (Aspect 9A) of the absorbent article according to any of the Embodiments 6A to 8A, the blood slipping agent is selected from the following (i ′) to (iii ′):
(I ') hydrocarbons,
(Ii ') (ii'-1) a hydrocarbon moiety, and (ii'-2) a carbonyl bond (-CO-), an ester bond (-COO) inserted between a C-C single bond of the hydrocarbon moiety -), A compound having one or more same or different bonds selected from the group consisting of carbonate bond (-OCOO-) and ether bond (-O-), and (iii ') (iii'-) 1) A carbonyl bond (-CO-), an ester bond (-COO-), a carbonate bond (-OCOO) inserted between a hydrocarbon moiety and (iii'-2) a C-C single bond of the hydrocarbon moiety -), And one or more same or different bonds selected from the group consisting of an ether bond (-O-) and (iii'-3) a carboxyl group replacing the hydrogen atom of the hydrocarbon moiety (iii'-3) -COOH) and hydroxyl A compound having one or more, same or different groups, selected from the group consisting of sil groups (—OH),
And any combination thereof (wherein in the compound (ii ') or (iii'), when two or more identical or different bonds are inserted, each bond is adjacent) Not).
 態様6A~9Aのいずれかに係る吸収性物品の好ましい態様(態様10A)では、前記血液滑性付与剤が、次の(A)~(F):
 (A) (A1)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(A2)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する1個のカルボキシル基とを有する化合物とのエステル、
 (B) (B1)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(B2)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエーテル、
 (C) (C1)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する、2~4個のカルボキシル基とを含むカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、(C2)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエステル、
 (D)鎖状炭化水素部分と、前記鎖状炭化水素部分のC-C単結合間に挿入された、エーテル結合(-O-)、カルボニル結合(-CO-)、エステル結合(-COO-)、及びカーボネート結合(-OCOO-)から成る群から選択されるいずれか1つの結合とを有する化合物、
 (E)ポリオキシC3~C6アルキレングリコール、又はそのアルキルエステル若しくはアルキルエーテル、及び
 (F)鎖状炭化水素、
 並びにそれらの任意の組み合わせから成る群から選択される。
In a preferred embodiment (Aspect 10A) of the absorbent article according to any one of the Embodiments 6A to 9A, the blood slipping agent is any one of the following (A) to (F):
(A) A compound having (A1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms of the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and the chain Ester with a compound having one carboxyl group replacing the hydrogen atom of the cyclic hydrocarbon moiety,
(B) a compound having (B1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the chain Ether with a compound having one hydroxyl group replacing the hydrogen atom of the cyclic hydrocarbon moiety,
(C) a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing a (C1) linear hydrocarbon moiety and 2 to 4 carboxyl groups replacing the hydrogen atom of the linear hydrocarbon moiety; C2) an ester of a compound having a chain hydrocarbon moiety and one hydroxyl group replacing a hydrogen atom of the chain hydrocarbon moiety,
(D) an ether bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO-) inserted between a chain hydrocarbon moiety and a C-C single bond of the chain hydrocarbon moiety ), And a compound having any one bond selected from the group consisting of carbonate bonds (—OCOO—),
(E) Polyoxy C 3 -C 6 alkylene glycol, or an alkyl ester or alkyl ether thereof, and (F) a chain hydrocarbon,
And any combination thereof.
 態様6A~10Aのいずれかに係る吸収性物品の好ましい態様(態様11A)では、前記血液滑性付与剤が、(a1)鎖状炭化水素テトラオールと少なくとも1の脂肪酸とのエステル、(a2)鎖状炭化水素トリオールと少なくとも1の脂肪酸とのエステル、(a3)鎖状炭化水素ジオールと少なくとも1の脂肪酸とのエステル、(b1)鎖状炭化水素テトラオールと少なくとも1の脂肪族1価アルコールとのエーテル、(b2)鎖状炭化水素トリオールと少なくとも1の脂肪族1価アルコールとのエーテル、(b3)鎖状炭化水素ジオールと少なくとも1の脂肪族1価アルコールとのエーテル、(c1)4個のカルボキシル基を有する鎖状炭化水素テトラカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、(c2)3個のカルボキシル基を有する鎖状炭化水素トリカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、(c3)2個のカルボキシル基を有する鎖状炭化水素ジカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、(d1)脂肪族1価アルコールと脂肪族1価アルコールとのエーテル、(d2)ジアルキルケトン、(d3)脂肪酸と脂肪族1価アルコールとのエステル、(d4)ジアルキルカーボネート、(e1)ポリオキシC3~C6アルキレングリコール、(e2)ポリオキシC3~C6アルキレングリコールと少なくとも1の脂肪酸とのエステル、(e3)ポリオキシC3~C6アルキレングリコールと少なくとも1の脂肪族1価アルコールとのエーテル、及び(f1)鎖状アルカン、並びにそれらの任意の組み合わせから成る群から選択される。 In a preferable embodiment (embodiment 11A) of the absorbent article according to any one of the embodiments 6A to 10A, the blood slipping agent is an ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid, (a 2 ) Ester of linear hydrocarbon triol and at least one fatty acid, ester of (a 3 ) linear hydrocarbon diol and at least one fatty acid, (b 1 ) linear hydrocarbon tetraol and at least one aliphatic Ether with monohydric alcohol, ether of (b 2 ) chain hydrocarbon triol and at least one aliphatic monohydric alcohol, ether of (b 3 ) chain hydrocarbon diol and at least one aliphatic monohydric alcohol , (c 1) chain hydrocarbon tetracarboxylic acids having 4 carboxyl groups, hydroxy acid, alkoxy acid or oxo acid, at least one aliphatic Esters of an alcohol, (c 2) a chain hydrocarbon tricarboxylic acids having 3 carboxyl groups, esters of hydroxy acids, alkoxy acid or oxoacid, and at least one aliphatic monohydric alcohol, (c 3) 2 (C 1 ) aliphatic monohydric alcohol and aliphatic monohydric alcohol, ester of linear hydrocarbon dicarboxylic acid having one carboxyl group, hydroxy acid, alkoxy acid or oxo acid with at least one aliphatic monohydric alcohol With ether, (d 2 ) dialkyl ketone, (d 3 ) ester of fatty acid and aliphatic monohydric alcohol, (d 4 ) dialkyl carbonate, (e 1 ) polyoxy C 3 -C 6 alkylene glycol, (e 2 ) esters of polyoxy C 3 ~ C 6 alkylene glycol and at least one fatty acid, (e 3) polyoxy C 3 ~ C 6 a Sharp glycol and at least one aliphatic monohydric ethers of alcohols, and (f 1) a chain alkane, and is selected from the group consisting of any combination thereof.
 態様6A~11Aのいずれかに係る吸収性物品の好ましい態様(態様12A)では、前記血液滑性付与剤が、1気圧及び40℃において、0.00~0.01Paの蒸気圧を有する。 In a preferred embodiment (Aspect 12A) of the absorbent article according to any of Embodiments 6A to 11A, the blood slipping agent has a vapor pressure of 0.00 to 0.01 Pa at 1 atmospheric pressure and 40 ° C.
 態様1Bに係る製造方法は、トップシート及び吸収体の積層体をエンボス加工して、前記トップシートを貫通して前記吸収体に至る凹部を形成する工程を含む、吸収性物品の製造方法であって、前記エンボス加工が、前記トップシートに切断開口部を形成する段階と、前記切断開口部の形成の際に生じたトップシート断片を前記凹部の底部に圧着させる段階とを含む、前記製造方法である。 The manufacturing method according to aspect 1B is a manufacturing method of an absorbent article, including a step of embossing a laminate of a top sheet and an absorbent to form a recess penetrating the top sheet to reach the absorbent. Said manufacturing method comprising the steps of: forming the cutting opening in the top sheet; and pressing the top sheet fragment generated in forming the cutting opening onto the bottom of the recess. It is.
 態様1Bに係る製造方法の好ましい態様(態様2B)では、前記エンボス加工に、複数の突起が設けられた外周面を有する突起ロールと、平滑な外周面を有するプレーンロールが使用され、前記積層体が前記突起ロールと前記プレーンロールとの間を通過する際、前記突起の剪断力によって前記トップシートに前記切断開口部が形成されるとともに、前記突起の前記吸収体への圧入によって前記凹部の底部に前記トップシート断片が圧着される。 In a preferred embodiment (embodiment 2B) of the manufacturing method according to embodiment 1B, a protrusion roll having an outer peripheral surface provided with a plurality of protrusions and a plain roll having a smooth outer peripheral surface are used for the embossing. When the sheet passes between the projecting roll and the plain roll, the shearing force of the projection forms the cutting opening in the top sheet, and the projection is pressed into the absorber by the bottom of the recess. The top sheet fragments are crimped onto the
 本発明の吸収性物品において、2種以上の態様を組み合わせることができる。 In the absorbent article of the present invention, two or more types of embodiments can be combined.
 本発明の吸収性物品の種類及び用途は特に限定されない。吸収性物品としては、例えば、生理用ナプキン、パンティーライナー等の衛生用品・生理用品が挙げられ、これらはヒトを対象としてもよいし、ペット等のヒト以外の動物を対象としてもよい。吸収性物品が吸収対象とする液体は特に限定されないが、主として、経血等の液状排泄物である。
 以下、生理用ナプキンを例とし、図面に基づいて、本発明の吸収性物品の実施形態を説明する。
The type and use of the absorbent article of the present invention are not particularly limited. Examples of the absorbent articles include sanitary products and sanitary products such as sanitary napkins and panty liners, which may be humans or non-human animals such as pets. The liquid to be absorbed by the absorbent article is not particularly limited, but is mainly liquid excrement such as menstrual blood.
Hereinafter, taking a sanitary napkin as an example, an embodiment of the absorbent article of the present invention will be described based on the drawings.
 本発明の吸収性物品の一実施形態に係る生理用ナプキン1は、図1及び図2に示すように、液体透過性のトップシート2と、液体不透過性のバックシート3と、トップシート2及びバックシート3の間に設けられた吸収体4と、トップシート2を貫通して吸収体4に至る凹部5とを備える。 A sanitary napkin 1 according to one embodiment of the absorbent article of the present invention is, as shown in FIGS. 1 and 2, a liquid-permeable top sheet 2, a liquid-impermeable back sheet 3, and a top sheet 2. And an absorbent body 4 provided between the back sheet 3 and a recess 5 penetrating the top sheet 2 to reach the absorbent body 4.
 図1において、X軸方向は生理用ナプキン1の幅方向に、Y軸方向は生理用ナプキン1の長手方向に、X軸Y軸方向に広がる平面の方向は生理用ナプキン1の平面方向に相当する。他の図においても同様である。 In FIG. 1, the X axis direction corresponds to the width direction of the sanitary napkin 1, the Y axis direction corresponds to the longitudinal direction of the sanitary napkin 1, and the direction of the plane spreading in the X axis Y axis direction corresponds to the plane direction of the sanitary napkin 1. Do. The same applies to the other figures.
 生理用ナプキン1は、経血等の液状排泄物を吸収する目的で着用される。この際、トップシート2が着用者の肌側に、バックシート3が着用者の着衣(下着)側に位置するように着用される。経血等の液状排泄物は、トップシート2を透過して吸収体4に至り、吸収体4で吸収・保持される。吸収体4で吸収・保持される液状排泄物の漏れは、バックシート3によって防止される。 The sanitary napkin 1 is worn for the purpose of absorbing liquid excrement such as menstrual blood. At this time, the top sheet 2 is worn on the skin side of the wearer and the back sheet 3 is located on the clothes (underwear) side of the wearer. Liquid excrement such as menstrual blood passes through the top sheet 2 to reach the absorber 4, and is absorbed and held by the absorber 4. Leakage of liquid excrement absorbed and held by the absorber 4 is prevented by the back sheet 3.
 図1に示すように、トップシート2及びバックシート3は、長手方向の端部同士がシール部11a,11bによって接合され、本体部6を形成するとともに、幅方向の端部同士がシール部12a,12bによって接合され、本体部6から幅方向に延出する略矩形状のウイング部7a,7bを形成している。 As shown in FIG. 1, the top sheet 2 and the back sheet 3 have their longitudinal ends joined by the sealing portions 11a and 11b to form the main body 6, and the widthwise ends have the sealing portions 12a. , 12b to form substantially rectangular wing portions 7a, 7b extending in the width direction from the main body portion 6.
 本体部6の形状は、着用者の身体、下着等に適合する範囲で適宜調整することができ、本体部6の形状としては、例えば、略長方形、略楕円形、略瓢箪形等が挙げられる。本体部6の長手方向の延べ寸法は、通常100~500mm、好ましくは150~350mmであり、本体部6の幅方向の延べ寸法は、通常30~200mm、好ましくは40~180mmである。 The shape of the main body portion 6 can be appropriately adjusted within a range that suits the wearer's body, underwear and the like, and the shape of the main body portion 6 includes, for example, a substantially rectangular shape, a substantially elliptical shape, a substantially wedge shape or the like . The longitudinal dimension of the main body portion 6 is usually 100 to 500 mm, preferably 150 to 350 mm, and the transverse dimension of the main body portion 6 is usually 30 to 200 mm, preferably 40 to 180 mm.
 シール部11a,11b,12a,12bによる接合様式としては、例えば、エンボス加工、超音波、ホットメルト型接着剤等が挙げられる。接合強度を高めるために、2種以上の接合様式を組み合わせてもよい(例えば、ホットメルト型接着剤による接合後に、エンボス加工を施す等)。 Examples of the bonding method by the seal portions 11a, 11b, 12a, 12b include embossing, ultrasonic waves, and a hot melt adhesive. In order to enhance the bonding strength, two or more bonding modes may be combined (for example, after bonding with a hot melt adhesive, embossing, etc.).
 エンボス加工としては、例えば、パターニングされた凸部を有するエンボスロールとフラットロールとの間に、トップシート2及びバックシート3を合わせて通過させてエンボス加工する方法(いわゆるラウンドシールと呼ばれる方法)等が挙げられる。この方法では、エンボスロール及び/又はフラットロールの加熱により、各シートが軟化するため、シール部が明瞭になりやすい。エンボスパターンとしては、例えば、格子状パターン、千鳥状パターン、波状パターン等が挙げられる。 As the embossing, for example, a method in which the top sheet 2 and the back sheet 3 are combined and passed between an embossing roll having a patterned convex portion and a flat roll (a method called a so-called round seal), etc. Can be mentioned. In this method, heating of the emboss roll and / or the flat roll softens the respective sheets, so that the seal portion tends to be clear. As an embossing pattern, a lattice-like pattern, a zigzag pattern, a wavelike pattern etc. are mentioned, for example.
 ホットメルト接着剤としては、例えば、スチレン-エチレン-ブタジエン-スチレン(SEBS)、スチレン-ブタジエン-スチレン(SBS)、スチレン-イソプレン-スチレン(SIS)等のゴム系を主体とした、又は直鎖状低密度ポリエチレン等のオレフィン系を主体とした感圧型接着剤又は感熱型接着剤;水溶性高分子(例えば、ポリビニルアルコール、カルボキシルメチルセルロース、ゼラチン等)又は水膨潤性高分子(例えば、ポリビニルアセテート、ポリアクリル酸ナトリウム等)からなる感水性接着剤等が挙げられる。接着剤の塗工方法としては、例えば、スパイラル塗工、コーター塗工、カーテンコーター塗工、サミットガン塗工等が挙げられる。 As a hot melt adhesive, for example, a rubber-based material such as styrene-ethylene-butadiene-styrene (SEBS), styrene-butadiene-styrene (SBS), styrene-isoprene-styrene (SIS) or the like, or linear Pressure-sensitive adhesives or thermosensitive adhesives mainly composed of olefins such as low density polyethylene; water-soluble polymers (eg, polyvinyl alcohol, carboxyl methyl cellulose, gelatin etc.) or water-swellable polymers (eg, polyvinyl acetate, poly And water-sensitive adhesives made of sodium acrylate etc.). As a coating method of an adhesive agent, spiral coating, coater coating, curtain coater coating, summit gun coating etc. are mentioned, for example.
 図2に示すように、ウイング部7a,7bを形成するバックシート3の着衣側には、粘着部13a,13bが設けられており、本体部6を形成するバックシート3の着衣側には、粘着部13cが設けられている。粘着部13cが下着のクロッチ部に貼付されるとともに、ウイング部7a,7bが下着の外面側に折り曲げられ、粘着部13a,13bが下着のクロッチ部に貼付されることにより、生理用ナプキン1は下着に安定して固定される。 As shown in FIG. 2, adhesive parts 13 a and 13 b are provided on the clothes side of the back sheet 3 forming the wing parts 7 a and 7 b, and on the clothes side of the back sheet 3 forming the main body part 6 The adhesion part 13c is provided. The sanitary napkin 1 is made by sticking the adhesive portion 13c to the crotch portion of the undergarment, bending the wing portions 7a and 7b to the outer surface side of the undergarment, and sticking the adhesive portions 13a and 13b to the crotch portion of the undergarment. It is stably fixed to the underwear.
 粘着部13a,13b,13cに含有される粘着剤としては、例えば、スチレン-エチレン-ブチレン-スチレンブロック共重合体、スチレン-ブチレン重合体、スチレン-ブチレン-スチレンブロック共重合体、スチレン-イソブチレン-スチレン共重合体等のスチレン系ポリマー;C5系石油樹脂、C9系石油樹脂、ジシクロペンタジエン系石油樹脂、ロジン系石油樹脂、ポリテルペン樹脂、テルペンフェノール樹脂等の粘着付与剤;リン酸トリフレシル、フタル酸ジブチル、フタル酸ジオクチル等のモノマー可塑剤;ビニル重合体、ポリエステル等のポリマー可塑剤等が挙げられる。 Examples of the adhesive contained in the adhesive portions 13a, 13b and 13c include styrene-ethylene-butylene-styrene block copolymer, styrene-butylene polymer, styrene-butylene-styrene block copolymer, styrene-isobutylene- Styrene polymers such as styrene copolymer; C5 petroleum resin, C9 petroleum resin, dicyclopentadiene petroleum resin, rosin petroleum resin, polyterpene resin, tackifier such as terpene phenol resin, etc .; Monomer plasticizers such as dibutyl and dioctyl phthalate; and polymer plasticizers such as vinyl polymers and polyesters.
 図1及び図2に示すように、トップシート2は、肌当接面側に設けられた第1層21と、非肌当接面側に設けられた第2層22とを有する。第1層21及び第2層22は、それぞれ液透過性を有する。これにより、トップシート2は全体として液透過性を有し、経血等の液状排泄物が透過可能となっている。 As shown in FIG.1 and FIG.2, the top sheet 2 has the 1st layer 21 provided in the skin contacting surface side, and the 2nd layer 22 provided in the non-skin-contacting surface side. The first layer 21 and the second layer 22 each have liquid permeability. Thereby, the top sheet 2 has liquid permeability as a whole, and can permeate liquid excrement such as menstrual blood.
 第1層21の一方の面は肌当接面である。第1層21の他方の面には、第2層22が積層されており、トップシート2は2層構造となっている。トップシート2は、第1層21及び第2層22に加えて、1又は2以上の第3層を有していてもよい。第2層22が第1層21の非肌当接面側に設けられる限り、第3層が設けられる位置は特に限定されない。例えば、第1層21と第2層22との間に1又は2以上の第3層を設けてもよいし、第2層22の第1層21側と反対側の面に1又は2以上の第3層を設けてもよい。 One surface of the first layer 21 is a skin contact surface. The second layer 22 is laminated on the other surface of the first layer 21, and the top sheet 2 has a two-layer structure. The top sheet 2 may have one or more third layers in addition to the first layer 21 and the second layer 22. As long as the second layer 22 is provided on the non-skin contact surface side of the first layer 21, the position at which the third layer is provided is not particularly limited. For example, one or more third layers may be provided between the first layer 21 and the second layer 22, or one or more on the surface of the second layer 22 opposite to the first layer 21 side. A third layer of
 第1層21及び第2層22は、経血等の液状排泄物が透過可能である限り特に限定されない。第1層21及び第2層22としては、例えば、不織布、液透過孔が形成され合成樹脂フィルム、合成樹脂フィルムと不織布との積層体等が挙げられるが、好ましくは、不織布である。トップシート2が、第1層21及び第2層22に加えて、1又は2以上の第3層を有する場合、第3層の具体例としても同様のものが挙げられる。 The first layer 21 and the second layer 22 are not particularly limited as long as liquid excrement such as menstrual blood can be permeated. Examples of the first layer 21 and the second layer 22 include nonwoven fabrics, synthetic resin films in which liquid permeation holes are formed, and laminates of synthetic resin films and nonwoven fabrics, and the like, with preference given to nonwoven fabrics. When the top sheet 2 includes one or more third layers in addition to the first layer 21 and the second layer 22, similar ones may be mentioned as specific examples of the third layer.
 不織布としては、例えば、エアースルー不織布、ヒートボンド不織布、スパンボンド不織布、メルトブローン不織布、スパンレース不織布、ニードルパンチ不織布等が挙げられる。不織布を構成する繊維としては、例えば、天然繊維(羊毛,コットン等)、再生繊維(レーヨン,アセテート等)、無機繊維(ガラス繊維,炭素繊維等)、合成樹脂繊維(ポリエチレン、ポリプロピレン、ポリブチレン、エチレン-酢酸ビニル共重合体、エチレン-アクリル酸エチル共重合体、エチレン-アクリル酸共重合体、アイオノマー樹脂等のポリオレフィン;ポリエチレンテレフタレート、ポリブチレンテレフタラート、ポリトリメチレンテレフタラート、ポリ乳酸等のポリエステル;ナイロン等のポリアミド)等が挙げられる。不織布を構成する繊維の形態としては、例えば、芯・鞘型繊維、サイド・バイ・サイド型繊維、島/海型繊維等の複合繊維;中空タイプの繊維;扁平、Y型、C型等の異型繊維;潜在捲縮又は顕在捲縮の立体捲縮繊維;水流、熱、エンボス加工等の物理的負荷により分割する分割繊維等が挙げられる。不織布を構成する繊維の繊度は、好ましくは1~20dtex、さらに好ましくは1.5~4dtexである。 Examples of the non-woven fabric include an air through non-woven fabric, a heat-bonded non-woven fabric, a spun-bonded non-woven fabric, a melt-blown non-woven fabric, a spun lace non-woven fabric, and a needle punched non-woven fabric. Examples of fibers constituting the non-woven fabric include natural fibers (such as wool and cotton), regenerated fibers (such as rayon and acetate), inorganic fibers (such as glass fibers and carbon fibers), and synthetic resin fibers (such as polyethylene, polypropylene, polybutylene, and ethylene). -Polyolefins such as vinyl acetate copolymer, ethylene-ethyl acrylate copolymer, ethylene-acrylic acid copolymer, ionomer resin, etc .; Polyester such as polyethylene terephthalate, polybutylene terephthalate, polytrimethylene terephthalate, polylactic acid, etc. And polyamides such as nylon). The form of the fibers constituting the non-woven fabric is, for example, composite fibers such as core-sheath type fibers, side-by-side type fibers, island / sea type fibers; hollow type fibers; flat type, Y type, C type etc Atypical fibers; three-dimensional crimped fibers of latent crimp or manifest crimp; split fibers divided by physical load such as water flow, heat, embossing, etc. may be mentioned. The fineness of the fibers constituting the non-woven fabric is preferably 1 to 20 dtex, more preferably 1.5 to 4 dtex.
 第1層21及び第2層22の厚み、坪量等は、凹部5の形成性等を考慮して適宜調整することができる。厚みは、通常0.1~5mm、好ましくは0.5~2mmであり、坪量は、通常10~50g/m2、好ましくは20~40g/m2である。 The thickness, basis weight and the like of the first layer 21 and the second layer 22 can be appropriately adjusted in consideration of the formability of the recess 5 and the like. The thickness is usually 0.1 to 5 mm, preferably 0.5 to 2 mm, and the basis weight is usually 10 to 50 g / m 2 , preferably 20 to 40 g / m 2 .
 第2層22の密度は、第1層21の密度よりも大きいことが好ましい。これにより、第1層21から第2層22への経血移行性を向上させることができる。 The density of the second layer 22 is preferably larger than the density of the first layer 21. Thereby, menstrual blood transferability from the first layer 21 to the second layer 22 can be improved.
 第1層21及び/又は第2層22は、トップシート2の隠ぺい性を高める観点から、酸化チタン、硫酸バリウム、炭酸カルシウム等の無機フィラーを含有してもよい。 The first layer 21 and / or the second layer 22 may contain an inorganic filler such as titanium oxide, barium sulfate, calcium carbonate or the like from the viewpoint of enhancing the hiding power of the top sheet 2.
 第1層21及び/又は第2層22は、親水化処理されていることが好ましい。親水化処理としては、例えば、親水剤による第1層21及び/又は第2層22の表面コーティング、第1層21及び/又は第2層22の構成成分への親水剤の添加、コロナ処理、プラズマ処理等が挙げられる。第1層21及び/又は第2層22が親水化処理されていると、血液滑性付与剤に由来する親油性領域と、親水剤に由来する親水性領域とがトップシート2にまばらに共存することになり、経血が凹部5の開口部(トップシート2に形成されている切断開口部51)から凹部5の内部(吸収体4に形成されている吸収体凹部52)に滑落し、吸収体4に移行しやすくなる。 It is preferable that the first layer 21 and / or the second layer 22 be subjected to a hydrophilization treatment. As the hydrophilization treatment, for example, the surface coating of the first layer 21 and / or the second layer 22 with a hydrophilic agent, the addition of the hydrophilic agent to the component of the first layer 21 and / or the second layer 22, corona treatment, Plasma processing etc. are mentioned. When the first layer 21 and / or the second layer 22 is hydrophilized, the lipophilic region derived from the blood slipping agent and the hydrophilic region derived from the hydrophilic agent coexist in the top sheet 2 sparsely. Menstrual blood slips from the opening of the recess 5 (the cutting opening 51 formed in the top sheet 2) to the inside of the recess 5 (the absorber recess 52 formed in the absorber 4), It becomes easy to shift to the absorber 4.
 バックシート3は、液不透過性を有する。経血等の液状排泄物はバックシート3を透過できないので、バックシート3によって、吸収体4に吸収された液状排泄物の漏れが防止される。バックシートの一方の面は、非肌当接面(本実施形態では、着用者の着衣(下着)が当接する面)である。バックシート3は、着用時のムレを低減させるために、液体不透過性に加えて、透湿性を有することが好ましい。 The back sheet 3 is liquid impermeable. Since liquid excrement such as menstrual blood can not permeate the back sheet 3, the back sheet 3 prevents leakage of the liquid excrement absorbed by the absorber 4. One surface of the back sheet is a non-skin contact surface (in the present embodiment, a surface on which a wearer's clothing (underwear) contacts). The back sheet 3 preferably has moisture permeability in addition to liquid impermeability in order to reduce stuffiness when worn.
 バックシート3としては、例えば、防水処理を施した不織布、合成樹脂(例えば、ポリエチレン、ポリプロピレン、ポリエチレンテレフタレート等)フィルム、不織布と合成樹脂フィルムとの複合シート(例えば、スパンボンド、スパンレース等の不織布に通気性の合成樹脂フィルムが接合された複合フィルム)、耐水性の高いメルトブローン不織布を強度の強いスパンボンド不織布で挟んだSMS不織布等が挙げられる。 The back sheet 3 may be, for example, a non-woven fabric waterproofed, a synthetic resin (for example, polyethylene, polypropylene, polyethylene terephthalate etc.) film, a composite sheet of non-woven fabric and a synthetic resin film (for example non-woven fabric such as spunbond or spunlace) And a composite film in which a breathable synthetic resin film is joined, an SMS non-woven fabric in which a highly water-resistant meltblown non-woven fabric is sandwiched by a strong spunbond non-woven fabric, and the like.
 吸収体4は、経血等の液状排泄物を吸収する吸収性材料を含有する。吸収体4に含有される吸収性材料は、経血等の液状排泄物を吸収・保持可能である限り特に限定されない。吸収性材料としては、例えば、吸水性繊維、高吸水性材料(例えば、高吸水性樹脂、高吸水性繊維等)が挙げられる。吸収体4は、酸化防止剤、光安定剤、紫外線吸収剤、中和剤、造核剤、エポキシ安定剤、滑剤、抗菌剤、難燃剤、帯電防止剤、顔料、可塑剤等の添加剤を必要に応じて含有してもよい。 The absorber 4 contains the absorptive material which absorbs liquid excretion, such as menstrual blood. The absorbent material contained in the absorber 4 is not particularly limited as long as it can absorb and retain liquid excrement such as menstrual blood. Examples of the absorbent material include water-absorbent fibers and highly water-absorbent materials (for example, highly water-absorbent resin, highly water-absorbent fibers, etc.). Absorber 4 is an additive such as an antioxidant, a light stabilizer, an ultraviolet light absorber, a neutralizer, a nucleating agent, an epoxy stabilizer, a lubricant, an antibacterial agent, a flame retardant, an antistatic agent, a pigment, and a plasticizer You may contain as needed.
 吸水性繊維としては、例えば、針葉樹又は広葉樹を原料として得られる木材パルプ(例えば、砕木パルプ、リファイナーグランドパルプ、サーモメカニカルパルプ、ケミサーモメカニカルパルプ等の機械パルプ;クラフトパルプ、サルファイドパルプ、アルカリパルプ等の化学パルプ;半化学パルプ等);木材パルプに化学処理を施して得られるマーセル化パルプ又は架橋パルプ;バガス、ケナフ、竹、麻、綿(例えばコットンリンター)等の非木材パルプ;レーヨン、フィブリルレーヨン等の再生セルロース;アセテート、トリアセテート等の半合成セルロース等が挙げられるが、コストが低く、成形しやすいこと点から、粉砕パルプが好ましい。 Examples of water-absorbent fibers include wood pulps obtained from softwood or hardwood as raw materials (for example, mechanical pulps such as ground pulp, refiner ground pulp, thermomechanical pulp, chemithermomechanical pulp, etc .; kraft pulp, sulfide pulp, alkaline pulp, etc. Semi-chemical pulp, etc.); mercerized pulp obtained by subjecting wood pulp to chemical treatment or crosslinked pulp; non-wood pulp such as bagasse, kenaf, bamboo, hemp, cotton (eg cotton linters); rayon, fibril Regenerated celluloses such as rayon; semi-synthetic celluloses such as acetate and triacetate may, for example, be mentioned, but ground pulp is preferred from the viewpoint of low cost and ease of molding.
 高吸水性材料としては、例えば、デンプン系、セルロース系、合成ポリマー系の高吸水性材料が挙げられる。デンプン系又はセルロース系の高吸水性材料としては、例えば、デンプン-アクリル酸(塩)グラフト共重合体、デンプン-アクリロニトリル共重合体のケン化物、ナトリウムカルボキシメチルセルロースの架橋物等が挙げられ、合成ポリマー系の高吸水性材料としては、例えば、ポリアクリル酸塩系、ポリスルホン酸塩系、無水マレイン酸塩系、ポリアクリルアミド系、ポリビニルアルコール系、ポリエチレンオキシド系、ポリアスパラギン酸塩系、ポリグルタミン酸塩系、ポリアルギン酸塩系、デンプン系、セルロース系等の高吸水性樹脂(Superabsorbent Polymer:SAP)等が挙げられるが、これらのうちポリアクリル酸塩系(特に、ポリアクリル酸ナトリウム系)の高吸水性樹脂が好ましい。高吸水性材料の形状としては、例えば、粒子状、繊維状、鱗片状等が挙げられ、粒子状である場合、粒径は、好ましくは50~1000μmであり、さらに好ましくは100~600μmである。 Examples of the superabsorbent material include starch-based, cellulose-based, synthetic polymer-based superabsorbent materials. Examples of starch-based or cellulose-based superabsorbent materials include starch-acrylic acid (salt) graft copolymers, saponified starch-acrylonitrile copolymers, crosslinked products of sodium carboxymethylcellulose, etc. Synthetic polymers Examples of superabsorbent materials of the type include polyacrylates, polysulfonates, anhydrides maleates, polyacrylamides, polyvinyl alcohols, polyethylene oxides, polyaspartates and polyglutamates. And polyalginate-based, starch-based, and cellulose-based superabsorbent polymers (Superabsorbent Polymers: SAP), among which, among these, polyacrylate-based (especially, sodium polyacrylate-based) superabsorbent Resins are preferred. Examples of the shape of the superabsorbent material include particles, fibers, scaly and the like, and in the case of particles, the particle size is preferably 50 to 1000 μm, more preferably 100 to 600 μm. .
 吸収体4が高吸水性材料(例えば、高吸水性樹脂、高吸水性繊維等)を含有する場合、高吸水性材料の含有量は、吸収体4の通常5~80質量%、好ましくは10~60質量%、さらに好ましくは20~40質量%である。 When the absorbent body 4 contains a highly water-absorptive material (for example, highly water-absorptive resin, highly water-absorptive fiber, etc.), the content of the highly water-absorptive material is usually 5 to 80% by mass, preferably 10 of the absorbent body 4 It is at most 60% by mass, more preferably 20 to 40% by mass.
 吸収体4は、銀、銅、亜鉛、シリカ、活性炭、アルミノケイ酸塩化合物、ゼオライト等を含有してもよい。これにより、消臭性、抗菌性、吸熱効果等の機能を吸収体に付与することができる。 The absorber 4 may contain silver, copper, zinc, silica, activated carbon, an aluminosilicate compound, zeolite or the like. Thereby, functions, such as deodorizing property, antibacterial property, an endothermic effect, can be provided to an absorber.
 吸収体4の厚み、目付等は、生理用ナプキン1が備えるべき特性(例えば吸収性、強度、軽量性等)に応じて適宜調整することができる。吸収体4の厚みは、通常0.1~15mm、好ましくは1~10mm、さらに好ましくは2~5mmであり、目付は、通常20~1000g/m2、好ましくは50~800g/m2、さらに好ましくは100~500g/m2である。なお、吸収体4の厚み、目付等は、吸収体4全体にわたって一定であってもよいし、部分的に異なっていてもよい。 The thickness, fabric weight and the like of the absorber 4 can be appropriately adjusted in accordance with the characteristics (for example, absorbability, strength, lightness, and the like) that the sanitary napkin 1 should have. The thickness of the absorber 4 is usually 0.1 to 15 mm, preferably 1 to 10 mm, more preferably 2 to 5 mm, and the basis weight is usually 20 to 1000 g / m 2 , preferably 50 to 800 g / m 2 , Preferably it is 100 to 500 g / m 2 . In addition, the thickness of a absorber 4, a fabric weight, etc. may be constant over the absorber 4 whole, and may differ partially.
 吸収体4は、吸収性材料を含有するコアと、コアを被覆するコアラップとを有していてもよい。コアラップは、液体透過性及び吸収体保持性を有する限り特に限定されない。コアラップとしては、例えば、不織布、織布、液体透過孔が形成された合成樹脂フィルム、網目を有するネット状シート等が挙げられるが、低コスト性等の点から、粉砕パルプを主材料として湿式法で成形されるティッシュが好ましい。 Absorbent body 4 may have a core containing an absorptive material, and a core wrap which covers a core. The core wrap is not particularly limited as long as it has liquid permeability and absorber retention. Examples of core wraps include nonwoven fabrics, woven fabrics, synthetic resin films having liquid permeation holes, and net-like sheets having a mesh. However, from the viewpoint of low cost, etc., a wet method is mainly used with crushed pulp. Tissues molded with are preferred.
 図1及び図2に示すように、生理用ナプキン1には、複数の凹部5が形成されている。
 図2に示すように、凹部5は、トップシート2を貫通して、生理用ナプキン1の厚さ方向に延び、吸収体4の内部に至っている。
As shown in FIGS. 1 and 2, the sanitary napkin 1 is formed with a plurality of recesses 5.
As shown in FIG. 2, the recess 5 penetrates the top sheet 2, extends in the thickness direction of the sanitary napkin 1, and reaches the inside of the absorbent body 4.
 図1に示すように、生理用ナプキン1をトップシート2側から平面視したとき、凹部5は、トップシート2の肌当接面のうち排泄口当接領域20に形成されている。凹部5は、トップシート2の肌当接面のうち、排泄口当接領域20を含む吸収体配置領域の略全体に形成されていてもよい。なお、吸収体配置領域は、吸収体4をトップシート2に投影したときに、吸収体4がトップシート2と重なる領域である(図1参照)。 As shown in FIG. 1, when the sanitary napkin 1 is viewed in plan from the top sheet 2 side, the concave portion 5 is formed in the excretory opening contact area 20 of the skin contact surface of the top sheet 2. The recess 5 may be formed on substantially the entire absorbent placement area including the discharge opening contact area 20 in the skin contact surface of the top sheet 2. In addition, when the absorber arrangement | positioning area | region projects the absorber 4 on the top sheet 2, it is an area | region which the absorber 4 overlaps with the top sheet 2 (refer FIG. 1).
 排泄口当接領域20は、生理用ナプキン1の着用時に、着用者の排泄口(例えば、小陰唇、大陰唇等)が当接する領域である。図1に示すように、排泄口当接領域20は、吸収体配置領域の略中央に設定されている。排泄口当接領域20の位置、面積等は、適宜調整することができる。排泄口当接領域20は、実際に排泄口が当接する領域と略同一の領域として設定されてもよいし、それよりも大きい領域として設定されてもよいが、経血等の液状排泄物の外部への漏れ出しを防止する点から、実際に排泄口が当接する領域よりも大きい領域として設定されることが好ましい。排泄口当接領域20の長さは通常50~200mm、好ましくは70~150mmであり、幅は通常10~80mm、好ましくは20~50mmである。 The excretory opening contact area 20 is an area where the wearer's excretory opening (for example, the minor labia, the labia majora, etc.) abuts when the sanitary napkin 1 is worn. As shown in FIG. 1, the excretion opening contact area 20 is set at substantially the center of the absorber placement area. The position, area, and the like of the discharge port contact region 20 can be appropriately adjusted. The discharge opening contact region 20 may be set as a region substantially identical to the region to which the discharge opening actually contacts, or may be set to a region larger than that, but the liquid discharge such as menstrual blood In order to prevent the leakage to the outside, it is preferable to set as a region larger than the region where the discharge port actually abuts. The length of the discharge port contact area 20 is usually 50 to 200 mm, preferably 70 to 150 mm, and the width is usually 10 to 80 mm, preferably 20 to 50 mm.
 本実施形態において、排泄口当接領域20は、仮想領域として設定されているが、視覚的に認識可能な領域として設定されていてもよい。視覚的な認識は、例えば、排泄口当接領域20の着色、排泄口当接領域20の周縁における凹部(例えば、ヒートエンボス処理により形成されるエンボス部)の形成等により可能である。 In the present embodiment, the excretory opening contact area 20 is set as a virtual area, but may be set as a visually recognizable area. Visual recognition can be made, for example, by coloring the excretory opening contact area 20, forming a recess in the periphery of the excretory opening contact area 20 (for example, an embossed section formed by heat embossing), or the like.
 図2に示すように、凹部5は、トップシート2を貫通する切断開口部51と、吸収体4のトップシート2側の面において開口し、吸収体4の厚さ方向に延びる吸収体凹部52とを有する。 As shown in FIG. 2, the recess 5 is a cutting opening 51 passing through the top sheet 2, and an absorber recess 52 that opens in the surface of the absorber 4 on the top sheet 2 side and extends in the thickness direction of the absorber 4. And.
 凹部5は、切断開口部51から吸収体凹部52へ液体を導く流路となっており、着用者から排泄された経血は、切断開口部51を通じて吸収体凹部52へ移行し、吸収体凹部52の側部521及び底部522から吸収される。切断開口部51の形成により、トップシート2から吸収体4への経血移行性が向上しているとともに、吸収体凹部52の形成により、吸収体4のトップシート2側の面の表面積が増加しており、これに伴って吸収体4の経血吸収性が向上している。特に、本実施形態では、図2に示すように、吸収体4に含有される吸収性材料が、吸収体凹部52の側部521から露出しているので、着用者から排泄された経血は、切断開口部51を通じて吸収体凹部52へ移行しやすく、吸収体凹部52の側部521から吸収されやすい。また、吸収体凹部52の側部521から露出している場合、パルプ等のコアラップが破断されているため、吸収体凹部52の周囲部分において吸収性材料が圧迫を受けにくく、吸収体凹部52の厚みを出しやすい。 The recess 5 is a flow path for guiding the liquid from the cutting opening 51 to the absorber recess 52, and menstrual blood excreted from the wearer is transferred to the absorber recess 52 through the cutting opening 51, and the absorber recess is Absorbed from the side 521 and bottom 522 of 52. The formation of the cutting opening 51 improves menstrual transferability from the top sheet 2 to the absorber 4, and the formation of the absorber recess 52 increases the surface area of the surface of the absorber 4 on the top sheet 2 side. Along with this, the menstrual blood absorbability of the absorber 4 is improved. In particular, in the present embodiment, as shown in FIG. 2, since the absorbent material contained in the absorber 4 is exposed from the side portion 521 of the absorber recess 52, menstrual blood excreted from the wearer is It is easy to shift to the absorber recess 52 through the cutting opening 51 and easily absorbed from the side portion 521 of the absorber recess 52. Further, when exposed from the side portion 521 of the absorbent concavity 52, the core wrap such as pulp is broken, so that the absorbent material is less susceptible to pressure in the peripheral portion of the absorbent concavity 52, and It is easy to put out the thickness.
 本実施形態において、凹部5は、トップシート2及び吸収体4の穿孔により形成された穿孔部であり、切断開口部51及び吸収体凹部52は一体的に形成されている。したがって、図2に示すように、吸収体凹部52は、切断開口部51の位置と対応する位置に設けられており、切断開口部51と通じている。すなわち、凹部5において、切断開口部51の開口端部と吸収体凹部52の開口端部とは連続しており、切断開口部51の開口径は、吸収体凹部52の開口径とほぼ一致している。 In the present embodiment, the recess 5 is a perforated portion formed by the perforation of the top sheet 2 and the absorber 4, and the cutting opening 51 and the absorber recess 52 are integrally formed. Therefore, as shown in FIG. 2, the absorber recess 52 is provided at a position corresponding to the position of the cutting opening 51 and is in communication with the cutting opening 51. That is, in the recess 5, the opening end of the cutting opening 51 and the opening end of the absorber recess 52 are continuous, and the opening diameter of the cutting opening 51 substantially matches the opening diameter of the absorber recess 52. ing.
 生理用ナプキン1をトップシート2側から平面視したとき(図1参照)、排泄口当接領域20の1cm当たりの凹部5の数は、好ましくは0.5~5個であり、さらに好ましくは1~3個である。排泄口当接領域20の1cm当たりの凹部5の数が0.5個よりも少ないと、凹部5の形成による経血移行性及び経血吸収性の向上効果が十分に現れないおそれがある一方、排泄口当接領域20の1cm当たりの凹部5の数が5個よりも大きいと、吸収体4に吸収された経血の平面方向への拡散が妨げられるため、吸収体4の特定の領域に経血が集中してリウェット(一旦吸収された経血の逆戻り)を生じるおそれがある。 When the sanitary napkin 1 is viewed in plan from the top sheet 2 side (see FIG. 1), the number of recesses 5 per 1 cm 2 of the discharge port contact area 20 is preferably 0.5 to 5, and more preferably Are one to three. If the number of concave portions 5 per 1 cm 2 of the excretion opening contact area 20 is smaller than 0.5, there is a possibility that the improvement effect of menstrual blood transferability and menstrual blood absorbability by the formation of the concave portions 5 does not sufficiently appear. On the other hand, if the number of recesses 5 per 1 cm 2 of the excretion opening contact area 20 is larger than five, the diffusion of menstrual blood absorbed by the absorber 4 in the planar direction is prevented, and thus the absorber 4 is specified The concentration of menstrual blood in the area of (4) may cause rewet (relapse of menstrual blood once absorbed).
 凹部5の開口径(切断開口部51の開口径,吸収体凹部52の開口径)は、好ましくは0.3~6mmであり、さらに好ましくは0.6~3mmである。なお、開口形状が円形でない場合、外接する円の直径を開口径とする。凹部5の開口径が0.3mmよりも小さいと、切断開口部51から吸収体凹部52へ経血移行性が低下するおそれがある一方、凹部5の開口径が6mmよりも大きいと、凹部5が設けられている部分の剛性の低下が顕著となり、生理用ナプキン1の装着時にヨレが生じやすくなるおそれがある。 The opening diameter of the recess 5 (the opening diameter of the cutting opening 51, the opening diameter of the absorber recess 52) is preferably 0.3 to 6 mm, more preferably 0.6 to 3 mm. In addition, when opening shape is not circular, let the diameter of a circumscribed circle be opening diameter. When the opening diameter of the recess 5 is smaller than 0.3 mm, there is a possibility that menstrual transferability from the cutting opening 51 to the absorber recess 52 may be reduced, while if the opening diameter of the recess 5 is larger than 6 mm, the recess 5 The decrease in rigidity of the portion provided with is significantly reduced, and there is a possibility that the deflection is likely to occur when the sanitary napkin 1 is attached.
 切断開口部51は、トップシート2(第1層21及び第2層22)の所定部分が切断されることにより形成されている。切断開口部51の形成により、トップシート2と着用者の肌との間の接触面積を低減させ、これに伴って、トップシート2と着用者の肌との間の摩擦を低減させることができる。 The cutting opening 51 is formed by cutting a predetermined portion of the top sheet 2 (the first layer 21 and the second layer 22). By forming the cutting opening 51, the contact area between the top sheet 2 and the skin of the wearer can be reduced, and accordingly, the friction between the top sheet 2 and the skin of the wearer can be reduced. .
 切断開口部51の形成の際、トップシート2から分断されたトップシート断片9が生じる。図2に示すように、切断開口部51の形成の際に生じたトップシート断片9は、吸収体凹部52の底部522を被覆している。これにより、生理用ナプキン1をトップシート2側から見たとき、吸収体4に吸収された経血はマスキングされて見えにくくなっている。トップシート断片9は、吸収体凹部52の底部522に加えて、吸収体凹部52の側面521の一部を被覆していてもよい。 During the formation of the cutting openings 51, the top sheet fragments 9 separated from the top sheet 2 result. As shown in FIG. 2, the top sheet fragments 9 formed during the formation of the cutting openings 51 cover the bottom 522 of the absorber recess 52. As a result, when the sanitary napkin 1 is viewed from the top sheet 2 side, menstrual blood absorbed by the absorbent body 4 is masked and hardly visible. The top sheet fragment 9 may cover a part of the side surface 521 of the absorber recess 52 in addition to the bottom 522 of the absorber recess 52.
 トップシート断片9は、吸収体凹部52の底部522と圧着していることが好ましい。これにより、トップシート断片9は、吸収体凹部52の底部522と一体的に圧密化され、吸収体凹部52の底部522の剛性が増加するので、生理用ナプキン1の装着時に生じ得る、凹部5の閉塞及びこれに起因するトップシート2から吸収体4への経血移行性の低下を抑制することができる。 The top sheet fragment 9 is preferably crimped to the bottom 522 of the absorber recess 52. As a result, the top sheet fragment 9 is consolidated integrally with the bottom 522 of the absorber recess 52, and the rigidity of the bottom 522 of the absorber recess 52 is increased, so that the recess 5 may occur when the sanitary napkin 1 is attached. And the reduction in menstrual blood transferability from the top sheet 2 to the absorber 4 due to the blockage.
 第1層21及び第2層22は、切断開口部51の周囲部分で相互に圧着されていることが好ましい。これにより、切断開口部51の周囲部分が高密度化され、切断開口部51の周囲部分の剛性が増加するので、生理用ナプキン1の装着時に生じ得る、切断開口部51の閉塞、第1層21及び第2層22の離間、並びにこれらに起因するトップシート2から吸収体4への経血移行性の低下を抑制することができる。また、切断開口部51の周囲部分の高密度化により、着用者から排泄された経血が、切断開口部51の周囲部分に集まりやすくなり、切断開口部51から吸収体凹部52への経血移行性が向上する。 The first layer 21 and the second layer 22 are preferably crimped to each other at the peripheral portion of the cutting opening 51. As a result, the peripheral portion of the cutting opening 51 is densified, and the rigidity of the peripheral portion of the cutting opening 51 is increased, so that closing of the cutting opening 51 that may occur when the sanitary napkin 1 is attached, the first layer It is possible to suppress the separation of the first and second layers 22 and the decrease in menstrual transferability from the top sheet 2 to the absorber 4 due to these. Further, due to the densification of the peripheral portion of the cutting opening 51, menstrual blood excreted from the wearer is likely to be collected at the peripheral portion of the cutting opening 51, and the menstrual blood from the cutting opening 51 to the absorbent recess 52 Migration is improved.
 切断開口部51の形成の際、トップシート2のうち、切断される部分(切断後にトップシート断片9となる部分)とともに、その周囲部分も圧縮される。この圧縮によって、切断開口部51の周囲部分における第1層21及び第2層22の圧着が可能である。また、切断開口部51の周囲部分において第1層21及び第2層22が圧着することにより、切断開口部51の周囲部分の高密度化が可能である。特に、第1層21及び第2層22が不織布である場合、切断開口部51の周囲部分で第1層21及び第2層22を相互に圧着させやすく、したがって、切断開口部51の周囲部分を高密度化させやすい。 When forming the cutting opening 51, the top sheet 2 is compressed along with the part to be cut (the part to be the top sheet fragment 9 after cutting) and its surrounding part. By this compression, crimping of the first layer 21 and the second layer 22 in the peripheral portion of the cutting opening 51 is possible. Further, by pressure bonding the first layer 21 and the second layer 22 in the peripheral portion of the cutting opening 51, the density of the peripheral portion of the cutting opening 51 can be increased. In particular, in the case where the first layer 21 and the second layer 22 are non-woven fabrics, the first layer 21 and the second layer 22 are easily crimped to each other at the peripheral portion of the cutting opening 51. It is easy to densify the
 吸収体4のバックシート3側の面において、吸収体凹部52の底部522に対向する部分50は、バックシート3から離間していることが好ましい。これにより、吸収体凹部52の底部522近傍における吸収体4の膨張が可能となり、吸収体4が、吸収体凹部52の底部522近傍においても経血を吸収・保持することができる。 In the surface on the back sheet 3 side of the absorber 4, it is preferable that a portion 50 facing the bottom 522 of the absorber recess 52 be separated from the back sheet 3. As a result, the absorber 4 can expand in the vicinity of the bottom 522 of the absorber recess 52, and the absorber 4 can absorb and hold menstrual blood also in the vicinity of the bottom 522 of the absorber recess 52.
 トップシート2の排泄口当接領域20には、40℃における動粘度が0.01~80mm2/s、抱水率が0.01~4.0質量%、重量平均分子量が1,000未満である血液滑性付与剤が塗工されている。なお、図1において、排泄口当接領域20内の斜線部分は、血液滑性付与剤が塗工されている部分である。 The kinematic viscosity at 40 ° C. is 0.01 to 80 mm 2 / s, the water retention rate is 0.01 to 4.0 mass%, and the weight average molecular weight is less than 1,000 in the discharge opening contact area 20 of the top sheet 2 The blood slipping agent which is In addition, in FIG. 1, the hatched part in the excretion opening | mouth contact | abutting area | region 20 is a part by which the blood slipping agent is coated.
 血液滑性付与剤については、別項目で詳細に説明する。 The blood slipping agent will be described in detail in a separate item.
 本実施形態では、排泄口当接領域20の略全体に血液滑性付与剤が塗工されているが、血液滑性付与剤は、排泄口当接領域20のうち切断開口部51の周囲部分に塗工されていればよい。血液滑性付与剤は、排泄口当接領域20のうち切断開口部51の周囲部分に塗工されている限り、排泄口当接領域20のうち切断開口部51の周囲部分以外に塗工されていてもよいし、肌当接面のうち排泄口当接領域20以外の領域(例えば、排泄口当接領域20の周辺領域)に塗工されていてもよい。例えば、血液滑性付与剤は、肌当接面の略全体又は吸収体配置領域の略全体に塗工することができる。 In the present embodiment, the blood slipping agent is coated on substantially the whole of the excretory opening contact region 20, but the blood slipping agent is the peripheral portion of the cutting opening 51 in the excretory opening contact region 20. It should just be coated by. As long as the blood slipping agent is coated on the periphery of the cutting opening 51 in the drainage opening abutting region 20, the blood slip imparting agent is coated on other than the periphery of the cutting opening 51 on the drainage opening abutting region 20. It may be coated, and may be applied to a region of the skin contact surface other than the discharge opening contact region 20 (for example, a peripheral region of the discharge opening contact region 20). For example, the blood slipping agent can be applied to substantially the entire skin contact surface or substantially the entire absorbent placement area.
 血液滑性付与剤が、排泄口当接領域20のうち少なくとも切断開口部51の周囲部分に塗工されていることにより、次の作用効果が発揮される。着用者から排泄された経血が排泄口当接領域20に到達すると、切断開口部51の周囲部分に存在する血液滑性付与剤とともに凹部5に滑落する(すなわち、切断開口部51を通じて吸収体凹部52へ移行する)。したがって、生理用ナプキン1は、トップシート2から吸収体4への向上した経血移行性を有し、トップシート2に残存する経血を低減させることができる。このため、トップシート2の肌当接面のべたつき感が防止され、サラサラ感が維持される。このような血液滑性付与剤の作用効果は、月経時の経血排出量の変化に関わらず(すなわち、一度に排出される経血が大量であっても少量であっても)発揮される。 By coating the blood slipping agent on at least the peripheral portion of the cutting opening 51 in the excretory opening contact region 20, the following effects are exhibited. When the menstrual blood excreted from the wearer reaches the excretory opening contact area 20, it slides down into the recess 5 together with the blood slipping agent present in the peripheral portion of the cutting opening 51 (ie, the absorber through the cutting opening 51) Transition to the recess 52). Therefore, the sanitary napkin 1 has an improved menstrual blood transferability from the top sheet 2 to the absorbent body 4, and the menstrual blood remaining in the top sheet 2 can be reduced. For this reason, the sticky feeling of the skin contact surface of the top sheet 2 is prevented, and a smooth feeling is maintained. The action and effect of such a blood slipping agent is exhibited regardless of the change in menstrual blood discharge during menstruation (that is, whether the amount of menstrual blood discharged at one time is large or small) .
 本実施形態では、排泄口当接領域20に凹部5が存在し、凹部5が存在しない部分が相対的に凸部となっているので、血液滑性付与剤の作用効果が効果的に発揮される。血液滑性付与剤の作用効果は、凹部5の周囲に加えて、凹部5の内面(例えば、切断開口部51の内周面、吸収体凹部52の内側面)にも血液滑性付与剤を塗工することにより、増強させることができる。 In the present embodiment, since the recess 5 exists in the excretion opening contact region 20 and the portion where the recess 5 does not exist is relatively a protrusion, the function and effect of the blood slipping agent are effectively exhibited. Ru. In addition to the periphery of the recess 5, the action and effect of the blood slipping agent is also applied to the inner surface of the recess 5 (for example, the inner peripheral surface of the cutting opening 51, the inner surface of the absorber recess 52). It can be enhanced by coating.
 なお、血液滑性付与剤は、潤滑剤としても作用し、繊維同士の摩擦を低減させるので、トップシート2全体のしなやかさを向上させることができる。 In addition, since the blood slipping agent also acts as a lubricant and reduces the friction between the fibers, the flexibility of the entire top sheet 2 can be improved.
 生理用ナプキン1は、スキンケア組成物、ローション組成物等を含む公知の吸収性物品とは異なり、エモリエント剤、固定化剤等の成分は不要であり、血液滑性付与剤は、単体で、トップシート2に適用することができる。 Unlike the known absorbent articles including skin care compositions, lotion compositions and the like, the sanitary napkin 1 does not require components such as an emollient and a fixing agent, and the blood slipping agent alone is a top It can be applied to the sheet 2.
 血液滑性付与剤の坪量は、通常約1~30g/m2、好ましくは約2~20g/m2、さらに好ましくは約3~10g/m2である。血液滑性付与剤の坪量が、約1g/m2を下回ると、経血がトップシート2に残存しやすくなる一方、血液滑性付与剤の坪量が約30g/m2を超えると、着用中のべたべた感が増加しやすい。 The basis weight of the blood slipping agent is usually about 1 to 30 g / m 2 , preferably about 2 to 20 g / m 2 , and more preferably about 3 to 10 g / m 2 . When the basis weight of the blood slipping agent is less than about 1 g / m 2 , menstrual blood tends to remain on the top sheet 2 while when the basis weight of the blood slipping agent exceeds about 30 g / m 2 , Sticky feeling is likely to increase during wearing.
 血液滑性付与剤の坪量は、例えば、以下のように測定することができる。
(1)トップシートの測定すべき範囲を、鋭利な刃物、例えば、カッターの替え刃を用いて、できるだけその厚さを変化させないように切り出して、サンプルを得る。
(2)サンプルの面積:SA(m2)及び質量:SM0(g)を測定する。
(3)サンプルを、血液滑性付与剤を溶解させることができる溶媒、例えば、エタノール、アセトン等の中で、少なくとも3分間攪拌し、血液滑性付与剤を溶媒中に溶解させる。
(4)サンプルを、質量を測定したろ紙の上でろ過し、ろ紙上で、サンプルを溶媒で十分に洗浄する。ろ紙上のサンプルを、60℃のオーブン内で乾燥させる。
(5)ろ紙及びサンプルの質量を測定し、そこからろ紙の質量を減ずることにより、乾燥後のサンプルの質量:SM1(g)を算出する。
(6)血液滑性付与剤の坪量BBS(g/m2)を、次の式:
 BBS(g/m2)=[SM0(g)-SM1(g)]/SA(m2
 により算出する。
 なお、誤差を少なくするために、サンプルの総面積が100cm2を超えるように、複数の吸収性物品から複数のサンプルを採取し、複数回実験を繰り返し、それらの平均値を採用する。
The basis weight of the blood slipping agent can be measured, for example, as follows.
(1) A sample is obtained by cutting out the range to be measured of the top sheet using a sharp blade, for example, a replaceable blade of a cutter so as not to change its thickness as much as possible.
(2) Measure the area of the sample: SA (m 2 ) and the mass: SM 0 (g).
(3) The sample is stirred in a solvent capable of dissolving the blood slipping agent such as ethanol, acetone or the like for at least 3 minutes to dissolve the blood slipping agent in the solvent.
(4) The sample is filtered on the weighed filter paper, and the sample is thoroughly washed with the solvent on the filter paper. The sample on filter paper is dried in an oven at 60 ° C.
(5) The mass of the filter paper and the sample is measured, and the mass of the filter paper is reduced therefrom to calculate the mass of the sample after drying: SM 1 (g).
(6) The basis weight BBS (g / m 2 ) of the blood slipping agent is represented by the following formula:
BBS (g / m 2 ) = [SM 0 (g) -SM 1 (g)] / SA (m 2 )
Calculated by
In addition, in order to reduce an error, a plurality of samples are collected from a plurality of absorbent articles so that the total area of the samples exceeds 100 cm 2 , the experiment is repeated a plurality of times, and their average value is adopted.
 血液滑性付与剤は、トップシート2の繊維間の空隙を閉塞しないように塗工されていることが好ましい。例えば、血液滑性付与剤は、トップシート2の繊維の表面に液滴状又は粒子状で付着しているか、又は繊維の表面を覆っている。 It is preferable that the blood slipping agent be applied so as not to close the space between the fibers of the top sheet 2. For example, the blood slipping agent adheres to the surface of the fibers of the top sheet 2 in the form of droplets or particles, or covers the surface of the fibers.
 血液滑性付与剤は、その表面積が大きくなるように塗工されていることが好ましい。これにより、血液滑性付与剤と経血との接触面積が大きくなり、血液滑性付与剤が経血とともに滑落しやすくなる。血液滑性付与剤が液滴状又は粒子状で存在する場合には、粒径を小さくすることにより、表面積を大きくすることができる。 The blood slipping agent is preferably applied so as to increase the surface area. As a result, the contact area between the blood slipping agent and the menstrual blood increases, and the blood slipping agent tends to slip off with the menstrual blood. When the blood slipping agent is present in the form of droplets or particles, the surface area can be increased by decreasing the particle size.
 血液滑性付与剤の塗工方法としては、例えば、塗布装置(例えば、スパイラルコーター、カーテンコーター、スプレーコーター、ディップコーター等の非接触式のコーター、接触式のコーター等)を用いる方法が挙げられる。好ましい塗布装置は、非接触式のコーターである。これにより、液滴状又は粒子状の血液滑性付与剤を全体に均一に分散させることができるとともに、トップシート2に与えるダメージを低減することができる。 As a coating method of the blood slipping agent, for example, a method using a coating apparatus (for example, non-contact coater such as spiral coater, curtain coater, spray coater, dip coater, contact coater, etc.) may be mentioned. . The preferred coating apparatus is a noncontact coater. As a result, the droplet-like or particulate blood-slipper can be dispersed uniformly throughout, and damage to the top sheet 2 can be reduced.
 血液滑性付与剤は、所望により、揮発性溶媒、例えば、アルコール系溶媒、エステル系溶媒、芳香族系溶媒等を含む塗布液として塗装することができる。塗布液が揮発性溶媒を含むことにより、血液滑性付与剤を含む塗布液の粘度が下がるために、塗布が容易になる、塗装時の加温が不要になる等の塗布工程の簡易化が図れる。 The blood slipping agent can be optionally coated as a coating solution containing a volatile solvent such as an alcohol solvent, an ester solvent, an aromatic solvent and the like. When the coating solution contains a volatile solvent, the viscosity of the coating solution containing the blood slipping agent is lowered, which facilitates the coating process, simplifies the coating process such as not requiring heating during coating, etc. It can be done.
 血液滑性付与剤は、例えば、室温で液体の場合にはそのまま、又は粘度を下げるために加熱して、室温で固体の場合には液化するように加熱して、コントロールシームHMA(Hot Melt Adhesive)ガンによって塗工することができる。コントロールシームHMAガンのエアー圧を高くすることにより、微粒子状の血液滑性付与剤を塗工することができる。なお、血液滑性付与剤の塗布量は、例えば、コントロールシームHMAガンからの塗出量を増減することにより調節することができる。 For example, the blood slipping agent is heated at room temperature as it is, or heated to lower its viscosity, and heated at room temperature so as to liquefy in the case of a solid, to control seam HMA (Hot Melt Adhesive ) Can be coated by gun. A particulate blood slipping agent can be applied by increasing the air pressure of the control seam HMA gun. The application amount of the blood slipping agent can be adjusted, for example, by increasing or decreasing the amount of application from the control seam HMA gun.
 血液滑性付与剤は、トップシート2を製造する際に塗工してもよいし、生理用ナプキン1の製造ラインにおいて塗工してもよい。設備投資を抑制する観点からは、生理用ナプキン1の製造ラインにおいて、血液滑性付与剤を塗工することが好ましく、さらに、血液滑性付与剤が脱落し、ラインを汚染することを抑制するためには、製造ラインの川下工程、具体的には、製品を個包装に封入する直前に、血液滑性付与剤を塗工することが好ましい。 The blood slipping agent may be applied when producing the top sheet 2 or may be applied in the production line of the sanitary napkin 1. From the viewpoint of suppressing equipment investment, it is preferable to apply a blood slipping agent on the manufacturing line of the sanitary napkin 1, and furthermore, the blood slipping agent is prevented from dropping off and contaminating the line. For this purpose, it is preferable to apply a blood slipping agent immediately downstream of the production line, specifically, immediately before enclosing the product in an individual package.
 生理用ナプキン1は、液透過性層として、トップシート2に加えて、トップシート2及び吸収体4の間に配置されたセカンドシートを備えていてもよい。この場合、血液滑性付与剤はセカンドシートに塗工されていてもよい。 The sanitary napkin 1 may include a second sheet disposed between the top sheet 2 and the absorbent body 4 in addition to the top sheet 2 as a liquid-permeable layer. In this case, the blood slipping agent may be applied to the second sheet.
 セカンドシートは、経血等の液状排泄物が透過可能である限り特に限定されず、セカンドシートの厚み、目付、密度等は、経血等の液状排泄物が透過可能である範囲で適宜調整することができる。 The second sheet is not particularly limited as long as liquid excrement such as menstrual blood can be permeated, and the thickness, basis weight, density, etc. of the second sheet are appropriately adjusted in the range in which liquid excrement such as menstrual blood can permeate. be able to.
 セカンドシートとしては、例えば、不織布、織布、液体透過孔が形成された合成樹脂フィルム、網目を有するネット状シート等が挙げられる。不織布としては、例えば、エアスルー不織布、スパンボンド不織布、ポイントボンド不織布、スパンレース不織布、ニードルパンチ不織布、メルトブローン不織布、及びこれらの組み合わせ(例えば、SMS等)等が挙げられ、不織布を構成する繊維としては、例えば、天然繊維(羊毛,コットン等)、再生繊維(レーヨン,アセテート等)、無機繊維(ガラス繊維,炭素繊維等)、合成樹脂繊維(ポリエチレン、ポリプロピレン、ポリブチレン、エチレン-酢酸ビニル共重合体、エチレン-アクリル酸エチル共重合体、エチレン-アクリル酸共重合体、アイオノマー樹脂等のポリオレフィン;ポリエチレンテレフタレート、ポリブチレンテレフタラート、ポリトリメチレンテレフタラート、ポリ乳酸等のポリエステル;ナイロン等のポリアミド)等が挙げられる。不織布には、芯・鞘型繊維、サイド・バイ・サイド型繊維、島/海型繊維等の複合繊維;中空タイプの繊維;扁平、Y型、C型等の異型繊維;潜在捲縮又は顕在捲縮の立体捲縮繊維;水流、熱、エンボス加工等の物理的負荷により分割する分割繊維等が混合されていてもよい。 Examples of the second sheet include nonwoven fabrics, woven fabrics, synthetic resin films in which liquid permeation holes are formed, and net-like sheets having a mesh. Non-woven fabrics include, for example, air-through non-woven fabrics, spun-bonded non-woven fabrics, point-bonded non-woven fabrics, spun-laced non-woven fabrics, needle-punched non-woven fabrics, melt-blown non-woven fabrics, and combinations thereof (for example, SMS etc.) etc. For example, natural fibers (wool, cotton, etc.), regenerated fibers (rayon, acetate, etc.), inorganic fibers (glass fibers, carbon fibers, etc.), synthetic resin fibers (polyethylene, polypropylene, polybutylene, ethylene-vinyl acetate copolymer, Polyolefins such as ethylene-ethyl acrylate copolymer, ethylene-acrylic acid copolymer, ionomer resin; polyesters such as polyethylene terephthalate, polybutylene terephthalate, polytrimethylene terephthalate, polylactic acid; De), and the like. Non-woven fabrics include core / sheath fibers, side-by-side fibers, composite fibers such as island / sea fibers; hollow fibers; flat fibers, irregular fibers such as Y-type and C-type; latent crimp or overt presence A crimped three-dimensional crimped fiber; split fibers divided by physical load such as water flow, heat, embossing, etc. may be mixed.
 次に、図3に基づいて、凹部5の形成方法の一実施形態を説明する。 Next, an embodiment of a method of forming the recess 5 will be described based on FIG.
 ロール120から繰り出された第1層21が、搬送方向MDに向かって進むキャリアシート110上に供給される。次いで、ロール130から繰り出された供給された第2層22が、第1層21上に積層される。 The first layer 21 unwound from the roll 120 is supplied onto the carrier sheet 110 advancing in the transport direction MD. Then, the supplied second layer 22 unrolled from the roll 130 is laminated on the first layer 21.
 搬送方向MDへ回転するサクションドラム140の周面には、吸収体材料142を詰める型として凹部144が周方向に所要のピッチで形成されている。サクションドラム140が回転して凹部144が材料供給部141へ進入すると、サクション部146が凹部144に作用し、材料供給部141から供給された吸収体材料142は凹部144に真空吸引される。材料供給部141は、サクションドラム140を覆うように形成されており、材料供給部141は、吸収体材料142を空気搬送により凹部144に対して供給し、凹部144には吸収体4が形成される。凹部144に形成された吸収体4は、搬送方向MDに向かって進むキャリアシート110上に転写される。こうして、吸収体4,第2層22及び第1層21が順に積層された積層体152が形成される。 Recesses 144 are formed on the circumferential surface of the suction drum 140 rotating in the transport direction MD at a required pitch in the circumferential direction as a mold for packing the absorber material 142. When the suction drum 140 rotates and the concave portion 144 enters the material supply portion 141, the suction portion 146 acts on the concave portion 144, and the absorber material 142 supplied from the material supply portion 141 is vacuum suctioned to the concave portion 144. The material supply unit 141 is formed to cover the suction drum 140, and the material supply unit 141 supplies the absorber material 142 to the recess 144 by air conveyance, and the absorber 4 is formed in the recess 144. Ru. The absorber 4 formed in the concave portion 144 is transferred onto the carrier sheet 110 advancing in the transport direction MD. Thus, a laminate 152 in which the absorber 4, the second layer 22 and the first layer 21 are laminated in order is formed.
 なお、図示しないが、キャリアシート110は、搬送方向MDに向かって両側に延びる2本のベルトで、積層体152を支持している。すなわち、積層体152のキャリアシート側表面(図3において下面)のうち、搬送方向MDに向かって両側に延びる両側部分はキャリアシート110で支持されているが、搬送方向MDに向かって延びる中央部分は、キャリアシート110で支持されておらず、キャリアシート110の2本のベルトの間から露出している。この露出している部分が、次工程において、エンボス加工処置160で加工される。したがって、積層体152は、キャリアシート110上に載置された状態のまま、次工程においてエンボス加工処置160で加工される。本実施形態を変更して、キャリアシート110による積層体152の支持を、エンボス加工処置160による加工の前に終了してもよい。この場合、積層体152は、キャリアシート110上に載置された状態ではなく、第1層21及び第2層22のテンションで支えられた状態で、エンボス加工処置160によって加工される。積層体152は、エンボス加工処置160による加工の後、再びキャリアシート110上に載置されて搬送されてもよい。 Although not shown, the carrier sheet 110 supports the laminate 152 with two belts extending on both sides in the transport direction MD. That is, of the surface on the carrier sheet side (the lower surface in FIG. 3) of the laminate 152, both side portions extending on both sides in the conveying direction MD are supported by the carrier sheet 110, but a central portion extending in the conveying direction MD Are not supported by the carrier sheet 110 and are exposed from between the two belts of the carrier sheet 110. This exposed portion is processed in the embossing process 160 in the next step. Therefore, the layered product 152 is processed by the embossing treatment 160 in the next step while being placed on the carrier sheet 110. This embodiment may be modified to end the support of the laminate 152 by the carrier sheet 110 before processing by the embossing procedure 160. In this case, the laminate 152 is not processed on the carrier sheet 110 but processed by the embossing treatment 160 in a state supported by the tension of the first layer 21 and the second layer 22. The laminate 152 may be placed on the carrier sheet 110 and conveyed again after being processed by the embossing treatment 160.
 次に、エンボス加工装置160によって、積層体152に凹部5が形成される。凹部5は、第1層21及び第2層22を貫通して、吸収体4の厚さ方向に延び、吸収体4の内部に至るように形成される。エンボス加工装置160は、針状、円柱形状、円錐形状等の形状の複数の突起161aを外周の表面に有する突起ロール161と、平滑な表面を外周に有するプレーンロール162とを含む。 Next, the recess 5 is formed in the laminate 152 by the embossing device 160. The recess 5 is formed to extend through the first layer 21 and the second layer 22 in the thickness direction of the absorber 4 and to reach the inside of the absorber 4. Embossing device 160 includes a projecting roll 161 having a plurality of projections 161a having a needle shape, a cylindrical shape, a conical shape, and the like on the outer peripheral surface, and a plain roll 162 having a smooth surface on the outer peripheral.
 搬送方向MDに向かって回転する突起ロール161及びプレーンロール162間に、積層体152を通過するとき、突起ロール161の突起161aは、第1層21及び第2層22の所定部分を厚さ方向に押圧し、押圧部分を剪断して切断開口部51を形成する。そして、切断開口部51から分断されたトップシート断片9とともに吸収体4に圧入し、吸収体凹部52を形成するとともに、トップシート断片9を吸収体凹部5の底部522に圧着させる。さらに、積層体152から突起ロール161の突起161aが抜け出るとき、吸収体凹部52の底部522が引っ張られ、吸収体4の表面のうち、吸収体凹部52が開口する面と反対側の面(図3において上面)には、吸収体凹部52の底部と対向する部分に不図示の凹部(図2の部分50)が形成される。 When passing through the laminated body 152 between the projecting roll 161 and the plain roll 162 rotating in the transport direction MD, the projection 161 a of the projecting roll 161 forms a predetermined portion of the first layer 21 and the second layer 22 in the thickness direction , And shear the pressed portion to form the cutting opening 51. Then, the top sheet fragment 9 divided from the cutting opening 51 is pressed into the absorber 4 to form the absorber recess 52, and the top sheet fragment 9 is crimped to the bottom 522 of the absorber recess 5. Furthermore, when the protrusion 161a of the protrusion roll 161 comes out of the laminated body 152, the bottom 522 of the absorber recess 52 is pulled, and the surface of the absorber 4 on the opposite side to the surface where the absorber recess 52 opens (see FIG. A recess (not shown) (portion 50 in FIG. 2) is formed on the upper surface of the upper surface 3 at a portion facing the bottom of the absorber recess 52.
 図4に基づいて、凹部5の形成過程を詳細に説明する。図4(a),(b)はエンボス加工の一例を説明するための図である。 The formation process of the recessed part 5 is demonstrated in detail based on FIG. FIGS. 4A and 4B are diagrams for explaining an example of embossing.
 図4(a)に示すように、最初に、突起ロール161の突起161aの先端がトップシート2に当接する。そして、突起161aがトップシート2を圧縮するときにより生じる突起161aの剪断力により、突起161aの当接領域の端の部分(符号10bで表される部分)が切断される。突起161aの剪断力によりトップシート2が切断されることによって、トップシート断片9が形成される。 As shown in FIG. 4A, first, the tip end of the protrusion 161 a of the protrusion roll 161 abuts on the top sheet 2. Then, the shear force of the protrusion 161 a generated when the protrusion 161 a compresses the top sheet 2 cuts the end portion (the portion represented by reference numeral 10 b) of the contact area of the protrusion 161 a. The top sheet 2 is cut by the shear force of the projections 161 a to form the top sheet fragment 9.
 突起161aによる剪断力を大きくするためには、突起161aの高さはできるだけ高い方が好ましい。また、突起161aの先端と、突起161aの付け根を結ぶラインの角度はより垂直に近いほうがよい。すなわち、突起161aの側面と突起ロール161の外周面とのなす角度は90°に近い方がよい。突起161aの高さは、凹部5が形成される前の吸収体4の厚さの1/3の厚さよりも大きく、凹部5が形成される前の吸収体4の厚さの10倍の厚さよりも小さいことが好ましく、凹部5が形成される前の吸収体4の厚さの1/2の厚さよりも大きく、凹部5が形成される前の吸収体4の厚さの5倍の厚さよりも小さいことがさらに好ましい。突起161aの高さが、凹部5が形成される前の吸収体4の厚さの1/3の厚さよりも小さい場合、吸収体4は凹部5が形成されない部分においても厚さ方向に圧縮され、吸収体4全体が堅くなるおそれがある。また、突起161aの高さが、凹部5が形成される前の吸収体4の厚さの10倍の厚さよりも大きい場合、突起161aが折れるおそれがある。突起161aが円柱形状である場合、突起161aの先端角度は、好ましくは20~45°である。突起161aの先端角度が20°よりも小さいと、突起161aの耐久性が低下するおそれがあり、突起161aの先端角度が45°よりも大きいと、突起161aによる剪断力が低下するおそれがある。 In order to increase the shearing force by the protrusion 161a, the height of the protrusion 161a is preferably as high as possible. Further, it is preferable that the angle of the line connecting the tip of the protrusion 161a and the root of the protrusion 161a be closer to perpendicular. That is, the angle between the side surface of the protrusion 161 a and the outer peripheral surface of the protrusion roll 161 is preferably close to 90 °. The height of the protrusion 161 a is larger than one-third the thickness of the absorber 4 before the recess 5 is formed, and ten times the thickness of the absorber 4 before the recess 5 is formed. Is preferably smaller than half the thickness of the absorber 4 before the recess 5 is formed, and is five times the thickness of the absorber 4 before the recess 5 is formed. It is further preferred that it be smaller than When the height of the protrusion 161a is smaller than 1/3 of the thickness of the absorber 4 before the recess 5 is formed, the absorber 4 is compressed in the thickness direction even in the portion where the recess 5 is not formed. The whole of the absorber 4 may become rigid. When the height of the protrusion 161a is larger than 10 times the thickness of the absorber 4 before the recess 5 is formed, the protrusion 161a may be broken. When the protrusion 161a has a cylindrical shape, the tip angle of the protrusion 161a is preferably 20 to 45 °. If the tip angle of the protrusion 161 a is smaller than 20 °, the durability of the protrusion 161 a may be reduced. If the tip angle of the protrusion 161 a is larger than 45 °, the shearing force by the protrusion 161 a may be reduced.
 突起ロール161の回転速度を大きくすると、突起161aが吸収体4に圧入する速度は速くなる。したがって、突起ロール161の回転速度を大きくすることによって突起161aの剪断力を大きくすることができる。 When the rotational speed of the protrusion roll 161 is increased, the speed at which the protrusion 161 a is pressed into the absorber 4 is increased. Therefore, by increasing the rotational speed of the projecting roll 161, the shearing force of the projection 161a can be increased.
 図4(b)に示すように、次いで、突起ロール161の突起161aは吸収体4に圧入する。これにより、トップシート断片9は、吸収体凹部52の底部522と圧着され、一体的に圧密化されて高密度化する。トップシート断片9は、トップシート2の本体から完全に分断されているので、トップシート断片9が突起161aから応力を受けても、トップシート2が受ける応力は弱い。すなわち、突起161aが吸収体4に圧入するときに生じるトップシート2の引張応力は弱いので、吸収体4が吸収体凹部52の周囲部分において厚さ方向に圧縮されることが抑制される。 Next, as shown in FIG. 4 (b), the protrusions 161 a of the protrusion roll 161 are pressed into the absorber 4. As a result, the top sheet piece 9 is crimped to the bottom 522 of the absorber recess 52, and is consolidated and densified integrally. Since the top sheet fragments 9 are completely separated from the main body of the top sheet 2, even if the top sheet fragments 9 receive stress from the protrusions 161a, the stress to which the top sheet 2 is subjected is weak. That is, since the tensile stress of the top sheet 2 generated when the protrusion 161 a is press-fit into the absorber 4 is weak, the absorber 4 is suppressed from being compressed in the thickness direction in the peripheral portion of the absorber recess 52.
 突起161aが吸収体4に圧入するとき、トップシート2の切断開口部51の周囲部分には、厚さ方向の応力が生じる。これにより、トップシートの切断開口部51の周囲部分において第1層21及び第2層22が相互に圧着され、切断開口部51の周囲部分が高密度化される。 When the protrusion 161 a is press-fit into the absorber 4, stress in the thickness direction is generated in the peripheral portion of the cutting opening 51 of the top sheet 2. Thereby, the first layer 21 and the second layer 22 are pressure-bonded to each other in the peripheral portion of the cutting opening 51 of the top sheet, and the peripheral portion of the cutting opening 51 is densified.
 エンボス加工後の積層体152の電子顕微鏡写真を図5に示す。図5に示すように、トップシート2には、切断開口部51が設けられている。トップシート2の切断開口部51の縁(切断部分)10bは、吸収体凹部52の側面521に延在していないことから、切断開口部51は、トップシート2(第1層21及び第2層22)を切断部分10bで切断することにより形成されたことがわかる。また、吸収体凹部52の底部522には、圧縮されたトップシート断片9が存在する。吸収体凹部52が形成された面の反対側の面において、吸収体凹部52の底部に対向する部分に凹部50が形成されている。 The electron micrograph of the laminated body 152 after embossing is shown in FIG. As shown in FIG. 5, the top sheet 2 is provided with a cutting opening 51. Since the edge (cut portion) 10 b of the cutting opening 51 of the top sheet 2 does not extend to the side surface 521 of the absorber recess 52, the cutting opening 51 corresponds to the top sheet 2 (first layer 21 and second layer). It can be seen that it was formed by cutting the layer 22) at the cutting portion 10b. In addition, at the bottom 522 of the absorber recess 52, the compressed top sheet fragment 9 is present. In the surface opposite to the surface on which the absorber recess 52 is formed, the recess 50 is formed in a portion facing the bottom of the absorber recess 52.
 図1に示すサイドシート8は、経血がトップシート2を通って生理用ナプキン1の幅方向外側へ漏れることを防止する。サイドシート8は、疎水性又は撥水性を有することが好ましい。サイドシート8には、例えば、スパンボンド不織布、SMS不織布等が使用される。また、着用者の肌と接触するため、肌への擦れ刺激を低減できるエアスルー不織布をサイドシート8として使用することが好ましい。なお、生理用ナプキン1において、サイドシート8を省略してもよい。 The side sheet 8 shown in FIG. 1 prevents menstrual blood from leaking outward in the width direction of the sanitary napkin 1 through the top sheet 2. The side sheets 8 preferably have hydrophobicity or water repellency. For the side sheet 8, for example, a spunbond nonwoven fabric, an SMS nonwoven fabric, or the like is used. Moreover, in order to contact with a wearer's skin, it is preferable to use the air through nonwoven fabric which can reduce rubbing irritation to skin as the side sheet 8. In the sanitary napkin 1, the side sheet 8 may be omitted.
<血液滑性付与剤>
 血液滑性付与剤は、40℃における動粘度が約0.01~約80mm2/sであり、抱水率が約0.05~約4.0質量%であり、重量平均分子量が約1,000未満である。
<Blood lubricity imparting agent>
The blood slipping agent has a kinematic viscosity of about 0.01 to about 80 mm 2 / s at 40 ° C., a water retention of about 0.05 to about 4.0% by mass, and a weight average molecular weight of about 1 Less than 1,000.
 血液滑性付与剤の40℃における動粘度は、約0~約80mm2/sの範囲において適宜調整することができるが、好ましくは約1~約70mm2/s、さらに好ましくは約3~約60mm2/s、さらに一層好ましくは約5~約50mm2/s、さらに一層好ましくは約7~約45mm2/sである。なお、本明細書では、40℃における動粘度を、単に「動粘度」と称する場合がある。 The kinematic viscosity of the blood slipping agent at 40 ° C. can be appropriately adjusted in the range of about 0 to about 80 mm 2 / s, preferably about 1 to about 70 mm 2 / s, more preferably about 3 to about 3 60 mm 2 / s, still more preferably about 5 to about 50 mm 2 / s, still more preferably about 7 to about 45 mm 2 / s. In the present specification, the kinematic viscosity at 40 ° C. may be simply referred to as “kinetic viscosity”.
 動粘度は、a)血液滑性付与剤の分子量が大きくなるほど、b)極性基、例えば、カルボニル結合(-CO-)、エーテル結合(-O-)、カルボキシル基(-COOH)、ヒドロキシル基(-OH)等の比率が高いほど、そしてc)IOBが大きくなるほど、高くなる傾向がある。 The kinematic viscosity is a) as the molecular weight of the blood slipping agent is increased, b) polar groups such as carbonyl bond (-CO-), ether bond (-O-), carboxyl group (-COOH), hydroxyl group The higher the ratio, such as -OH), and c) the larger the IOB, the higher the tendency.
 40℃において、約0~約80mm2/sの動粘度を有するためには、血液滑性付与剤の融点が45℃以下であることが好ましい。血液滑性付与剤が40℃で結晶を含むと、その動粘度が高くなる傾向があるからである。 In order to have a kinematic viscosity of about 0 to about 80 mm 2 / s at 40 ° C., the melting point of the blood slipping agent is preferably 45 ° C. or less. When the blood slipping agent contains crystals at 40 ° C., the kinematic viscosity tends to be high.
 血液滑性付与剤における動粘度の意義については後述するが、動粘度が約80mm2/sを超えると、血液滑性付与剤の粘性が高く、トップシートの肌当接面に到達した経血と共に、凸部から凹部に滑落し、次いで吸収体内部に移行することが難しくなる傾向がある。 Although the significance of the kinematic viscosity in the blood slipping agent will be described later, when the kinematic viscosity exceeds about 80 mm 2 / s, the viscosity of the blood slipping agent is high, and the menstrual blood reached the skin contact surface of the top sheet At the same time, it tends to be difficult to slide from the convex portion to the concave portion and then to move into the inside of the absorber.
 動粘度は、JIS K 2283:2000の「5.動粘度試験方法」に従って、キャノンフェンスケ逆流形粘度計を用いて、40℃の試験温度で測定されることができる。 The kinematic viscosity can be measured at a test temperature of 40 ° C. using a Canon Fentzberg reverse flow viscometer according to “5. Dynamic viscosity test method” of JIS K 2283: 2000.
 血液滑性付与剤の抱水率は、約0.01~約4.0質量%の範囲で適宜調整することができるが、好ましくは約0.02~約3.5質量%、さらに好ましくは約0.03~約3.0質量%、さらに一層好ましくは約0.04~約2.5質量%、さらに一層好ましくは約0.05~約2.0質量%である。 The water retention rate of the blood slipping agent can be appropriately adjusted in the range of about 0.01 to about 4.0% by mass, preferably about 0.02 to about 3.5% by mass, and more preferably It is about 0.03 to about 3.0% by weight, still more preferably about 0.04 to about 2.5% by weight, and still more preferably about 0.05 to about 2.0% by weight.
 本明細書において、「抱水率」は、物質が、保持することができる水の比率(質量)を意味し、以下の通りに測定することができる。
(1)40℃の恒温室に、20mLの試験管、ゴム栓、測定すべき物質及び脱イオン水を一昼夜静置する。
(2)恒温室で、試験管に、測定すべき物質5.0gと、脱イオン水5.0gを投入する。
(3)恒温室で、試験管の口をゴム栓をし、試験管を1回転させ、5分間静置する。
(4)恒温室で、測定すべき物質の層(通常は、上層)3.0gを、直径90mmの、質量:W0(g)のガラス製シャーレに採取する。
(5)シャーレを、オーブン内で、105℃で3時間加熱し、水分を蒸発させ、シャーレごと、質量:W1(g)を測定する。
(6)抱水率を、以下の式に従って算出する。
 抱水率(質量%)=100×[W0(g)-W1(g)]/3.0(g)
 測定は3回実施し、平均値を採用する。
As used herein, "water-retaining rate" means the proportion (mass) of water that a substance can hold, and can be measured as follows.
(1) In a temperature-controlled room at 40 ° C., leave a 20 mL test tube, rubber stopper, substance to be measured and deionized water overnight.
(2) In a temperature-controlled room, 5.0 g of a substance to be measured and 5.0 g of deionized water are put into a test tube.
(3) In a temperature-controlled room, put a rubber stopper on the mouth of the test tube, rotate the test tube once, and leave it for 5 minutes.
(4) In a temperature-controlled room, 3.0 g of a layer to be measured (usually, the upper layer) is collected in a glass petri dish having a diameter of 90 mm and a weight of W 0 (g).
(5) Heat the petri dish in an oven at 105 ° C. for 3 hours to evaporate water, measure the mass of the petri dish, and weight: W 1 (g).
(6) Calculate the water retention rate according to the following equation.
Water holding ratio (mass%) = 100 × [W 0 (g) -W 1 (g)] / 3.0 (g)
The measurement is carried out three times and the average value is adopted.
 血液滑性付与剤における抱水率の意義については後述するが、抱水率が低くなると、血液滑性付与剤と、経血との親和性が低下し、トップシートの肌当接面に到達した経血と共に吸収体に移行しにくくなる傾向がある。一方、抱水率が高くなると、界面活性剤のように、経血との親和性が非常に高くなり、トップシートの肌当接面に、吸収した血液が残存し、トップシートの肌当接面が赤く着色しやすくなる傾向がある。 Although the significance of the water retention rate in the blood slipping agent will be described later, when the water retention rate decreases, the affinity between the blood slipping agent and menstrual blood decreases and reaches the skin contact surface of the top sheet. With menstrual blood, it tends to be difficult to shift to an absorber. On the other hand, when the water retention rate becomes high, affinity with menstrual blood becomes very high like surfactants, and absorbed blood remains on the skin contact surface of the top sheet, and the skin contact of the top sheet There is a tendency for the face to be red and to be easily colored.
 抱水率は、a)血液滑性付与剤の分子量が小さくなるほど、そしてb)極性基、例えば、カルボニル結合(-CO-)、エーテル結合(-O-)、カルボキシル基(-COOH)、ヒドロキシル基(-OH)等の比率が高いほど、値が大きくなる傾向がある。血液滑性付与剤が、より親水性を有するからである。また、抱水率は、IOBが大きくなるほど、すなわち、無機性値が高いほど、そして有機性値が小さいほど、値が大きくなる傾向がある。血液滑性付与剤が、より親水性を有することになるからである。 The water retention rate is a) as the molecular weight of the blood slipping agent decreases, and b) polar groups such as carbonyl bond (-CO-), ether bond (-O-), carboxyl group (-COOH), hydroxyl The higher the ratio of the group (-OH) or the like, the larger the value tends to be. It is because a blood slipping agent has more hydrophilicity. Also, the water retention rate tends to increase as the IOB increases, that is, as the inorganic value increases and as the organic value decreases. It is because a blood slipping agent will have more hydrophilicity.
 血液滑性付与剤における動粘度と、抱水率との意義について説明する。 The significance of the kinematic viscosity of the blood slipping agent and the water retention rate will be described.
 着用者から排泄された経血が排泄口当接領域に到達すると、凸部に存在する血液滑性付与剤と接触し、これとともに凹部に滑落し、トップシートを通過して吸収体に移行する。 When menstrual blood excreted from the wearer reaches the excretory opening contact area, it contacts the blood slipping agent present in the convex part, slides along with it into the concave part, passes through the top sheet, and transfers to the absorber .
 より詳細には、40℃において約0.01~約80mm2/sの動粘度を有する血液滑性付与剤は、着用者の体温付近で非常に低粘度であり且つ経血と一定の親和性を有するため、経血とともに、凸部から凹部に滑落し、その滑落の際の勢いを利用して、経血が、トップシートを通過し、吸収体に迅速に移行することができると考えられる。また、凸部に存在する血液滑性付与剤は、約0.01~約4.0質量%の抱水率を有するため、経血中の、主に親水性成分(血漿等)と親和性を有しないため、経血をトップシート上に残存させにくいと考えられる。 More specifically, a blood slipping agent having a kinematic viscosity of about 0.01 to about 80 mm 2 / s at 40 ° C. has a very low viscosity near the wearer's body temperature and has constant affinity with menstrual blood It is thought that menstrual blood passes through the top sheet and can be rapidly transferred to the absorbent body by using the force of sliding when the menstrual blood slides down from the convex part to the concave part and has a sliding effect. . In addition, since the blood slipping agent present in the convex portion has a water retention rate of about 0.01 to about 4.0% by mass, it is mainly compatible with hydrophilic components (such as plasma) in the blood. It is thought that menstrual blood does not easily remain on the top sheet.
 着用者から排出された経血が大量である場合には、経血そのものの運動エネルギーが大きく、血液滑性付与剤の動粘度の値が比較的高く経血と共に滑落しにくい場合であっても、抱水率の値が比較的高く経血の親水性成分と親和性が高い場合であっても、重量分子量の値が比較的高く経血と共に滑落しにくい場合であっても、そしてトップシートの肌当接面に凹凸構造がない場合であっても、経血は吸収体に移行しやすいと考えられる。 Even if there is a large amount of menstrual blood excreted from the wearer, the kinetic energy of the menstrual blood itself is large, and the value of the kinematic viscosity of the blood slipping agent is relatively high and it is difficult to slip off with menstrual blood Even if the water retention rate is relatively high and the affinity with the hydrophilic component of menses is high, the weight molecular weight is relatively high and it is difficult to slide off with menstrual blood, and the top sheet Even in the case where there is no uneven structure on the skin contact surface of the above, it is considered that menstrual blood is easily transferred to the absorber.
 一方、着用者から排出された経血が少量である場合には、経血の運動エネルギーが小さく、トップシートの肌当接面に到達した経血が、その場に留まりやすい傾向がある。従って、血液滑性付与剤が、経血とともに、凸部から凹部に滑落し、そして経血をトップシートの内部に引き込み、次いで吸収体に引き込むことにより、経血を迅速に吸収体に移行させることができる。 On the other hand, when the amount of menstrual blood discharged from the wearer is small, the kinetic energy of the menstrual blood is small, and menstrual blood that has reached the skin contact surface of the top sheet tends to be easily held there. Therefore, the blood slipping agent slips along with menstrual blood from the convex part to the concave part and draws menstrual blood into the interior of the top sheet and then withdraws into the absorbent body, thereby rapidly transferring the menstrual blood to the absorbent body be able to.
 血液滑性付与剤は、約1,000未満の重量平均分子量を有し、そして好ましくは約900未満の重量平均分子量を有する。重量平均分子量が約1,000以上であると、血液滑性付与剤そのものにタック性が生じ、着用者に不快感を与える傾向があるからである。また、重量平均分子量が高くなると、血液滑性付与剤の粘度が高くなる傾向があるため、加温により、血液滑性付与剤の粘度を、塗工に適した粘度に下げることが難しくなり、その結果、血液滑性付与剤を、溶媒で希釈しなければならない場合も生じうる。 The blood slipping agent has a weight average molecular weight of less than about 1,000 and preferably has a weight average molecular weight of less than about 900. When the weight-average molecular weight is about 1,000 or more, the blood slipping agent itself is tacky, which tends to make the wearer uncomfortable. In addition, when the weight average molecular weight is high, the viscosity of the blood slipping agent tends to be high, so it is difficult to lower the viscosity of the blood slipping agent to a viscosity suitable for coating by heating. As a result, the blood slipping agent may occur if it has to be diluted with a solvent.
 血液滑性付与剤は、約100以上の重量平均分子量を有することが好ましく、そして約200以上の重量平均分子量を有することがより好ましい。重量平均分子量が小さくなると、血液滑性付与剤の蒸気圧が高くなり、保存中に気化し、量の減少、着用時の臭気等の問題が発生する場合があるからである。 The blood slipping agent preferably has a weight average molecular weight of about 100 or more, and more preferably about 200 or more. If the weight-average molecular weight is decreased, the vapor pressure of the blood slipping agent may be increased to be vaporized during storage, which may cause problems such as a decrease in amount and an odor when worn.
 なお、本明細書において、「重量平均分子量」は、多分散系の化合物(例えば、逐次重合により製造された化合物、複数の脂肪酸と、複数の脂肪族1価アルコールとから生成されたエステル)と、単一化合物(例えば、1種の脂肪酸と、1種の脂肪族1価アルコールから生成されたエステル)とを含む概念であり、Ni個の分子量Miの分子(i=1、又はi=1,2・・・)からなる系において、次の式:
 Mw=ΣNii 2/ΣNii
 により求められるMwを意味する。
In the present specification, “weight-average molecular weight” refers to a polydispersed compound (for example, a compound produced by sequential polymerization, an ester produced from a plurality of fatty acids and a plurality of aliphatic monohydric alcohols) , A concept including a single compound (for example, one fatty acid and an ester formed from one aliphatic monohydric alcohol), and a molecule having N i molecular weights M i (i = 1, or i In a system consisting of = 1, 2 ..., the following equation:
M w = ΣN i M i 2 / ΣN i M i
Means M w determined by
 本明細書において、重量平均分子量は、ゲルパーミエーションクロマトグラフィー(GPC)により求められる、ポリスチレン換算の値を意味する。
 GPCの測定条件としては、例えば、以下が挙げられる。
 機種:(株)日立ハイテクノロジーズ製 高速液体クロマトグラム Lachrom Elite
 カラム:昭和電工(株)製 SHODEX KF-801、KF-803及びKF-804
 溶離液:THF
 流量 :1.0mL/分
 打込み量:100μL
 検出:RI(示差屈折計)
 なお、本明細書の実施例に記載される重量平均分子量は、上記条件により測定したものである。
In the present specification, the weight average molecular weight means a value in terms of polystyrene, which is determined by gel permeation chromatography (GPC).
Examples of GPC measurement conditions include the following.
Model: High-performance liquid chromatogram Lachrom Elite manufactured by Hitachi High-Technologies Corporation
Column: Showa Denko KK SHODEX KF-801, KF-803 and KF-804
Eluent: THF
Flow rate: 1.0 mL / min Implanted volume: 100 μL
Detection: RI (differential refractometer)
In addition, the weight average molecular weight described in the Example of this specification is measured based on the said conditions.
 血液滑性付与剤は、約0.00~約0.60のIOBを有することができる。
 IOB(Inorganic Organic Balance)は、親水性及び親油性のバランスを示す指標であり、本明細書では、小田らによる次式:
 IOB=無機性値/有機性値
 により算出される値を意味する。
The blood slipping agent can have an IOB of about 0.00 to about 0.60.
IOB (Inorganic Organic Balance) is an index showing the balance of hydrophilicity and lipophilicity, and in the present specification, the following equation by Oda et al .:
It means the value calculated by IOB = inorganic value / organic value.
 無機性値及び有機性値は、藤田穆「有機化合物の予測と有機概念図」化学の領域Vol.11,No.10(1957)p.719-725)に記載される有機概念図に基づく。
 藤田氏による、主要な基の有機性値及び無機性値を、下記表1にまとめる。
The inorganicity value and the organicity value are described in Fujida, T. 11, No. 10 (1957) p. Based on the organic conceptual diagram described in 719-725).
The organic and inorganic values of the major groups according to Mr. Fujita are summarized in Table 1 below.
Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000001
 例えば、炭素数14のテトラデカン酸と、炭素数12のドデシルアルコールとのエステルの場合には、有機性値が520(CH2,20×26個)、無機性値が60(-COOR,60×1個)となるため、IOB=0.12となる。 For example, in the case of an ester of C14 tetradecanoic acid and C12 dodecyl alcohol, the organic value is 520 (CH 2 , 20 × 26), and the inorganic value is 60 (-COOR, 60 ×). Therefore, IOB = 0.12.
 血液滑性付与剤において、IOBは、約0.00~約0.60であることが好ましく、約0.00~約0.50であることがより好ましく、約0.00~約0.40であることがさらに好ましく、そして約0.00~約0.30であることがさらに好ましい。IOBが上述の範囲にあると、抱水力及び動粘度が、上述の要件を満たしやすくなるからである。 In the blood slipping agent, the IOB is preferably about 0.00 to about 0.60, more preferably about 0.00 to about 0.50, and about 0.00 to about 0.40. More preferably, it is about 0.00 to about 0.30. When the IOB is in the above-mentioned range, the hydrostatic capacity and the kinematic viscosity tend to satisfy the above-mentioned requirements.
 血液滑性付与剤は、45℃以下の融点を有することが好ましく、40℃以下の融点を有することがさらに好ましい。血液滑性付与剤が45℃以下の融点を有することにより、血液滑性付与剤が、上述の範囲の動粘度を有しやすくなるからである。 The blood slipping agent preferably has a melting point of 45 ° C. or less, more preferably 40 ° C. or less. When the blood slipping agent has a melting point of 45 ° C. or less, the blood slipping agent tends to have a kinematic viscosity in the range described above.
 本明細書において、「融点」は、示差走査熱量分析計において、昇温速度10℃/分で測定した場合の、固形状から液状に変化する際の吸熱ピークのピークトップ温度を意味する。融点は、例えば、島津製作所社製のDSC-60型DSC測定装置を用いて測定することができる。 In the present specification, the "melting point" means the peak top temperature of an endothermic peak when changing from solid state to liquid state when measured at a temperature rising rate of 10 ° C./min in a differential scanning calorimeter. The melting point can be measured, for example, using a DSC-60 type DSC measurement apparatus manufactured by Shimadzu Corporation.
 血液滑性付与剤は、約45℃以下の融点を有すれば、室温(約25℃)で液体であっても、又は固体であってもよい、すなわち、融点が約25℃以上でも、又は約25℃未満でもよく、そして例えば、約-5℃、約-20℃等の融点を有することができる。 The blood slipping agent may be liquid or solid at room temperature (about 25 ° C.) as long as it has a melting point of about 45 ° C. or less, ie, even if the melting point is about 25 ° C. or higher, or It may be less than about 25.degree. C. and may have a melting point such as, for example, about -5.degree. C., about -20.degree.
 血液滑性付与剤は、その融点に下限は存在しないが、その蒸気圧が低いことが好ましい。血液滑性付与剤の蒸気圧は、25℃(1気圧)で約0~約200Paであることが好ましく、約0~約100Paであることがより好ましく、約0~約10Paであることがさらに好ましく、約0~約1Paであることがさらに一層好ましく、約0.0~約0.1Paであることがさらに一層好ましい。 There is no lower limit to the melting point of the blood slipping agent, but its vapor pressure is preferably low. The vapor pressure of the blood slipping agent is preferably about 0 to about 200 Pa at 25 ° C. (1 atm), more preferably about 0 to about 100 Pa, and further preferably about 0 to about 10 Pa Preferably, it is still more preferably about 0 to about 1 Pa, and even more preferably about 0.0 to about 0.1 Pa.
 本開示の吸収性物品が、人体に接して用いられることを考慮すると、上記蒸気圧は、40℃(1気圧)で約0~約700Paであることが好ましく、約0~約100Paであることがより好ましく、約0~約10Paであることがさらに好ましく、約0~約1Paであることがさらに一層好ましく、約0.0~約0.1Paであることがさらに一層好ましい。血液滑性付与剤の蒸気圧が高いと、保存中に気化し、その量の減少、着用時の臭気等の問題が発生する場合があるからである。 Considering that the absorbent article of the present disclosure is used in contact with the human body, the vapor pressure is preferably about 0 to about 700 Pa and about 0 to about 100 Pa at 40 ° C. (1 atm). Is more preferably about 0 to about 10 Pa, still more preferably about 0 to about 1 Pa, and still more preferably about 0.0 to about 0.1 Pa. If the vapor pressure of the blood slipping agent is high, it may be vaporized during storage, which may cause problems such as reduction of the amount and odor when worn.
 また、血液滑性付与剤の融点を、気候、着用時間の長さ等に応じて選択することができる。例えば、平均気温が約10℃以下の地域では、約10℃以下の融点を有する血液滑性付与剤を採用することにより、経血が排泄された後、周囲温度によって冷却された場合であっても、血液滑性付与剤が機能しやすいと考えられる。 Further, the melting point of the blood slipping agent can be selected according to the weather, the length of wearing time, and the like. For example, in areas where the average temperature is about 10 ° C. or less, menstrual blood may be excreted and then cooled by the ambient temperature by employing a blood slipping agent having a melting point of about 10 ° C. or less. Also, it is considered that the blood slipping agent is easy to function.
 また、吸収性物品が長時間にわたって使用される場合には、血液滑性付与剤の融点は、約45℃以下の範囲で高い方が好ましい。汗、着用時の摩擦等の影響を受けにくく、長時間着用した場合であっても、血液滑性付与剤が偏りにくいからである。 When the absorbent article is used for a long time, the melting point of the blood slipping agent is preferably higher in the range of about 45 ° C. or less. It is because it is hard to be influenced by sweat, friction at the time of wearing, etc., and even when it is worn for a long time, the blood slipping agent is hardly biased.
 当技術分野では、経血の表面張力等を変化させ、経血を迅速に吸収することを目的として、トップシートの肌当接面を、界面活性剤でコーティングすることが行われている。しかし、界面活性剤がコーティングされたトップシートは、経血中の親水性成分(血漿等)と親和性が高く、それらを引き寄せ、むしろ経血をトップシートに残存させるようにはたらく傾向がある。血液滑性付与剤は、従来公知の界面活性剤と異なり、経血と親和性が低く、経血をトップシートに残存させず、迅速に吸収体に移行させることができる。 In the art, the skin contact surface of the top sheet is coated with a surfactant for the purpose of changing the surface tension of menstrual blood and the like to rapidly absorb menstrual blood. However, the surfactant-coated top sheet has high affinity with hydrophilic components (blood plasma etc.) in the blood, and tends to attract them and rather keep menstrual blood remaining on the top sheet. Unlike conventionally known surfactants, the blood slipping agent has low affinity with menstrual blood, and can be rapidly transferred to the absorber without leaving menstrual blood on the top sheet.
 血液滑性付与剤は、好ましくは、次の(i)~(iii)、
 (i)炭化水素、
 (ii) (ii-1)炭化水素部分と、(ii-2)炭化水素部分のC-C単結合間に挿入された、カルボニル基(-CO-)及びオキシ基(-O-)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、及び
 (iii) (iii-1)炭化水素部分と、(iii-2)炭化水素部分のC-C単結合間に挿入された、カルボニル基(-CO-)及びオキシ基(-O-)から成る群から選択される、一又は複数の、同一又は異なる基と、(iii-3)炭化水素部分の水素原子を置換する、カルボキシル基(-COOH)及びヒドロキシル基(-OH)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、
 並びにそれらの任意の組み合わせから成る群から選択される。
The blood slipping agent is preferably selected from the following (i) to (iii),
(I) Hydrocarbons,
(Ii) consisting of (ii-1) hydrocarbon moiety and (ii-2) carbonyl group (-CO-) and oxy group (-O-) inserted between C-C single bonds of hydrocarbon moiety A compound having one or more same or different groups selected from the group, and (iii) (iii-1) between a hydrocarbon moiety and a CC single bond of (iii-2) hydrocarbon moiety And one or more identical or different groups selected from the group consisting of a carbonyl group (-CO-) and an oxy group (-O-) inserted, and (iii-3) a hydrogen atom of a hydrocarbon moiety A compound having one or more same or different groups selected from the group consisting of carboxyl group (—COOH) and hydroxyl group (—OH) to be substituted,
And any combination thereof.
 本明細書において、「炭化水素」は、炭素と水素とから成る化合物を意味し、鎖状炭化水素、例えば、パラフィン系炭化水素(二重結合及び三重結合を含まない、アルカンとも称される)、オレフィン系炭化水素(二重結合を1つ含む、アルケンとも称される)、アセチレン系炭化水素(三重結合を1つ含む、アルキンとも称される)、及び二重結合及び三重結合から成る群から選択される結合を2つ以上含む炭化水素、並びに環状炭化水素、例えば、芳香族炭化水素、脂環式炭化水素が挙げられる。 In the present specification, "hydrocarbon" means a compound consisting of carbon and hydrogen, and is a chain hydrocarbon, for example, paraffinic hydrocarbon (also referred to as alkane not containing double bond and triple bond) Olefinic hydrocarbons (containing one double bond, also referred to as alkenes), acetylenic hydrocarbons (containing one triple bond, also called alkynes), and a group consisting of double bonds and triple bonds And hydrocarbons containing two or more bonds selected from the following, as well as cyclic hydrocarbons such as aromatic hydrocarbons and alicyclic hydrocarbons.
 炭化水素としては、鎖状炭化水素及び脂環式炭化水素であることが好ましく、鎖状炭化水素であることがより好ましく、パラフィン系炭化水素、オレフィン系炭化水素、及び二重結合を2つ以上含む炭化水素(三重結合を含まない)であることがさらに好ましく、そしてパラフィン系炭化水素であることがさらに好ましい。
 鎖状炭化水素には、直鎖状炭化水素及び分岐鎖状炭化水素が含まれる。
The hydrocarbon is preferably a chain hydrocarbon and an alicyclic hydrocarbon, more preferably a chain hydrocarbon, paraffin hydrocarbon, olefin hydrocarbon, and two or more double bonds. More preferably, they are hydrocarbons containing (without triple bonds), and more preferably paraffinic hydrocarbons.
The chain hydrocarbon includes straight chain hydrocarbon and branched chain hydrocarbon.
 上記(ii)及び(iii)の化合物において、オキシ基(-O-)が2つ以上挿入されている場合には、各オキシ基(-O-)は隣接していない。従って、上記(ii)及び(iii)の化合物には、オキシ基が連続する化合物(いわゆる、過酸化物)は含まれない。 In the compounds (ii) and (iii), when two or more oxy groups (—O—) are inserted, each oxy group (—O—) is not adjacent. Accordingly, the compounds (ii) and (iii) do not include compounds having a continuous oxy group (so-called peroxides).
 また、上記(iii)の化合物では、炭化水素部分の少なくとも1つの水素原子がカルボキシル基(-COOH)で置換された化合物よりも、炭化水素部分の少なくとも1つの水素原子が、ヒドロキシル基(-OH)で置換された化合物の方が好ましい。カルボキシル基は、経血中の金属等と結合し、血液滑性付与剤の抱水率が高くなり、所定の範囲を超える場合があるからである。これは、IOBの観点からも同様である。表1に示すように、カルボキシル基は、経血中の金属等と結合し、無機性値が150から、400以上へと大幅に上昇するため、カルボキシル基を有する血液滑性付与剤は、使用時にIOBの値が約0.60を上回る場合がありうる。 Further, in the compound of (iii) above, at least one hydrogen atom of the hydrocarbon moiety is more hydroxyl group (-OH than a compound in which at least one hydrogen atom of the hydrocarbon moiety is substituted with a carboxyl group (—COOH) Compounds substituted with) are preferred. This is because the carboxyl group is bonded to a metal or the like in blood, and the water retention rate of the blood slipping agent is increased to exceed the predetermined range in some cases. This is also true from the point of view of the IOB. As shown in Table 1, since the carboxyl group binds to metals and the like in the blood, and the inorganic value greatly increases from 150 to 400 or more, the blood slipping agent having the carboxyl group is used Occasionally, the value of IOB may exceed about 0.60.
 血液滑性付与剤は、より好ましくは、次の(i’)~(iii’)、
 (i’)炭化水素、
 (ii’) (ii’-1)炭化水素部分と、(ii’-2)炭化水素部分のC-C単結合間に挿入された、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)、及びエーテル結合(-O-)から成る群から選択される、一又は複数の、同一又は異なる結合とを有する化合物、及び
 (iii’) (iii’-1)炭化水素部分と、(iii’-2)炭化水素部分のC-C単結合間に挿入された、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)、及びエーテル結合(-O-)から成る群から選択される、一又は複数の、同一又は異なる結合と、(iii’-3)炭化水素部分の水素原子を置換する、カルボキシル基(-COOH)及びヒドロキシル基(-OH)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、
 並びにそれらの任意の組み合わせから成る群から選択される。
More preferably, the blood slipping agent is selected from the following (i ') to (iii'),
(I ') hydrocarbons,
(Ii ') Carbonyl bond (-CO-), ester bond (-COO-) inserted between (ii'-1) hydrocarbon moiety and C-C single bond of (ii'-2) hydrocarbon moiety A compound having one or more same or different bonds selected from the group consisting of carbonate bond (-OCOO-) and ether bond (-O-), and (iii ') (iii'-1) ) Carbonyl bond (-CO-), ester bond (-COO-), carbonate bond (-OCOO-) inserted between the hydrocarbon moiety and the C-C single bond of (iii'-2) hydrocarbon moiety , And an ether bond (—O—), one or more, same or different bond, and (iii′-3) a hydrogen atom of a hydrocarbon moiety, a carboxyl group (—COOH) And hydroxyl group (-O H) a compound having one or more same or different groups selected from the group consisting of
And any combination thereof.
 上記(ii’)及び(iii’)の化合物において、2以上の同一又は異なる結合が挿入されている場合、すなわち、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)及びエーテル結合(-O-)から選択される2以上の同一又は異なる結合が挿入されている場合には、各結合は隣接しておらず、各結合の間には、少なくとも、炭素原子が1つ介在する。 In the compounds of (ii ′) and (iii ′) above, when two or more identical or different bonds are inserted, ie, a carbonyl bond (—CO—), an ester bond (—COO—), a carbonate bond (— When two or more identical or different bonds selected from OCOO-) and an ether bond (-O-) are inserted, each bond is not adjacent, and at least carbon is separated between each bond. One atom intervenes.
 血液滑性付与剤は、さらに好ましくは、炭化水素部分に、炭素原子10個当たり、カルボニル結合(-CO-)を約1.8個以下、エステル結合(-COO-)を2個以下、カーボネート結合(-OCOO-)を約1.5個以下、エーテル結合(-O-)を約6個以下、カルボキシル基(-COOH)を約0.8個以下、そして/又はヒドロキシル基(-OH)を約1.2個以下有することができる。 More preferably, the blood slipping agent has about 1.8 or less carbonyl bond (-CO-) and 2 or less ester bond (-COO-) per 10 carbon atoms in the hydrocarbon moiety, carbonate About 1.5 or less bonds (-OCOO-), about 6 or less ether bonds (-O-), about 0.8 or less carboxyl groups (-COOH), and / or hydroxyl groups (-OH) Or less.
 血液滑性付与剤は、さらに好ましくは、次の(A)~(F)、
 (A) (A1)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(A2)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する1個のカルボキシル基とを有する化合物とのエステル、
 (B) (B1)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(B2)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエーテル、
 (C) (C1)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する、2~4個のカルボキシル基とを含むカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、(C2)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエステル、
 (D)鎖状炭化水素部分と、鎖状炭化水素部分のC-C単結合間に挿入された、エーテル結合(-O-)、カルボニル結合(-CO-)、エステル結合(-COO-)、及びカーボネート結合(-OCOO-)から成る群から選択されるいずれか1つの結合とを有する化合物、
 (E)ポリオキシC3~C6アルキレングリコール、又はそのアルキルエステル若しくはアルキルエーテル、及び
 (F)鎖状炭化水素、
 並びにそれらの任意の組み合わせから成る群から選択される。
 以下、(A)~(F)に従う血液滑性付与剤について詳細に説明する。
More preferably, the blood slipping agent is any one of the following (A) to (F),
(A) A compound having (A1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms of the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and a chain hydrocarbon An ester with a compound having one carboxyl group replacing the hydrogen atom of the hydrogen moiety,
(B) A compound having (B1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and a chain hydrocarbon An ether with a compound having one hydroxyl group replacing the hydrogen atom of the hydrogen moiety,
(C) a carboxylic acid, hydroxy acid, alkoxy acid or oxo acid containing (C1) a chain hydrocarbon moiety and 2 to 4 carboxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (C2 And d) an ester of a compound having a chain hydrocarbon portion and one hydroxyl group replacing a hydrogen atom of the chain hydrocarbon portion,
(D) Ether bond (-O-), carbonyl bond (-CO-), ester bond (-COO-) inserted between chain hydrocarbon moiety and C-C single bond of chain hydrocarbon moiety And a compound having any one bond selected from the group consisting of carbonate bonds (—OCOO—),
(E) Polyoxy C 3 -C 6 alkylene glycol, or an alkyl ester or alkyl ether thereof, and (F) a chain hydrocarbon,
And any combination thereof.
Hereinafter, the blood slipping agent according to (A) to (F) will be described in detail.
[(A) (A1)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(A2)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する1個のカルボキシル基とを有する化合物とのエステル]
 (A)(A1)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(A2)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する1個のカルボキシル基とを有する化合物とのエステル(以下、「化合物(A)」と称する場合がある)は、上述の動粘度、抱水率及び重量平均分子量を有する限り、全てのヒドロキシル基がエステル化されていなくともよい。
[(A) (A1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms of the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, a chain Ester with a compound having one carboxyl group replacing the hydrogen atom of the hydrocarbon moiety]
(A) A compound having (A1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms of the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, a chain hydrocarbon The ester with a compound having one carboxyl group replacing the hydrogen atom of the hydrogen portion (hereinafter sometimes referred to as “compound (A)”) has the above-mentioned kinematic viscosity, water retention rate and weight average molecular weight As long as it has, not all hydroxyl groups may be esterified.
 (A1)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物(以下、「化合物(A1)」と称する場合がある)としては、例えば、鎖状炭化水素テトラオール、例えば、アルカンテトラオール、例えば、ペンタエリトリトール、鎖状炭化水素トリオール、例えば、アルカントリオール、例えば、グリセリン、及び鎖状炭化水素ジオール、例えば、アルカンジオール、例えば、グリコールが挙げられる。 Examples of the compound (A1) having a chain hydrocarbon portion and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon portion (hereinafter sometimes referred to as “compound (A1)”) include For example, linear hydrocarbon tetraols such as alkanetetraols such as pentaerythritol, linear hydrocarbon triols such as alkanetriols such as glycerin, and linear hydrocarbon diols such as alkanediols such as glycol Can be mentioned.
 (A2)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する1個のカルボキシル基とを有する化合物としては、例えば、炭化水素上の1つの水素原子が、1つのカルボキシル基(-COOH)で置換された化合物、例えば、脂肪酸が挙げられる。
 化合物(A)としては、例えば、(a1)鎖状炭化水素テトラオールと少なくとも1の脂肪酸とのエステル、(a2)鎖状炭化水素トリオールと少なくとも1の脂肪酸とのエステル、及び(a3)鎖状炭化水素ジオールと少なくとも1の脂肪酸とのエステルが挙げられる。
(A2) As a compound having a chain hydrocarbon portion and one carboxyl group replacing a hydrogen atom of the chain hydrocarbon portion, for example, one hydrogen atom on a hydrocarbon is one carboxyl group ( And -COOH) substituted compounds such as fatty acids.
Examples of the compound (A) include an ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid, an ester of (a 2 ) chain hydrocarbon triol and at least one fatty acid, and (a 3 And esters of linear hydrocarbon diols and at least one fatty acid.
[(a1)鎖状炭化水素テトラオールと少なくとも1の脂肪酸とのエステル]
 鎖状炭化水素テトラオールと少なくとも1の脂肪酸とのエステルとしては、例えば、次の式(1):
Figure JPOXMLDOC01-appb-C000002
 のペンタエリトリトールと脂肪酸とのテトラエステル、次の式(2):
Figure JPOXMLDOC01-appb-C000003
 のペンタエリトリトールと脂肪酸とのトリエステル、次の式(3):
Figure JPOXMLDOC01-appb-C000004
 のペンタエリトリトールと脂肪酸とのジエステル、次の式(4):
Figure JPOXMLDOC01-appb-C000005
 のペンタエリトリトールと脂肪酸とのモノエステルが挙げられる。
 (式中、R1~R4は、それぞれ、鎖状炭化水素である)
[Ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid]
As an ester of a chain hydrocarbon tetraol and at least one fatty acid, for example, the following formula (1):
Figure JPOXMLDOC01-appb-C000002
Tetraester of pentaerythritol with fatty acid, the following formula (2):
Figure JPOXMLDOC01-appb-C000003
Triester of pentaerythritol with fatty acid, the following formula (3):
Figure JPOXMLDOC01-appb-C000004
A diester of pentaerythritol with fatty acid, the following formula (4):
Figure JPOXMLDOC01-appb-C000005
And monoesters of fatty acid with pentaerythritol.
(Wherein, R 1 to R 4 are each a chain hydrocarbon)
 ペンタエリトリトールと脂肪酸とのエステルを構成する脂肪酸(R1COOH、R2COOH,R3COOH,及びR4COOH)としては、ペンタエリトリトールと脂肪酸とのエステルが、動粘度、抱水率及び重量平均分子量の要件を満たすものであれば、特に制限されないが、例えば、飽和脂肪酸、例えば、C2~C30の飽和脂肪酸、例えば、酢酸(C2)(C2は、炭素数を示し、R1C、R2C,R3C又はR4Cの炭素数に相当する、以下同じ)、プロパン酸(C3)、ブタン酸(C4)及びその異性体、例えば、2-メチルプロパン酸(C4)、ペンタン酸(C5)及びその異性体、例えば、2-メチルブタン酸(C5)、2,2-ジメチルプロパン酸(C5)、ヘキサン酸(C6)、ヘプタン酸(C7)、オクタン酸(C8)及びその異性体、例えば、2-エチルヘキサン酸(C8)、ノナン酸(C9)、デカン酸(C10)、ドデカン酸(C12)、テトラデカン酸(C14)、ヘキサデカン酸(C16)、ヘプタデカン酸(C17)、オクタデカン酸(C18)、エイコサン酸(C20)、ドコサン酸(C22)、テトラコサン酸(C24)、ヘキサコサン酸(C26)、オクタコサン酸(C28)、トリアコンタン酸(C30)等、並びに列挙されていないこれらの異性体が挙げられる。 As fatty acids (R 1 COOH, R 2 COOH, R 3 COOH, and R 4 COOH) constituting esters of pentaerythritol and fatty acids, esters of pentaerythritol and fatty acids have kinematic viscosity, water retention and weight average For example, saturated fatty acids such as C 2 -C 30 saturated fatty acids such as acetic acid (C 2 ) (C 2 represents a carbon number, R 1 is not particularly limited as long as it satisfies the molecular weight requirements. C, R 2 C, R 3 C or R 4 C corresponding to the carbon number of the R 4 C, hereinafter the same), propanoic acid (C 3 ), butanoic acid (C 4 ) and isomers thereof, for example, 2-methylpropanoic acid ( C 4 ), pentanoic acid (C 5 ) and its isomers, such as 2-methylbutanoic acid (C 5 ), 2,2-dimethylpropanoic acid (C 5 ), hexanoic acid (C 6 ), heptanoic acid (C 7) ), octanoic acid (C 8) Beauty isomers thereof, e.g., 2-ethylhexanoic acid (C 8), nonanoic acid (C 9), decanoic acid (C 10), dodecanoic acid (C 12), tetradecanoic acid (C 14), hexadecanoic acid (C 16) , Heptadecanoic acid (C 17 ), octadecanoic acid (C 18 ), eicosanoic acid (C 20 ), docosanoic acid (C 22 ), tetracosanoic acid (C 24 ), hexacosanoic acid (C 26 ), octacosanoic acid (C 28 ), Triacontanic acid (C 30 ) and the like, as well as their isomers not listed.
 脂肪酸はまた、不飽和脂肪酸であることができる。不飽和脂肪酸としては、例えば、C3~C20の不飽和脂肪酸、例えば、モノ不飽和脂肪酸、例えば、クロトン酸(C4)、ミリストレイン酸(C14)、パルミトレイン酸(C16)、オレイン酸(C18)、エライジン酸(C18)、バクセン酸(C18)、ガドレイン酸(C20)、エイコセン酸(C20)等、ジ不飽和脂肪酸、例えば、リノール酸(C18)、エイコサジエン酸(C20)等、トリ不飽和脂肪酸、例えば、リノレン酸、例えば、α-リノレン酸(C18)及びγ-リノレン酸(C18)、ピノレン酸(C18)、エレオステアリン酸、例えば、α-エレオステアリン酸(C18)及びβ-エレオステアリン酸(C18)、ミード酸(C20)、ジホモ-γ-リノレン酸(C20)、エイコサトリエン酸(C20)等、テトラ不飽和脂肪酸、例えば、ステアリドン酸(C20)、アラキドン酸(C20)、エイコサテトラエン酸(C20)等、ペンタ不飽和脂肪酸、例えば、ボセオペンタエン酸(C18)、エイコサペンタエン酸(C20)等、並びにこれらの部分水素付加物が挙げられる。 The fatty acids can also be unsaturated fatty acids. Examples of unsaturated fatty acids include C 3 -C 20 unsaturated fatty acids, such as monounsaturated fatty acids such as crotonic acid (C 4 ), myristoleic acid (C 14 ), palmitoleic acid (C 16 ), olein Acid (C 18 ), elaidic acid (C 18 ), vacenic acid (C 18 ), gadeuric acid (C 20 ), eicosenic acid (C 20 ), etc., diunsaturated fatty acids such as linoleic acid (C 18 ), eicosadiene Acid (C 20 ), etc., triunsaturated fatty acids such as linolenic acid, eg α-linolenic acid (C 18 ) and γ-linolenic acid (C 18 ), pinolenic acid (C 18 ), eleostearic acid, eg , Α-eleostearic acid (C 18 ) and β-eleostearic acid (C 18 ), meade acid (C 20 ), dihomo-γ-linolenic acid (C 20 ), eicosatrienoic acid (C 20 ), etc. Tetra-unsaturated fatty acids, eg, stear Don acid (C 20), arachidonic acid (C 20), eicosatetraenoic acid (C 20), etc., penta unsaturated fatty acids, for example, bosseopentaenoic acid (C 18), such as eicosapentaenoic acid (C 20), as well as their Partially hydrogenated adducts of
 ペンタエリトリトールと脂肪酸とのエステルとしては、酸化等により変性する可能性を考慮すると、飽和脂肪酸に由来する、ペンタエリトリトールと脂肪酸とのエステル、すなわち、ペンタエリトリトールと飽和脂肪酸とのエステルであることが好ましい。
 また、ペンタエリトリトールと脂肪酸とのエステルとしては、抱水率の値を小さくする観点から、ジエステル、トリエステル又はテトラエステルであることが好ましく、トリエステル又はテトラエステルであることがより好ましく、そしてテトラエステルであることがさらに好ましい。
An ester of pentaerythritol and a fatty acid is preferably an ester of pentaerythritol and a fatty acid derived from a saturated fatty acid, that is, an ester of pentaerythritol and a saturated fatty acid, considering the possibility of modification by oxidation etc. .
Moreover, as ester of pentaerythritol and fatty acid, it is preferable that it is diester, triester or tetraester from the viewpoint of reducing the value of water retention rate, and it is more preferable that it is triester or tetraester, and tetraester More preferably, it is an ester.
 IOBを約0.00~約0.60とする観点から考察すると、ペンタエリトリトールと脂肪酸とのテトラエステルでは、ペンタエリトリトールと脂肪酸とのテトラエステルを構成する脂肪酸の炭素数の合計、すなわち、上記式(1)において、R1C、R2C、R3C及びR4C部分の炭素数の合計が、約15であることが好ましい(炭素数の合計が15の場合に、IOBが0.60となる)。 Considering that IOB is about 0.00 to about 0.60, in the tetraester of pentaerythritol and fatty acid, the total carbon number of fatty acids constituting the tetraester of pentaerythritol and fatty acid, ie, the above formula In (1), the total carbon number of the R 1 C, R 2 C, R 3 C and R 4 C moieties is preferably about 15 (when the total carbon number is 15, the IOB is 0. It becomes 60).
 ペンタエリトリトールと脂肪酸とのテトラエステルでは、例えば、ペンタエリトリトールと、ヘキサン酸(C6)、ヘプタン酸(C7)、オクタン酸(C8)、例えば、2-エチルヘキサン酸(C8)、ノナン酸(C9)、デカン酸(C10)及び/又はドデカン酸(C12)とのテトラエステルが挙げられる。 Examples of tetra-esters of pentaerythritol and fatty acid include pentaerythritol, hexanoic acid (C 6 ), heptanoic acid (C 7 ), octanoic acid (C 8 ), such as 2-ethylhexanoic acid (C 8 ), nonane Acid (C 9 ), decanoic acid (C 10 ) and / or tetraester with dodecanoic acid (C 12 ) are mentioned.
 IOBを約0.00~約0.60とする観点から考察すると、ペンタエリトリトールと脂肪酸とのトリエステルでは、ペンタエリトリトールと脂肪酸とのトリエステルを構成する脂肪酸の炭素数の合計、すなわち、上記式(2)において、R1C、R2C及びR3C部分の炭素数の合計が、約19以上であることが好ましい(炭素数の合計が19の場合に、IOBが0.58となる)。 In consideration of setting IOB to about 0.00 to about 0.60, in the triester of pentaerythritol and fatty acid, the total carbon number of fatty acids constituting the triester of pentaerythritol and fatty acid, ie, the above formula In (2), the total carbon number of the R 1 C, R 2 C and R 3 C moieties is preferably about 19 or more (when the total carbon number is 19, the IOB is 0.58) ).
 IOBを約0.00~約0.60とする観点から考察すると、ペンタエリトリトールと脂肪酸とのジエステルでは、ペンタエリトリトールと脂肪酸とのジエステルを構成する脂肪酸の炭素数の合計、すなわち、上記式(3)において、R1C及びR2C部分の炭素数の合計が、約22以上であることが好ましい(炭素数の合計が22の場合に、IOBが0.59となる)。 From the viewpoint of setting IOB to about 0.00 to about 0.60, in the diester of pentaerythritol and fatty acid, the total carbon number of fatty acids constituting the diester of pentaerythritol and fatty acid, ie, the above formula (3) Preferably, the total carbon number of the R 1 C and R 2 C moieties is about 22 or more (when the total carbon number is 22, the IOB is 0.59).
 IOBを約0.00~約0.60とする観点から考察すると、ペンタエリトリトールと脂肪酸とのモノエステルでは、ペンタエリトリトールと脂肪酸とのモノエステルを構成する脂肪酸の炭素数、すなわち、上記式(4)において、R1C部分の炭素数が、約25以上であることが好ましい(炭素数が25の場合に、IOBが0.60となる)。
 なお、IOBの計算に当たっては、二重結合、三重結合、iso分岐、及びtert分岐の影響は、考慮していない(以下、同様である)。
From the viewpoint of setting IOB to about 0.00 to about 0.60, in the monoester of pentaerythritol and fatty acid, the carbon number of the fatty acid constituting the monoester of pentaerythritol and fatty acid, that is, the above formula (4) Preferably, the carbon number of the R 1 C moiety is about 25 or more (when the carbon number is 25, the IOB is 0.60).
In the calculation of IOB, the effects of double bond, triple bond, iso branch, and tert branch are not considered (the same applies hereinafter).
 ペンタエリトリトールと脂肪酸とのエステルの市販品としては、ユニスター H-408BRS、H-2408BRS-22(混合品)等(以上、日油株式会社製)が挙げられる。 Examples of commercially available esters of pentaerythritol and fatty acid include Unistar H-408 BRS, H-2408 BRS-22 (mixed product) and the like (all manufactured by NOF Corporation).
[(a2)鎖状炭化水素トリオールと少なくとも1の脂肪酸とのエステル]
 鎖状炭化水素トリオールと少なくとも1の脂肪酸とのエステルとしては、例えば、次の式(5):
Figure JPOXMLDOC01-appb-C000006
 のグリセリンと脂肪酸とのトリエステル、次の式(6):
Figure JPOXMLDOC01-appb-C000007
 のグリセリンと脂肪酸とのジエステル、及び次の式(7):
Figure JPOXMLDOC01-appb-C000008
 (式中、R5~R7は、それぞれ、鎖状炭化水素である)
 のグリセリンと脂肪酸とのモノエステルが挙げられる。
[Ester of (a 2 ) chain hydrocarbon triol and at least one fatty acid]
As an ester of a linear hydrocarbon triol and at least one fatty acid, for example, the following formula (5):
Figure JPOXMLDOC01-appb-C000006
Triester of glycerin and fatty acid, the following formula (6):
Figure JPOXMLDOC01-appb-C000007
And a diester of fatty acid with glycerin and the following formula (7):
Figure JPOXMLDOC01-appb-C000008
(Wherein, each of R 5 to R 7 is a chain hydrocarbon)
And monoesters of glycerin and fatty acids.
 グリセリンと脂肪酸とのエステルを構成する脂肪酸(R5COOH、R6COOH及びR7COOH)としては、グリセリンと脂肪酸とのエステルが、動粘度、抱水率及び重量平均分子量の要件を満たすものであれば、特に制限されず、例えば、「(a1)鎖状炭化水素テトラオールと少なくとも1の脂肪酸とのエステル」において列挙される脂肪酸、すなわち、飽和脂肪酸及び不飽和脂肪酸が挙げられ、酸化等により変性する可能性を考慮すると、飽和脂肪酸に由来する、グリセリンと脂肪酸とのエステル、すなわち、グリセリンと飽和脂肪酸とのエステルであることが好ましい。 As fatty acids (R 5 COOH, R 6 COOH and R 7 COOH) constituting esters of glycerin and fatty acids, esters of glycerin and fatty acids satisfy the requirements of dynamic viscosity, water retention and weight average molecular weight There is no particular limitation, and examples thereof include fatty acids listed in “ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid”, that is, saturated fatty acids and unsaturated fatty acids, oxidation, etc. In consideration of the possibility of modification by the above, it is preferable to use an ester of glycerin and a fatty acid derived from a saturated fatty acid, that is, an ester of glycerin and a saturated fatty acid.
 また、グリセリンと脂肪酸とのエステルとしては、抱水率の値を小さくする観点から、ジエステル又はトリエステルであることが好ましく、そしてトリエステルであることがより好ましい。 Moreover, as ester of glycerol and a fatty acid, it is preferable that it is a diester or a triester from a viewpoint of making the value of water retention rate small, and it is more preferable that it is a triester.
 グリセリンと脂肪酸とのトリエステルは、トリグリセリドとも称され、例えば、グリセリンとオクタン酸(C8)とのトリエステル、グリセリンとデカン酸(C10)とのトリエステル、グリセリンとドデカン酸(C12)とのトリエステル、及びグリセリンと、2種又は3種の脂肪酸とのトリエステル、並びにこれらの混合物が挙げられる。 The triester of glycerin and fatty acid is also referred to as triglyceride, for example, triester of glycerin and octanoic acid (C 8 ), triester of glycerin and decanoic acid (C 10 ), glycerin and dodecanoic acid (C 12 ) And triesters of glycerin and two or three fatty acids, and mixtures thereof.
 グリセリンと、2種以上の脂肪酸とのトリエステルとしては、例えば、グリセリンと、オクタン酸(C8)及びデカン酸(C10)とのトリエステル、グリセリンと、オクタン酸(C8)、デカン酸(C10)及びドデカン酸(C12)とのトリエステル、グリセリンと、オクタン酸(C8)、デカン酸(C10)、ドデカン酸(C12)、テトラデカン酸(C14)、ヘキサデカン酸(C16)及びオクタデカン酸(C18)とのトリエステル等が挙げられる。 Examples of triesters of glycerin and two or more fatty acids include triesters of glycerin with octanoic acid (C 8 ) and decanoic acid (C 10 ), glycerin, octanoic acid (C 8 ), decanoic acid Triester with (C 10 ) and dodecanoic acid (C 12 ), glycerin and octanoic acid (C 8 ), decanoic acid (C 10 ), dodecanoic acid (C 12 ), tetradecanoic acid (C 14 ), hexadecanoic acid (C 10 ) Examples thereof include triesters with C 16 ) and octadecanoic acid (C 18 ).
 融点を約45℃以下とする観点から考察すると、グリセリンと脂肪酸とのトリエステルは、グリセリンと脂肪酸とのトリエステルを構成する脂肪酸の炭素数の合計、すなわち、式(5)において、R5C、R6C及びR7C部分の炭素数の合計が、約40以下であることが好ましい。 When considered from the viewpoint of setting the melting point to about 45 ° C. or less, the triester of glycerin and a fatty acid is the total carbon number of fatty acids constituting the triester of glycerin and a fatty acid, that is, in the formula (5), R 5 C Preferably, the sum of the carbon numbers of the R 6 C and R 7 C moieties is about 40 or less.
 IOBを約0.00~約0.60とする観点から考察すると、グリセリンと脂肪酸とのトリエステルでは、グリセリンと脂肪酸とのトリエステルを構成する脂肪酸の炭素数の合計、すなわち、式(5)において、R5C、R6C及びR7C部分の炭素数の合計が、約12以上であることが好ましい(炭素数の合計が12の場合に、IOBが0.60となる)。
 グリセリンと脂肪酸とのトリエステルは、いわゆる、脂肪であり、人体を構成しうる成分であるため、安全性の観点から好ましい。
Considering from the viewpoint of setting IOB to about 0.00 to about 0.60, in the case of triester of glycerin and fatty acid, the total carbon number of fatty acids constituting the triester of glycerin and fatty acid, ie, the formula (5) Preferably, the total carbon number of the R 5 C, R 6 C, and R 7 C moieties is about 12 or more (when the total carbon number is 12, the IOB is 0.60).
Triester of glycerin and a fatty acid is a so-called fat and is a component that can constitute the human body, and thus is preferable from the viewpoint of safety.
 グリセリンと脂肪酸とのトリエステルの市販品としては、トリヤシ油脂肪酸グリセリド、NA36、パナセート800、パナセート800B及びパナセート810S、並びにトリC2L油脂肪酸グリセリド及びトリCL油脂肪酸グリセリド(以上、日油株式会社製)等が挙げられる。 Commercial products of triester of glycerin and fatty acid include tricotic oil fatty acid glyceride, NA36, panaseto 800, panaseto 800B and panaceto 810S, and tri C2L oil fatty acid glyceride and tri CL oil fatty acid glyceride (manufactured by NOF Corporation) Etc.
 グリセリンと脂肪酸とのジエステルは、ジグリセリドとも称され、例えば、グリセリンとデカン酸(C10)とのジエステル、グリセリンとドデカン酸(C12)とのジエステル、グリセリンとヘキサデカン酸(C16)とのジエステル、及びグリセリンと、2種の脂肪酸とのジエステル、並びにこれらの混合物が挙げられる。 The diester of glycerin and fatty acid is also referred to as diglyceride, for example, a diester of glycerin and decanoic acid (C 10 ), a diester of glycerin and dodecanoic acid (C 12 ), a diester of glycerin and hexadecanoic acid (C 16 ) And diesters of glycerin with two fatty acids, and mixtures thereof.
 IOBを約0.00~約0.60とする観点から考察すると、グリセリンと脂肪酸とのジエステルでは、グリセリンと脂肪酸とのジエステルを構成する脂肪酸の炭素数の合計、すなわち、式(6)において、R5C及びR6C部分の炭素数の合計が、約16以上であることが好ましい(炭素数の合計が16の場合にIOBが0.58となる)。 In consideration of setting IOB to about 0.00 to about 0.60, in the diester of glycerin and fatty acid, the total carbon number of fatty acids constituting the diester of glycerin and fatty acid, that is, in the formula (6), The total carbon number of the R 5 C and R 6 C moieties is preferably about 16 or more (when the total carbon number is 16, the IOB is 0.58).
 グリセリンと脂肪酸とのモノエステルは、モノグリセリドとも称され、例えば、グリセリンのオクタデカン酸(C18)モノエステル、グリセリンのドコサン酸(C22)モノエステル等が挙げられる。 The monoester of glycerin and fatty acid is also referred to as monoglyceride, and examples thereof include octadecanoic acid (C 18 ) monoester of glycerin, docosanoic acid (C 22 ) monoester of glycerin and the like.
 IOBを約0.00~約0.60とする観点から考察すると、グリセリンと脂肪酸とのモノエステルでは、グリセリンと脂肪酸とのモノエステルを構成する脂肪酸の炭素数、すなわち、式(7)において、R5C部分の炭素数が、約19以上であることが好ましい(炭素数が19の場合に、IOBが0.59となる)。 Considering that IOB is about 0.00 to about 0.60, in the monoester of glycerin and fatty acid, the carbon number of the fatty acid constituting the monoester of glycerin and fatty acid, that is, in the formula (7), The carbon number of the R 5 C portion is preferably about 19 or more (when the carbon number is 19, the IOB is 0.59).
[(a3)鎖状炭化水素ジオールと少なくとも1の脂肪酸とのエステル]
 鎖状炭化水素ジオールと少なくとも1の脂肪酸とのエステルとしては、例えば、C2~C6の鎖状炭化水素ジオール、例えば、C2~C6のグリコール、例えば、エチレングリコール、プロピレングリコール、ブチレングリコール、ペンチレングリコール又はヘキシレングリコールと、脂肪酸とのモノエステル又はジエステルが挙げられる。
[Ester of (a 3 ) chain hydrocarbon diol and at least one fatty acid]
As an ester of a linear hydrocarbon diol and at least one fatty acid, for example, a C 2 to C 6 linear hydrocarbon diol, for example, a C 2 to C 6 glycol, such as ethylene glycol, propylene glycol, butylene glycol And mono- or diesters of pentylene glycol or hexylene glycol with a fatty acid.
 具体的には、鎖状炭化水素ジオールと少なくとも1の脂肪酸とのエステルとしては、例えば、次の式(8):
 R8COOCk2kOCOR9 (8)
 (式中、kは、2~6の整数であり、そしてR8及びR9は、それぞれ、鎖状炭化水素である)
 のC2~C6グリコールと脂肪酸とのジエステル、及び次の式(9):
 R8COOCk2kOH (9)
 (式中、kは、2~6の整数であり、そしてR8は、鎖状炭化水素である)
 のC2~C6グリコールと脂肪酸とのモノエステルが挙げられる。
Specifically, as an ester of a chain hydrocarbon diol and at least one fatty acid, for example, the following formula (8):
R 8 COOC k H 2k OCOR 9 (8)
(Wherein k is an integer of 2 to 6 and R 8 and R 9 are each a chain hydrocarbon)
And a diester of a C 2 -C 6 glycol and a fatty acid, and the following formula (9):
R 8 COOC k H 2k OH (9)
(Wherein k is an integer of 2 to 6 and R 8 is a chain hydrocarbon)
And monoesters of fatty acid with C 2 -C 6 glycol.
 C2~C6グリコールと脂肪酸とのエステルにおいて、エステル化すべき脂肪酸(式(8)及び式(9)において、R8COOH及びR9COOHに相当する)としては、C2~C6グリコールと脂肪酸とのエステルが、動粘度、抱水率及び重量平均分子量の要件を満たすものであれば、特に制限されず、例えば、「(a1)鎖状炭化水素テトラオールと少なくとも1の脂肪酸とのエステル」において列挙されている脂肪酸、すなわち、飽和脂肪酸及び不飽和脂肪酸が挙げられ、酸化等により変性する可能性を考慮すると、飽和脂肪酸が好ましい。 Examples of the fatty acid to be esterified in the ester of C 2 -C 6 glycol and fatty acid (corresponding to R 8 COOH and R 9 COOH in formulas (8) and (9)) include C 2 -C 6 glycol and The ester with fatty acid is not particularly limited as long as it satisfies the requirements of dynamic viscosity, water content and weight average molecular weight, for example, “(a 1 ) chain hydrocarbon tetraol and at least one fatty acid The fatty acids listed in "Ester", that is, saturated fatty acids and unsaturated fatty acids are mentioned, and considering the possibility of modification by oxidation etc., saturated fatty acids are preferred.
 IOBを約0.00~約0.60とする観点から考察すると、式(8)に示されるブチレングリコール(k=4)と脂肪酸とのジエステルでは、R8C及びR9C部分の炭素数の合計が、約6以上であることが好ましい(炭素数の合計が6の場合に、IOBが0.60となる)。 From the viewpoint of setting IOB to about 0.00 to about 0.60, in the diester of butylene glycol (k = 4) represented by Formula (8) and a fatty acid, the carbon number of the R 8 C and R 9 C moiety is Is preferably about 6 or more (when the total carbon number is 6, the IOB is 0.60).
 IOBを約0.00~約0.60とする観点から考察すると、式(9)に示されるエチレングリコール(k=2)と脂肪酸とのモノエステルでは、R8C部分の炭素数が、約12以上であることが好ましい(炭素数が12の場合に、IOBが0.57となる)。 Considering from the viewpoint of setting IOB to about 0.00 to about 0.60, in the monoester of ethylene glycol (k = 2) shown in formula (9) and fatty acid, the carbon number of the R 8 C moiety is about It is preferable that it is 12 or more (when the carbon number is 12, the IOB is 0.57).
 C2~C6グリコールと脂肪酸とのエステルとしては、酸化等により変性する可能性を考慮すると、飽和脂肪酸に由来する、C2~C6グリコールと脂肪酸とのエステル、すわなち、C2~C6グリコールと飽和脂肪酸とのエステルであることが好ましい。 The esters of C 2 ~ C 6 glycols and fatty acid, in view of the potential for degradation by oxidation and the like, derived from saturated fatty acids, esters of C 2 ~ C 6 glycols and fatty acid, Nachi Suwa, C 2 ~ It is preferably an ester of C 6 glycol and a saturated fatty acid.
 また、C2~C6グリコールと脂肪酸とのエステルとしては、抱水率の値を小さくする観点から、炭素数の大きいグリコールに由来する、グリコールと脂肪酸とのエステル、例えば、ブチレングリコール、ペンチレングリコール又はヘキシレングリコールに由来するグリコールと脂肪酸とのエステルであることが好ましい。
 さらに、C2~C6グリコールと脂肪酸とのエステルとしては、抱水率の値を小さくする観点から、ジエステルであることが好ましい。
 C2~C6グリコールと脂肪酸とのエステルの市販品としては、例えば、コムポールBL、コムポールBS(以上、日油株式会社製)等が挙げられる。
As esters of C 2 -C 6 glycols and fatty acids, esters of glycols and fatty acids derived from glycols having a large number of carbon atoms, for example, butylene glycol, pentylene, from the viewpoint of reducing the water retention rate. It is preferable that it is ester of glycol and fatty acid derived from glycol or hexylene glycol.
Furthermore, as the ester of C 2 -C 6 glycol and fatty acid, a diester is preferable from the viewpoint of reducing the water retention rate.
Examples of commercially available esters of C 2 -C 6 glycol and fatty acid include Commol BL, Commol BS (all manufactured by NOF Corporation) and the like.
[(B) (B1)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(B2)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエーテル]
 (B) (B1)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(B2)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエーテル(以下、「化合物(B)」と称する場合がある)は、上述の動粘度、抱水率及び重量平均分子量を有する限り、全てのヒドロキシル基がエーテル化されていなくともよい。
[(B) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, a chain Ether with compound having one hydroxyl group replacing hydrogen atom of hydrocarbon moiety]
(B) A compound having (B1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and a chain hydrocarbon An ether with a compound having one hydroxyl group replacing a hydrogen atom of a hydrogen portion (hereinafter sometimes referred to as “compound (B)”) has the above-mentioned kinematic viscosity, water retention rate and weight average molecular weight As long as it has, not all hydroxyl groups may be etherified.
 (B1)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物(以下、「化合物(B1)」と称する場合がある)としては、「化合物(A)」において化合物(A1)として列挙されるもの、例えば、ペンタエリトリトール、グリセリン、及びグリコールが挙げられる。 (B1) a compound having a chain hydrocarbon portion and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon portion (hereinafter, may be referred to as “compound (B1)”), Those listed as the compound (A1) in the “compound (A)” include, for example, pentaerythritol, glycerin and glycol.
 (B2)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物(以下、「化合物(B2)」と称する場合がある)としては、例えば、炭化水素の1個の水素原子が、1個のヒドロキシル基(-OH)で置換された化合物、例えば、脂肪族1価アルコール、例えば、飽和脂肪族1価アルコール及び不飽和脂肪族1価アルコールが挙げられる。 Examples of (B2) a compound having a chain hydrocarbon portion and one hydroxyl group replacing a hydrogen atom of the chain hydrocarbon portion (hereinafter may be referred to as “compound (B2)”) include, for example, Compounds in which one hydrogen atom of hydrocarbon is substituted with one hydroxyl group (—OH), for example, aliphatic monohydric alcohols such as saturated aliphatic monohydric alcohols and unsaturated aliphatic monohydric alcohols It can be mentioned.
 飽和脂肪族1価アルコールとしては、例えば、C1~C20の飽和脂肪族1価アルコール、例えば、メチルアルコール(C1)(C1は、炭素数を示す、以下同じ)、エチルアルコール(C2)、プロピルアルコール(C3)及びその異性体、例えば、イソプロピルアルコール(C3)、ブチルアルコール(C4)及びその異性体、例えば、sec-ブチルアルコール(C4)及びtert-ブチルアルコール(C4)、ペンチルアルコール(C5)、ヘキシルアルコール(C6)、ヘプチルアルコール(C7)、オクチルアルコール(C8)及びその異性体、例えば、2-エチルヘキシルアルコール(C8)、ノニルアルコール(C9)、デシルアルコール(C10)、ドデシルアルコール(C12)、テトラデシルアルコール(C14)、ヘキサデシルアルコール(C16)、へプラデシルアルコール(C17)、オクタデシルアルコール(C18)、及びエイコシルアルコール(C20)、並びに列挙されていないこれらの異性体が挙げられる。 As a saturated aliphatic monohydric alcohol, for example, a C 1 to C 20 saturated aliphatic monohydric alcohol, for example, methyl alcohol (C 1 ) (C 1 represents a carbon number, the same applies hereinafter), ethyl alcohol (C 2 ), propyl alcohol (C 3 ) and its isomers such as isopropyl alcohol (C 3 ), butyl alcohol (C 4 ) and its isomers such as sec-butyl alcohol (C 4 ) and tert-butyl alcohol ( C 4 ), pentyl alcohol (C 5 ), hexyl alcohol (C 6 ), heptyl alcohol (C 7 ), octyl alcohol (C 8 ) and isomers thereof, such as 2-ethylhexyl alcohol (C 8 ), nonyl alcohol ( C 9), decyl alcohol (C 10), dodecyl alcohol (C 12), tetradecyl alcohol (C 14), hexyl Decyl alcohol (C 16), heptadecyl alcohol (C 17) to, octadecyl alcohol (C 18), and eicosyl alcohol (C 20), and isomers thereof that are not listed.
 不飽和脂肪族1価アルコールとしては、飽和脂肪族1価アルコールのC-C単結合の1つを、C=C二重結合で置換したもの、例えば、オレイルアルコールが挙げられ、例えば、新日本理化株式会社から、リカコールシリーズ及びアンジェコオールシリーズの名称で市販されている。 Examples of unsaturated aliphatic monohydric alcohols include those in which one of C—C single bonds of saturated aliphatic monohydric alcohols is substituted with C = C double bond, such as oleyl alcohol, for example, Nippon Nippon It is commercially available from Rika Co., Ltd. under the names of Rikacoll series and Angecool series.
 化合物(B)としては、例えば、(b1)鎖状炭化水素テトラオールと少なくとも1の脂肪族1価アルコールとのエーテル、例えば、モノエーテル、ジエーテル、トリエーテル及びテトラエーテル、好ましくはジエーテル、トリエーテル及びテトラエーテル、より好ましくはトリエーテル及びテトラエーテル、そしてさらに好ましくはテトラエーテル、(b2)鎖状炭化水素トリオールと少なくとも1の脂肪族1価アルコールとのエーテル、例えば、モノエーテル、ジエーテル及びトリエーテル、好ましくはジエーテル及びトリエーテル、そしてより好ましくはトリエーテル、並びに(b3)鎖状炭化水素ジオールと少なくとも1の脂肪族1価アルコールとのエーテル、例えば、モノエーテル及びジエーテル、そして好ましくはジエーテルが挙げられる。 As the compound (B), for example, an ether of (b 1 ) chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol, for example, monoether, diether, triether and tetraether, preferably diether, triether Ethers and tetraethers, more preferably triethers and tetraethers, and still more preferably tetraethers, ethers of (b 2 ) chain hydrocarbon triol and at least one aliphatic monohydric alcohol, such as monoethers, diethers and the like Triethers, preferably diethers and triethers, and more preferably triethers, and ethers of (b 3 ) chain hydrocarbon diol and at least one aliphatic monohydric alcohol, such as monoethers and diethers, and preferably Diether It is below.
 鎖状炭化水素テトラオールと少なくとも1の脂肪族1価アルコールとのエーテルとしては、例えば、次の式(10)~(13):
Figure JPOXMLDOC01-appb-C000009
 (式中、R10~R13は、それぞれ、鎖状炭化水素である。)
 の、ペンタエリトリトールと脂肪族1価アルコールとのテトラエーテル、トリエーテル、ジエーテル及びモノエーテルが挙げられる。
As the ether of a chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol, for example, the following formulas (10) to (13):
Figure JPOXMLDOC01-appb-C000009
(Wherein, each of R 10 to R 13 is a chain hydrocarbon).
And tetraethers of pentaerythritol and aliphatic monohydric alcohols, triethers, diethers and monoethers.
 鎖状炭化水素トリオールと少なくとも1の脂肪族1価アルコールとのエーテルとしては、例えば、次の式(14)~(16):
Figure JPOXMLDOC01-appb-C000010
 (式中、R14~R16は、それぞれ、鎖状炭化水素である。)
 の、グリセリンと脂肪族1価アルコールとのトリエーテル、ジエーテル及びモノエーテルが挙げられる。
Examples of ethers of chain hydrocarbon triol and at least one aliphatic monohydric alcohol include the following formulas (14) to (16):
Figure JPOXMLDOC01-appb-C000010
(Wherein, R 14 to R 16 are each a chain hydrocarbon).
And triethers of glycerin and aliphatic monohydric alcohols, diethers and monoethers.
 鎖状炭化水素ジオールと少なくとも1の脂肪族1価アルコールとのエーテルとしては、次の式(17):
 R17OCn2nOR18 (17)
 (式中、nは、2~6の整数であり、そしてR17及びR18は、それぞれ、鎖状炭化水素である)
 のC2~C6グリコールと脂肪族1価アルコールとのジエーテル、及び次の式(18):
 R17OCn2nOH (18)
 (式中、nは、2~6の整数であり、そしてR17は、鎖状炭化水素である)
 のC2~C6グリコールと脂肪族1価アルコールとのモノエーテルが挙げられる。
As the ether of a linear hydrocarbon diol and at least one aliphatic monohydric alcohol, the following formula (17):
R 17 OC n H 2n OR 18 (17)
(Wherein n is an integer of 2 to 6 and R 17 and R 18 are each a chain hydrocarbon)
Diethers of C 2 -C 6 glycols and aliphatic monohydric alcohols, and the following formula (18):
R 17 OC n H 2n OH (18)
(Wherein n is an integer of 2 to 6 and R 17 is a chain hydrocarbon)
And monoethers of C 2 -C 6 glycols and aliphatic monohydric alcohols.
 IOBを約0.00~約0.60とする観点から考察すると、ペンタエリトリトールと脂肪族1価アルコールとのテトラエーテルでは、ペンタエリトリトールと脂肪族1価アルコールとのテトラエーテルを構成する脂肪族1価アルコールの炭素数の合計、すなわち、上記式(10)において、R10、R11、R12及びR13部分の炭素数の合計が、約4以上であることが好ましい(炭素数の合計が4の場合に、IOBが0.44となる)。 Considering that IOB is about 0.00 to about 0.60, in the tetraether of pentaerythritol and aliphatic monohydric alcohol, an aliphatic 1 constituting a tetraether of pentaerythritol and aliphatic monohydric alcohol is used. The total carbon number of the polyhydric alcohol, that is, the total of the carbon numbers of the R 10 , R 11 , R 12 and R 13 moieties in the above formula (10) is preferably about 4 or more (the total carbon number is In the case of 4, the IOB is 0.44).
 IOBを約0.00~約0.60とする観点から考察すると、ペンタエリトリトールと脂肪族1価アルコールとのトリエーテルでは、ペンタエリトリトールと脂肪族1価アルコールとのトリエーテルを構成する脂肪族1価アルコールの炭素数の合計、すなわち、上記式(11)において、R10、R11及びR12部分の炭素数の合計が、約9以上であることが好ましい(炭素数の合計が9の場合に、IOBが0.57となる)。 Considering that IOB is about 0.00 to about 0.60, in the triether of pentaerythritol and aliphatic monohydric alcohol, an aliphatic 1 constituting the triether of pentaerythritol and aliphatic monohydric alcohol is used. The sum of carbon number of the polyhydric alcohol, that is, the sum of carbon numbers of R 10 , R 11 and R 12 in the above formula (11) is preferably about 9 or more (when the total carbon number is 9) , The IOB is 0.57).
 IOBを約0.00~約0.60とする観点から考察すると、ペンタエリトリトールと脂肪族1価アルコールとのジエーテルでは、ペンタエリトリトールと脂肪族1価アルコールとのジエーテルを構成する脂肪族1価アルコールの炭素数の合計、すなわち、上記式(12)において、R10及びR11部分の炭素数の合計が、約15以上であることが好ましい(炭素数の合計が15の場合に、IOBが0.60となる)。 Considering that IOB is about 0.00 to about 0.60, in the diether of pentaerythritol and aliphatic monohydric alcohol, an aliphatic monohydric alcohol constituting a diether of pentaerythritol and aliphatic monohydric alcohol. The sum of the carbon numbers of R 10 and R 11 in the above formula (12) is preferably about 15 or more (when the total carbon number is 15, IOB is 0 It becomes .60).
 IOBを約0.00~約0.60とする観点から考察すると、ペンタエリトリトールと脂肪族1価アルコールとのモノエーテルでは、ペンタエリトリトールと脂肪族1価アルコールとのモノエーテルを構成する脂肪族1価アルコールの炭素数、すなわち、上記式(13)において、R10部分の炭素数が、約22以上であることが好ましい(炭素数が22の場合に、IOBが0.59となる)。 Considering that IOB is about 0.00 to about 0.60, in the monoether of pentaerythritol and aliphatic monohydric alcohol, aliphatic 1 constituting the monoether of pentaerythritol and aliphatic monohydric alcohol The carbon number of the polyhydric alcohol, that is, the carbon number of the R 10 portion in the above formula (13) is preferably about 22 or more (when the carbon number is 22, the IOB is 0.59).
 また、IOBを約0.00~約0.60とする観点から考察すると、グリセリンと脂肪族1価アルコールとのトリエーテルでは、グリセリンと脂肪族1価アルコールとのトリエーテルを構成する脂肪族1価アルコールの炭素数の合計、すなわち、式(14)において、R14、R15及びR16部分の炭素数の合計が、約3以上であることが好ましい(炭素数の合計が3の場合に、IOBが0.50となる)。 Further, when considering from the viewpoint of setting IOB to about 0.00 to about 0.60, in the triether of glycerin and aliphatic monohydric alcohol, an aliphatic 1 constituting the triether of glycerin and aliphatic monohydric alcohol Preferably, the sum of carbon number of the polyhydric alcohol, that is, the sum of carbon numbers of R 14 , R 15 and R 16 in the formula (14) is about 3 or more (when the total carbon number is 3) , IOB is 0.50).
 IOBを約0.00~約0.60とする観点から考察すると、グリセリンと脂肪族1価アルコールとのジエーテルでは、グリセリンと脂肪族1価アルコールとのジエーテルを構成する脂肪族1価アルコールの炭素数の合計、すなわち、式(15)において、R14及びR15部分の炭素数の合計が、約9以上であることが好ましい(炭素数の合計が9の場合に、IOBが0.58となる)。 In consideration of setting IOB to about 0.00 to about 0.60, in the diether of glycerin and aliphatic monohydric alcohol, carbon of aliphatic monohydric alcohol constituting diether of glycerin and aliphatic monohydric alcohol is considered. The sum of the numbers, that is, the sum of carbon numbers of R 14 and R 15 in Formula (15) is preferably about 9 or more (when the total carbon number is 9, IOB is 0.58). Become).
 IOBを約0.00~約0.60とする観点から考察すると、グリセリンと脂肪族1価アルコールとのモノエーテルでは、グリセリンと脂肪族1価アルコールとのモノエーテルを構成する脂肪族1価アルコールの炭素数、すなわち、式(16)において、R14部分の炭素数が、約16以上であることが好ましい(炭素数が16の場合に、IOBが0.58となる)。 Considering that IOB is about 0.00 to about 0.60, in the monoether of glycerin and aliphatic monohydric alcohol, an aliphatic monohydric alcohol constituting a monoether of glycerin and aliphatic monohydric alcohol The carbon number of R 14 in the formula (16) is preferably about 16 or more (when the carbon number is 16, the IOB is 0.58).
 IOBを約0.00~約0.60とする観点から考察すると、式(17)に示されるブチレングリコール(n=4)と脂肪族1価アルコールとのジエーテルでは、R17及びR18部分の炭素数の合計が、約2以上であることが好ましい(炭素数の合計が2の場合に、IOBが0.33となる)。
 また、IOBを約0.00~約0.60とする観点から考察すると、式(18)に示されるエチレングリコール(n=2)と脂肪族1価アルコールとのモノエーテルでは、R17部分の炭素数が、約8以上であることが好ましい(炭素数が8の場合に、IOBが0.60となる)。
Considering from the viewpoint of setting IOB to about 0.00 to about 0.60, in the diether of butylene glycol (n = 4) represented by formula (17) and aliphatic monohydric alcohol, the R 17 and R 18 moieties The total carbon number is preferably about 2 or more (when the total carbon number is 2, IOB is 0.33).
Further, when considering from the viewpoint of setting IOB to about 0.00 to about 0.60, in the monoether of ethylene glycol (n = 2) shown in the formula (18) and aliphatic monohydric alcohol, the R 17 moiety is The carbon number is preferably about 8 or more (when the carbon number is 8, the IOB is 0.60).
 化合物(B)としては、化合物(B1)と、化合物(B2)とを、酸触媒の存在下で、脱水縮合することにより生成することができる。 The compound (B) can be produced by dehydration condensation of the compound (B1) and the compound (B2) in the presence of an acid catalyst.
[(C) (C1)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する、2~4個のカルボキシル基とを含むカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、(C2)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエステル]
 (C) (C1)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する、2~4個のカルボキシル基とを含むカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、(C2)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエステル(以下、「化合物(C)」と称する場合がある)は、上述の動粘度、抱水率及び重量平均分子量を有する限り、全てのカルボキシル基がエステル化されていなくともよい。
[(C) (C1) a linear hydrocarbon moiety and a carboxylic acid, hydroxy acid, alkoxy acid or oxo acid containing 2 to 4 carboxyl groups replacing the hydrogen atom of the linear hydrocarbon moiety ((C) C2) Ester of a compound having a chain hydrocarbon moiety and one hydroxyl group replacing a hydrogen atom of the chain hydrocarbon moiety]
(C) a carboxylic acid, hydroxy acid, alkoxy acid or oxo acid containing (C1) a chain hydrocarbon moiety and 2 to 4 carboxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (C2 An ester of a chain hydrocarbon moiety and a compound having one hydroxyl group which substitutes a hydrogen atom of the chain hydrocarbon moiety (hereinafter sometimes referred to as “compound (C)”) is the above-mentioned All carboxyl groups may not be esterified as long as they have a kinematic viscosity, water content and weight average molecular weight.
 (C1)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する、2~4個のカルボキシル基とを含むカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸(以下、「化合物(C1)」と称する場合がある)としては、例えば、2~4個のカルボキシル基を有する鎖状炭化水素カルボン酸、例えば、鎖状炭化水素ジカルボン酸、例えば、アルカンジカルボン酸、例えば、エタン二酸、プロパン二酸、ブタン二酸、ペンタン二酸、ヘキサン二酸、ヘプタン二酸、オクタン二酸、ノナン二酸及びデカン二酸、鎖状炭化水素トリカルボン酸、例えば、アルカントリカルボン酸、例えば、プロパン三酸、ブタン三酸、ペンタン三酸、ヘキサン三酸、ヘプタン三酸、オクタン三酸、ノナン三酸及びデカン三酸、並びに鎖状炭化水素テトラカルボン酸、例えば、アルカンテトラカルボン酸、例えば、ブタン四酸、ペンタン四酸、ヘキサン四酸、ヘプタン四酸、オクタン四酸、ノナン四酸及びデカン四酸が挙げられる。 (C1) a linear hydrocarbon moiety and a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing 2 to 4 carboxyl groups replacing the hydrogen atom of the linear hydrocarbon moiety (hereinafter referred to as “compound (C1 )) May be, for example, a linear hydrocarbon carboxylic acid having 2 to 4 carboxyl groups, such as a linear hydrocarbon dicarboxylic acid, such as an alkane dicarboxylic acid, such as ethanedioic acid, Propanedioic acid, butanedioic acid, pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid, nonanedioic acid and decanedioic acid, linear hydrocarbon tricarboxylic acids such as alkanetricarboxylic acids such as propane triacid Butane triacid, pentane triacid, hexane triacid, heptane triacid, octane triacid, nonane triacid and decane triacid, and chain hydrocarbon tetracarbo Acids such as alkane tetracarboxylic acids such as butane tetra acid, pentane tetra acid, hexane tetra acid, heptane tetra acid, octane tetra acid, octane tetra acid, nonane tetra acid and decane tetra acid.
 また、化合物(C1)には、2~4個のカルボキシル基を有する鎖状炭化水素ヒドロキシ酸、例えば、リンゴ酸、酒石酸、クエン酸、イソクエン酸等、2~4個のカルボキシル基を有する鎖状炭化水素アルコキシ酸、例えば、O-アセチルクエン酸、及び2~4個のカルボキシル基を有する鎖状炭化水素オキソ酸が含まれる。
 (C2)鎖状炭化水素部分と、鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物としては、「化合物(B)」の項で列挙されるもの、例えば、脂肪族1価アルコールが挙げられる。
Further, in the compound (C1), a linear hydrocarbon hydroxy acid having 2 to 4 carboxyl groups, for example, a linear chain having 2 to 4 carboxyl groups, such as malic acid, tartaric acid, citric acid, isocitric acid, etc. Hydrocarbon alkoxy acids, such as O-acetylcitric acid, and linear hydrocarbon oxoacids with 2 to 4 carboxyl groups are included.
Examples of the compound having (C2) a chain hydrocarbon portion and one hydroxyl group replacing a hydrogen atom of the chain hydrocarbon portion include those listed in the “compound (B)”, for example, fat And monohydric monohydric alcohols.
 化合物(C)としては、(c1)4個のカルボキシル基を有する鎖状炭化水素テトラカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、例えば、モノエステル、ジエステル、トリエステル及びテトラエステル、好ましくはジエステル、トリエステル及びテトラエステル、より好ましくはトリエステル及びテトラエステル、そしてさらに好ましくはテトラエステル、(c2)3個のカルボキシル基を有する鎖状炭化水素トリカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、例えば、モノエステル、ジエステル及びトリエステル、好ましくはジエステル及びトリエステル、そしてより好ましくはトリエステル、並びに(c3)2個のカルボキシル基を有する鎖状炭化水素ジカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、例えば、モノエステル及びジエステル、好ましくはジエステルが挙げられる。
 化合物(C)の例としては、アジピン酸ジオクチル、O-アセチルクエン酸トリブチル等が挙げられ、そして市販されている。
As the compound (C), an ester of (c 1 ) chain hydrocarbon tetracarboxylic acid having 4 carboxyl groups, a hydroxy acid, an alkoxy acid or an oxo acid, and at least one aliphatic monohydric alcohol, for example, Mono-, di-, tri- and tetra-esters, preferably diesters, tri- and tetra-esters, more preferably tri- and tetra-esters, and still more preferably tetra-esters, chained with 3 (c 2 ) carboxyl groups Esters of hydrocarbon tricarboxylic acids, hydroxy acids, alkoxy acids or oxo acids with at least one aliphatic monohydric alcohol, such as monoesters, diesters and triesters, preferably diesters and triesters, and more preferably triesters , And ( 3) chain hydrocarbon dicarboxylic acids having two carboxyl groups, hydroxy acids, esters of alkoxy acids or oxoacids, and at least one aliphatic monohydric alcohol, for example, mono- and diesters, preferably include diester Be
Examples of the compound (C) include dioctyl adipate, tributyl O-acetyl citrate and the like, and are commercially available.
[(D)鎖状炭化水素部分と、鎖状炭化水素部分のC-C単結合間に挿入された、エーテル結合(-O-)、カルボニル結合(-CO-)、エステル結合(-COO-)、及びカーボネート結合(-OCOO-)から成る群から選択されるいずれか1つの結合とを有する化合物]
 (D)鎖状炭化水素部分と、鎖状炭化水素部分のC-C単結合間に挿入された、エーテル結合(-O-)、カルボニル結合(-CO-)、エステル結合(-COO-)、及びカーボネート結合(-OCOO-)から成る群から選択されるいずれか1つの結合とを有する化合物(以下、「化合物(D)」と称する場合がある)としては、(d1)脂肪族1価アルコールと脂肪族1価アルコールとのエーテル、(d2)ジアルキルケトン、(d3)脂肪酸と脂肪族1価アルコールとのエステル、及び(d4)ジアルキルカーボネートが挙げられる。
[(D) a linear hydrocarbon moiety and an ether bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO-) inserted between the C-C single bond of the linear hydrocarbon moiety And a compound having any one bond selected from the group consisting of carbonate bonds (—OCOO—)]
(D) Ether bond (-O-), carbonyl bond (-CO-), ester bond (-COO-) inserted between chain hydrocarbon moiety and C-C single bond of chain hydrocarbon moiety , and carbonate bond (-OCOO-) compound having a any one bond selected from the group consisting of (hereinafter also referred to as "compound (D)") include, (d 1) aliphatic 1 Ethers of polyhydric alcohols and aliphatic monohydric alcohols, (d 2 ) dialkyl ketones, esters of (d 3 ) fatty acids and aliphatic monohydric alcohols, and (d 4 ) dialkyl carbonates can be mentioned.
[(d1)脂肪族1価アルコールと脂肪族1価アルコールとのエーテル]
 脂肪族1価アルコールと脂肪族1価アルコールとのエーテルとしては、次の式(19):
 R19OR20  (19)
 (式中、R19及びR20は、それぞれ、鎖状炭化水素である)
 を有する化合物が挙げられる。
[(D 1 ) ether of aliphatic monohydric alcohol and aliphatic monohydric alcohol]
As an ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol, the following formula (19):
R 19 OR 20 (19)
(Wherein, R 19 and R 20 are each a chain hydrocarbon)
And compounds having the formula:
 エーテルを構成する脂肪族1価アルコール(式(19)において、R19OH及びR20OHに相当する)としては、エーテルが、上述の動粘度、抱水率及び重量平均分子量の要件を満たすものであれば、特に制限されず、例えば、「化合物(B)」の項で列挙される脂肪族1価アルコールが挙げられる。 As an aliphatic monohydric alcohol constituting an ether (corresponding to R 19 OH and R 20 OH in the formula (19)), an ether satisfying the above-mentioned requirements for the kinematic viscosity, water content and weight average molecular weight It is not particularly limited, and examples thereof include aliphatic monohydric alcohols listed in the section "Compound (B)".
[(d2)ジアルキルケトン]
 ジアルキルケトンとしては、次の式(20):
 R21COR22  (20)
 (式中、R21及びR22は、それぞれ、アルキル基である)
 を有する化合物が挙げられる。
 ジアルキルケトンは、市販されている他、公知の方法、例えば、第二級アルコールを、クロム酸等で酸化することにより得ることができる。
[(D 2 ) dialkyl ketone]
As the dialkyl ketone, the following formula (20):
R 21 COR 22 (20)
(Wherein, each of R 21 and R 22 is an alkyl group)
And compounds having the formula:
The dialkyl ketone is commercially available and can be obtained by a known method, for example, by oxidizing a secondary alcohol with chromic acid or the like.
[(d3)脂肪酸と脂肪族1価アルコールとのエステル]
 脂肪酸と脂肪族1価アルコールとのエステルとしては、例えば、次の式(21):
 R23COOR24 (21)
 (式中、R23及びR24は、それぞれ、鎖状炭化水素である)
 を有する化合物が挙げられる。
[(D 3 ) ester of fatty acid and aliphatic monohydric alcohol]
As an ester of a fatty acid and an aliphatic monohydric alcohol, for example, the following formula (21):
R 23 COOR 24 (21)
(Wherein each of R 23 and R 24 is a chain hydrocarbon)
And compounds having the formula:
 エステルを構成する脂肪酸(式(21)において、R23COOHに相当する)としては、例えば、「(a1)鎖状炭化水素テトラオールと脂肪酸とのエステル」において列挙されている脂肪酸、すなわち、飽和脂肪酸又は不飽和脂肪酸が挙げられ、酸化等により変性する可能性を考慮すると、飽和脂肪酸が好ましい。エステルを構成する脂肪族1価アルコール(式(21)において、R24OHに相当する)としては、例えば、「化合物(B)」の項で列挙される脂肪族1価アルコールが挙げられる。 Examples of the fatty acid constituting the ester (corresponding to R 23 COOH in formula (21)) include, for example, fatty acids listed in “ester of (a 1 ) chain hydrocarbon tetraol and fatty acid”, ie, Saturated fatty acids or unsaturated fatty acids are mentioned, and in consideration of the possibility of modification by oxidation etc., saturated fatty acids are preferred. Examples of the aliphatic monohydric alcohol constituting the ester (corresponding to R 24 OH in the formula (21)) include, for example, the aliphatic monohydric alcohols listed in the “compound (B)” section.
 脂肪酸と脂肪族1価アルコールとのエステルの例としては、例えば、ドデカン酸(C12)と、ドデシルアルコール(C12)とのエステル、テトラデカン酸(C14)と、ドデシルアルコール(C12)とのエステル等が挙げられ、脂肪酸と脂肪族1価アルコールとのエステルの市販品としては、例えば、エレクトールWE20、及びエレクトールWE40(以上、日油株式会社製)が挙げられる。 Examples of esters of fatty acids and aliphatic monohydric alcohols include, for example, esters of dodecanoic acid (C 12 ), dodecyl alcohol (C 12 ), tetradecanoic acid (C 14 ), and dodecyl alcohol (C 12 ) Examples of commercially available esters of fatty acid and aliphatic monohydric alcohol include Electol WE20 and Electol WE40 (all manufactured by NOF Corporation).
[(d4)ジアルキルカーボネート]
 ジアルキルカーボネートとしては、次の式(22):
 R25OC(=O)OR26  (22)
 (式中、R25及びR26は、それぞれ、アルキル基である)
 を有する化合物が挙げられる。
 ジアルキルカーボネートは、市販されている他、ホスゲンとアルコールとの反応、塩化ギ酸エステルとアルコール又はアルコラートとの反応、及び炭酸銀とヨウ化アルキルとの反応により合成することができる。
[(D 4 ) dialkyl carbonate]
As the dialkyl carbonate, the following formula (22):
R 25 OC (= O) OR 26 (22)
(Wherein, R 25 and R 26 are each an alkyl group)
And compounds having the formula:
In addition to being commercially available, dialkyl carbonates can be synthesized by the reaction of phosgene with alcohol, the reaction of formic acid chloride with alcohol or alcoholate, and the reaction of silver carbonate with alkyl iodide.
 抱水率、蒸気圧等の観点から考察すると、(d1)脂肪族1価アルコールと脂肪族1価アルコールとのエーテル、(d2)ジアルキルケトン、(d3)脂肪酸と脂肪族1価アルコールとのエステル、及び(d4)ジアルキルカーボネートでは、重量平均分子量が約100以上であることが好ましく、そして約200以上であることがより好ましい。
 なお、(d2)ジアルキルケトンにおいて、炭素数の合計が約8の場合、例えば、5-ノナノンでは、融点は約-50℃であり、蒸気圧は20℃で約230Paである。
From the viewpoint of water retention, vapor pressure, etc., (d 1 ) ethers of aliphatic monohydric alcohols and aliphatic monohydric alcohols, (d 2 ) dialkyl ketones, (d 3 ) fatty acids and aliphatic monohydric alcohols And the (d 4 ) dialkyl carbonate, the weight average molecular weight is preferably about 100 or more, and more preferably about 200 or more.
In the case of (d 2 ) dialkyl ketone, when the total carbon number is about 8, for example, 5-nonanone, the melting point is about −50 ° C., and the vapor pressure is about 230 Pa at 20 ° C.
[(E)ポリオキシC3~C6アルキレングリコール、又はそのアルキルエステル若しくはアルキルエーテル]
 (E)ポリオキシC3~C6アルキレングリコール、又はそのアルキルエステル若しくはアルキルエーテル(以下、化合物(E)と称する場合がある)としては、(e1)ポリオキシC3~C6アルキレングリコール、(e2)ポリオキシC3~C6アルキレングリコールと少なくとも1の脂肪酸とのエステル、(e3)ポリオキシC3~C6アルキレングリコールと少なくとも1の脂肪族1価アルコールとのエーテルが挙げられる。以下、説明する。
[(E) Polyoxy C 3 -C 6 alkylene glycol, or its alkyl ester or alkyl ether]
Examples of (E) polyoxy C 3 -C 6 alkylene glycol, or an alkyl ester or alkyl ether thereof (hereinafter sometimes referred to as compound (E)) include (e 1 ) polyoxy C 3 -C 6 alkylene glycol, (e 2 ) Esters of polyoxy C 3 -C 6 alkylene glycol and at least one fatty acid, and (e 3 ) ethers of polyoxy C 3 -C 6 alkylene glycol and at least one aliphatic monohydric alcohol. This will be described below.
[(e1)ポリオキシC3~C6アルキレングリコール]
 ポリオキシC3~C6アルキレングリコールは、i)オキシC3~C6アルキレン骨格、すなわち、オキシプロピレン骨格、オキシブチレン骨格、オキシペンチレン骨格、及びオキシヘキシレン骨格から成る群から選択されるいずれか1種の骨格を有し且つ両末端にヒドロキシ基を有するホモポリマー、ii)上記群から選択される2種以上の骨格を有し且つ両末端にヒドロキシ基を有するブロックコポリマー、又はiii)上記群から選択される2種以上の骨格を有し且つ両末端にヒドロキシ基を有するランダムコポリマーを意味する。
[(E 1 ) polyoxy C 3 -C 6 alkylene glycol]
Polyoxy C 3 ~ C 6 alkylene glycol, i) oxy C 3 ~ C 6 alkylene backbone, i.e., oxypropylene backbone, oxybutylene backbone, any one selected from the group consisting of oxypentylene skeleton, and oxy hexylene backbone A homopolymer having one kind of skeleton and having a hydroxy group at both ends, ii) a block copolymer having two or more kinds of skeleton selected from the above group and having a hydroxy group at both ends, or iii) the above group It means a random copolymer having two or more types of backbones selected from and having a hydroxy group at both ends.
 ポリオキシC3~C6アルキレングリコールは、次の式(23):
 HO-(Cm2mO)n-H   (23)
 (式中、mは3~6の整数である)
 により表わされる。
The polyoxy C 3 -C 6 alkylene glycol has the following formula (23):
HO- (C m H 2m O) n -H (23)
(In the formula, m is an integer of 3 to 6)
Is represented by
 本発明者が確認したところ、ポリプロピレングリコール(式(23)において、m=3のホモポリマーに相当する)では、重量平均分子量が約1,000未満の場合には、抱水率の要件を満たさないことが見いだされた。従って、血液滑性付与剤の範囲に、ポリプロピレングリコールのホモポリマーは含まれず、プロピレングリコールは、他のグリコールとのコポリマー又はランダムポリマーとして、(e1)ポリオキシC3~C6アルキレングリコールに含まれるべきである。 As confirmed by the present inventor, polypropylene glycol (corresponding to a homopolymer of m = 3 in the formula (23)) satisfies the requirements for water retention when the weight average molecular weight is less than about 1,000. It was found not to be. Therefore, in the range of blood slipping agents, homopolymers of polypropylene glycol are not included, and propylene glycol is included in (e 1 ) polyoxy C 3 -C 6 alkylene glycol as a copolymer with another glycol or a random polymer It should.
 なお、本発明者が確認したところ、ポリエチレングリコール(式(23)において、m=2のホモポリマーに相当する)では、重量平均分子量が1,000未満では、動粘度及び抱水率の要件を満たし得ないことが示唆された。 According to the present inventor's confirmation, when the weight average molecular weight is less than 1,000, the requirements for the dynamic viscosity and the water retention rate are polyethylene glycol (corresponding to a homopolymer of m = 2 in the formula (23)). It was suggested that it could not be satisfied.
 IOBを約0.00~約0.60とする観点から考察すると、例えば、式(23)がポリブチレングリコール(m=4のホモポリマー)である場合には、n≧約7であることが好ましい(n=7の場合に、IOBが0.57となる)。 From the viewpoint of setting the IOB to about 0.00 to about 0.60, for example, when the formula (23) is polybutylene glycol (m = 4 homopolymer), n ホ モ about 7 Preferred (when n = 7, IOB is 0.57).
 ポリC3~C6アルキレングリコールの市販品としては、例えば、ユニオール(商標)PB-500及びPB-700(以上、日油株式会社製)が挙げられる。 Commercially available poly C 3 -C 6 alkylene glycols include, for example, Uniol (trademark) PB-500 and PB-700 (manufactured by NOF Corporation).
[(e2)ポリオキシC3~C6アルキレングリコールと少なくとも1の脂肪酸とのエステル]
 ポリオキシC3~C6アルキレングリコールと少なくとも1の脂肪酸とのエステルとしては、「(e1)ポリオキシC3~C6アルキレングリコール」の項で説明したポリオキシC3~C6アルキレングリコールのOH末端の一方又は両方が、脂肪酸によりエステル化されているもの、すなわち、モノエステル及びジエステルが挙げられる。
[Ester of (e 2 ) polyoxy C 3 -C 6 alkylene glycol with at least one fatty acid]
As ester of polyoxy C 3 -C 6 alkylene glycol and at least one fatty acid, OH terminal of polyoxy C 3 -C 6 alkylene glycol described in the section “(e 1 ) polyoxy C 3 -C 6 alkylene glycol” One or both may be esterified with fatty acids, ie, monoesters and diesters.
 ポリオキシC3~C6アルキレングリコールと少なくとも1の脂肪酸とのエステルにおいて、エステル化すべき脂肪酸としては、例えば、「(a1)鎖状炭化水素テトラオールと少なくとも1の脂肪酸とのエステル」において列挙されている脂肪酸、すなわち、飽和脂肪酸又は不飽和脂肪酸が挙げられ、酸化等により変性する可能性を考慮すると、飽和脂肪酸が好ましい。 In the ester of polyoxy C 3 -C 6 alkylene glycol and at least one fatty acid, the fatty acid to be esterified is, for example, listed in “ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid”. Fatty acids, that is, saturated fatty acids or unsaturated fatty acids, and in view of the possibility of modification by oxidation etc., saturated fatty acids are preferred.
[(e3)ポリオキシC3~C6アルキレングリコールと少なくとも1の脂肪族1価アルコールとのエーテル]
 ポリオキシC3~C6アルキレングリコールと少なくとも1の脂肪族1価アルコールとのエーテルとしては、「(e1)ポリオキシC3~C6アルキレングリコール」の項で説明したポリオキシC3~C6アルキレングリコールのOH末端の一方又は両方が、脂肪族1価アルコールによりエーテル化されているもの、すなわち、モノエーテル及びジエーテルが挙げられる。
 ポリオキシC3~C6アルキレングリコールと少なくとも1の脂肪族1価アルコールとのエーテルにおいて、エーテル化すべき脂肪族1価アルコールとしては、例えば、「化合物(B)」の項で列挙されている脂肪族1価アルコールが挙げられる。
[(E 3 ) Ether of polyoxy C 3 -C 6 alkylene glycol and at least one aliphatic monohydric alcohol]
The ether of polyoxy C 3 ~ C 6 alkylene glycol and at least one aliphatic monohydric alcohol, "(e 1) polyoxy C 3 ~ C 6 alkylene glycol" polyoxy C 3 ~ C 6 alkylene glycol is described in the section of Those obtained by etherifying one or both of the OH ends of (1) with an aliphatic monohydric alcohol, ie, monoethers and diethers.
In the ether of polyoxy C 3 -C 6 alkylene glycol and at least one aliphatic monohydric alcohol, as aliphatic monohydric alcohol to be etherified, for example, aliphatic listed in the “compound (B)” section Monohydric alcohol is mentioned.
[(F)鎖状炭化水素]
 鎖状炭化水素としては、例えば、(f1)鎖状アルカン、例えば、直鎖アルカン及び分岐鎖アルカンが挙げられる。直鎖アルカンは、融点が約45℃以下の場合には、炭素数が約22以下となり、そして蒸気圧が1気圧及び25℃で約0.01Pa以下である場合には、炭素数が約13以上となる。分岐鎖アルカンは、直鎖アルカンよりも、同一炭素数において融点が低い傾向がある。従って、分岐鎖アルカンは、融点が約45℃以下の場合でも、炭素数が22以上のものも含むことができる。
 炭化水素の市販品としては、例えば、パールリーム6(日油株式会社)が挙げられる。
 排泄口当接領域20のうち少なくとも凸部8には、血液滑性付与剤が単独で塗工されていてもよいし、血液滑性付与剤と、少なくとも1種の他の成分とを含有する血液滑性付与剤含有組成物が塗工されていてもよい。
[(F) chain hydrocarbon]
The chain hydrocarbon includes, for example, (f 1 ) chain alkanes, such as straight chain alkanes and branched alkanes. Linear alkanes have a carbon number of about 22 or less when the melting point is about 45 ° C. or less, and a carbon number of about 13 when the vapor pressure is about 0.01 Pa or less at 1 atmosphere and 25 ° C. It becomes above. Branched alkanes tend to have lower melting points at the same carbon number than linear alkanes. Thus, branched alkanes can also contain those having 22 or more carbons, even when the melting point is about 45 ° C. or less.
As a commercial item of hydrocarbon, for example, Pearl Reem 6 (NOF Corporation) can be mentioned.
A blood slipping agent may be coated alone on at least the convex portion 8 in the discharge port abutting region 20, or contains the blood slipping agent and at least one other component. The blood slipping agent-containing composition may be coated.
 以下、血液滑性付与剤含有組成物について説明する。なお、血液滑性付与剤含有組成物の塗工に関しては、血液滑性付与剤の塗工と同様であるので、説明を省略する。 Hereinafter, the blood slipping agent-containing composition will be described. In addition, about coating of a blood slipping agent containing composition, since it is the same as coating of a blood slipping agent, description is abbreviate | omitted.
[血液滑性付与剤含有組成物]
 血液滑性付与剤含有組成物は、上述の血液滑性付与剤と、少なくとも1種の他の成分とを含有する。他の成分としては、血液滑性付与剤の作用効果を阻害しないものであれば特に制限されず、当業界で吸収性物品、特にトップシートに慣用的に適用されるものを使用することができる。
[Blood lubricity agent-containing composition]
The blood slipping agent-containing composition contains the above-described blood slipping agent and at least one other component. The other components are not particularly limited as long as they do not inhibit the action and effect of the blood slipping agent, and materials conventionally applied to absorbent articles, particularly top sheets in the art can be used. .
 他の成分としては、例えば、シリコーンオイル、シリコーン、シリコーン系レジン等が挙げられる。 As other components, silicone oil, silicone, silicone resin etc. are mentioned, for example.
 他の成分としては、例えば、酸化防止剤、例えば、BHT(2,6-ジ-t-ブチル-p-クレゾール)、BHA(ブチル化ヒドロキシアニソール)、没食子酸プロピル等が挙げられる。 Other components include, for example, antioxidants, such as BHT (2,6-di-t-butyl-p-cresol), BHA (butylated hydroxyanisole), propyl gallate and the like.
 他の成分としては、例えば、ビタミン、例えば、天然ビタミン又は合成ビタミンが挙げられる。ビタミンとしては、例えば、水溶性ビタミン、例えば、ビタミンB群、例えば、ビタミンB1,ビタミンB2,ビタミンB3,ビタミンB5,ビタミンB6,ビタミンB7,ビタミンB9,ビタミンB12等、ビタミンCが挙げられる。 Other ingredients include, for example, vitamins, such as natural or synthetic vitamins. As vitamins, for example, water-soluble vitamins, such as vitamin B group, such as vitamin B 1, vitamin B 2, vitamin B 3, vitamin B 5, vitamin B 6, vitamin B 7, vitamin B 9, Vitamin B 12, etc. And vitamin C.
 ビタミンとしては、例えば、脂溶性ビタミン、例えば、ビタミンA群、ビタミンD群、ビタミンE群、およびビタミンK群等が挙げられる。ビタミンにはまた、それらの誘導体も含まれる。 Examples of vitamins include fat-soluble vitamins such as vitamin A group, vitamin D group, vitamin E group, and vitamin K group. Vitamins also include their derivatives.
 他の成分としては、例えば、アミノ酸、例えば、アラニン、アルギニン、リジン、ヒスチジン、プロリン、ヒドロキシプロリン等、並びにペプチドが挙げられる。 Other components include, for example, amino acids such as, for example, alanine, arginine, lysine, histidine, proline, hydroxyproline and the like, as well as peptides.
 他の成分としては、例えば、ゼオライト、例えば、天然ゼオライト、例えば、方沸石、菱沸石、輝沸石、ナトロライト、束沸石、及びソモソナイト、並びに、合成ゼオライトが挙げられる。 Other components include, for example, zeolites, such as natural zeolites, such as, for example, chabazite, chabazite, fluorite, natrolite, sodalite and somsonite, as well as synthetic zeolites.
 他の成分としては、例えば、コレステロール、ヒアルロン酸、レシチン、セラミド等が挙げられる。 Other components include, for example, cholesterol, hyaluronic acid, lecithin, ceramide and the like.
 他の成分としては、例えば、薬剤、例えば、皮膚収斂剤、抗ニキビ剤、抗シワ剤、抗セルライト剤、美白剤、抗菌剤、抗カビ剤等が挙げられる。 Other components include, for example, drugs such as skin astringent agents, anti-acne agents, anti-wrinkle agents, anti-cellulite agents, skin-whitening agents, antibacterial agents, antifungal agents and the like.
 皮膚収斂剤としては、例えば、酸化亜鉛、硫酸アルミニウム、タンニン酸等、油溶性皮膚収斂剤、例えば、油溶性ポリフェノールが挙げられる。油溶性ポリフェノールとしては、天然の油溶性ポリフェノール、例えば、オオバクエキス、オトギリソウエキス、オドリコソウエキス、カモミラエキス、ゴボウエキス、サルビアエキス、シナノキエキス、セイヨウボダイジュエキス、シラカバエキス、スギナエキス、セージエキス、サルビアエキス、テウチグルミエキス、ハイビスカスエキス、ビワ葉エキス、ボダイジュエキス、ホップエキス、マロニエエキス、ヨクイニンエキス等が挙げられる。 Examples of the skin astringent agent include oil-soluble skin astringent agents such as zinc oxide, aluminum sulfate, tannic acid and the like, for example, oil-soluble polyphenols. Examples of oil-soluble polyphenols include natural oil-soluble polyphenols, such as, for example, ginseng extract, hypericillium extract, prickly pear extract, kamomira extract, burdock extract, salvia extract, linden extract, bromeliad extract, birch extract, cedar extract, sage extract, salvia extract, Teuchichumimi extract, hibiscus extract, loquat leaf extract, bodaiji extract, hop extract, marronier extract, yokinin extract and the like.
 抗ニキビ剤としては、例えば、サリチル酸、過酸化ベンゾイル、レゾルシノール、イオウ、エリスロマイシン、亜鉛等が挙げられる。 Examples of the anti-acne agent include salicylic acid, benzoyl peroxide, resorcinol, sulfur, erythromycin, zinc and the like.
 抗シワ剤としては、例えば、乳酸、サリチル酸、サリチル酸誘導体、グリコール酸、フィチン酸、リポ酸、リソフォスファチド酸が挙げられる。 Examples of anti-wrinkle agents include lactic acid, salicylic acid, salicylic acid derivatives, glycolic acid, phytic acid, lipoic acid and lysophosphatidic acid.
 抗セルライト剤としては、例えば、キサンチン化合物、例えば、アミノフィリン、カフェイン、テオフィリン、テオブロミン等が挙げられる。 Examples of anti-cellulite agents include xanthine compounds such as aminophylline, caffeine, theophylline, theobromine and the like.
 美白剤としては、例えば、ナイアシンアミド、コウジ酸、アルブチン、グルコサミン及び誘導体、フィトステロール誘導体、アスコルビン酸及びその誘導体、並びにクワ抽出物及び胎盤抽出物が挙げられる。 Examples of the skin lightening agent include niacinamide, kojic acid, arbutin, glucosamine and derivatives, phytosterol derivatives, ascorbic acid and its derivatives, and mulberry extract and placenta extract.
 他の成分としては、例えば、抗炎症成分、pH調整剤、抗菌剤、保湿剤、香料、色素、染料、顔料、植物抽出エキス等が挙げられる。 Other components include, for example, anti-inflammatory ingredients, pH adjusters, antibacterial agents, moisturizers, perfumes, dyes, dyes, pigments, plant extracts and the like.
 抗炎症成分としては、例えば、天然由来の抗炎症剤、例えば、ボタン、オオゴン、オトギリソウ、カモミール、甘草、モモノハ、ヨモギ、シソエキス等、合成抗炎症剤、例えば、アラントイン、グリチルリチン酸ジカリウム等が挙げられる。 Examples of the anti-inflammatory component include naturally-occurring anti-inflammatory agents such as, for example, button, gogon, hyperglossia, chamomile, licorice, peach tree, sage extract, etc .
 pH調整剤としては、皮膚を弱酸性に保つためのもの、例えば、リンゴ酸、コハク酸、クエン酸、酒石酸、乳酸等が挙げられる。 Examples of pH adjusters include those for keeping the skin weakly acidic, such as malic acid, succinic acid, citric acid, tartaric acid, lactic acid and the like.
 顔料としては、例えば、酸化チタンが挙げられる。 As a pigment, a titanium oxide is mentioned, for example.
 血液滑性付与剤含有組成物は、血液滑性付与剤及び少なくとも1種の他の成分を、それぞれ、好ましくは約50~約99質量%及び約1~約50質量%、より好ましくは約60~約99質量%及び約1~約40質量%、さらに好ましくは約70~約99質量%及び約1~約30質量%、さらに一層好ましくは約80~約99質量%及び約1~約20質量%、さらに一層好ましくは約90~99質量%及び約1~約10質量%、さらに一層好ましくは約95~99質量%及び約1~約5質量%含む。血液滑性付与剤及び他の成分の作用効果の観点からである。 The blood slipping agent-containing composition preferably comprises about 50 to about 99% by weight and about 1 to about 50% by weight, more preferably about 60% by weight of the blood slipping agent and at least one other component, respectively. To about 99 wt% and about 1 to about 40 wt%, more preferably about 70 to about 99 wt% and about 1 to about 30 wt%, still more preferably about 80 to about 99 wt% and about 1 to about 20 % By weight, still more preferably about 90 to 99% by weight and about 1 to about 10% by weight, still more preferably about 95 to 99% by weight and about 1 to about 5% by weight. It is from the viewpoint of the effect of the blood slipping agent and other components.
 血液滑性付与剤含有組成物は、界面活性剤を、トップシート又はセカンドシートの親水化処理に由来する量以下で含むことが好ましい。より具体的には、血液滑性付与剤含有組成物は、界面活性剤を、好ましくは約0.0~約1.0g/m2、より好ましくは約0.0~約0.8g/m2、さらに好ましくは約0.1~約0.5g/m2、さらに一層好ましくは約0.1~約0.3g/m2の坪量の範囲で含む。 The blood slipping agent-containing composition preferably contains a surfactant in an amount equal to or less than the amount derived from the hydrophilization treatment of the top sheet or the second sheet. More specifically, the blood slipping agent-containing composition preferably contains a surfactant, preferably about 0.0 to about 1.0 g / m 2 , more preferably about 0.0 to about 0.8 g / m 2 2 , more preferably in the range of a basis weight of about 0.1 to about 0.5 g / m 2 , still more preferably about 0.1 to about 0.3 g / m 2 .
 界面活性剤の量が増えると、経血がトップシートに残存しやすい傾向があるからである。なお、界面活性剤は、抱水率の値を有しない。水と混和するため、測定すべき物質の層が存在しないからである。 This is because menstrual blood tends to remain on the top sheet as the amount of surfactant increases. The surfactant does not have a water retention value. This is because there is no layer of the substance to be measured because it is miscible with water.
 血液滑性付与剤含有組成物は、水を、好ましくは約0.0~約1.0g/m2、より好ましくは約0.0~約0.8g/m2、さらに好ましくは約0.1~約0.5g/m2、さらに一層好ましくは約0.1~約0.3g/m2の坪量の範囲で含む。水は、吸収性物品の吸収性能を低下させるため、少ないことが好ましい。 The blood slipping agent-containing composition preferably contains water, preferably about 0.0 to about 1.0 g / m 2 , more preferably about 0.0 to about 0.8 g / m 2 , still more preferably about 0. A basis weight ranging from 1 to about 0.5 g / m 2 , even more preferably from about 0.1 to about 0.3 g / m 2 is included. Water is preferably low to reduce the absorption performance of the absorbent article.
 血液滑性付与剤含有組成物は、血液滑性付与剤と同様に、組成物として、40℃において、約0~約80mm2/sの動粘度を有することが好ましく、約1~約70mm2/sの動粘度を有することがより好ましく、約3~約60mm2/sの動粘度を有することがさらに好ましく、約5~約50mm2/sの動粘度を有することがさらに一層好ましく、約7~約45mm2/sの動粘度を有することがさらに一層好ましい。 The blood slipping agent-containing composition, like the blood slipping agent, preferably has a kinematic viscosity of about 0 to about 80 mm 2 / s at 40 ° C. as a composition, and about 1 to about 70 mm 2. It is more preferred to have a kinematic viscosity of 1 / s, even more preferred to have a kinematic viscosity of about 3 to about 60 mm 2 / s, and even more preferred to have a kinematic viscosity of about 5 to about 50 mm 2 / s, Even more preferably, they have a kinematic viscosity of 7 to about 45 mm 2 / s.
 血液滑性付与剤含有組成物の動粘度が約80mm2/sを超えると、粘性が高く、トップシートの肌当接面に到達した経血と共に、血液滑性付与剤組成物が吸収性物品の内部に滑落することが難しくなる傾向があるからである。 When the kinematic viscosity of the blood slipping agent-containing composition exceeds about 80 mm 2 / s, the viscosity is high and the blood slipping agent composition is an absorbent article together with menstrual blood reaching the skin contact surface of the top sheet. Because it tends to be difficult to slip inside.
 血液滑性付与剤含有組成物が、少なくとも1種の他の成分として血液滑性付与剤と混和する成分を含む場合には、その他の成分は、好ましくは約1,000未満の重量平均分子量を有し、より好ましくは約900未満の重量平均分子量を有する。重量平均分子量が約1,000以上であると、血液滑性付与剤含有組成物そのものにタック性が生じ、着用者に不快感を与える傾向があるからである。また、重量平均分子量が高くなると、血液滑性付与剤含有組成物の粘度が高くなる傾向があるため、加温により、血液滑性付与剤組成物の粘度を、塗布に適した粘度に下げることが難しくなり、その結果、血液滑性付与剤を、溶媒で希釈しなければならない場合も生じうる。 Where the blood slipping agent containing composition includes a component that is miscible with the blood slipping agent as at least one other component, the other components preferably have a weight average molecular weight of less than about 1,000. Preferably, it has a weight average molecular weight of less than about 900. When the weight average molecular weight is about 1,000 or more, the blood slipping agent-containing composition itself is tacky and tends to cause discomfort to the wearer. In addition, when the weight average molecular weight is high, the viscosity of the blood slipping agent-containing composition tends to increase, so that the viscosity of the blood slipping agent composition is lowered to a viscosity suitable for application by heating. Can be difficult, and as a result, the blood slipping agent may occur if it has to be diluted with a solvent.
 血液滑性付与剤含有組成物は、組成物として、約0.01~約4.0質量%の抱水率を有し、約0.02~約3.5質量%の抱水率を有することが好ましく、約0.03~約3.0質量%の抱水率を有することがより好ましく、約0.04~約2.5質量%の抱水率を有することがさらに好ましく、そして約0.05~約2.0質量%の抱水率を有することがさらに好ましい。 The blood slipping agent-containing composition has, as a composition, a water retention rate of about 0.01 to about 4.0% by weight, and a water retention rate of about 0.02 to about 3.5% by weight More preferably about 0.03 to about 3.0% by weight, more preferably about 0.04 to about 2.5% by weight, and more preferably about It is further preferred to have a water retention of 0.05 to about 2.0% by weight.
 抱水率が低くなると、血液滑性付与剤組成物と、経血との親和性が低下し、トップシートの肌当接面に到達した経血が吸収性物品の内部に滑落しにくくなる傾向がある。
 なお、血液滑性付与剤含有組成物が固形物を含む場合には、動粘度及び抱水率の測定において、それらを濾過により取り除くことが好ましい。
When the water retention rate decreases, the affinity between the blood slipping agent composition and menstrual blood decreases, and menstrual blood that has reached the skin contact surface of the top sheet tends not to slip off inside the absorbent article. There is.
When the blood slipping agent-containing composition contains a solid, it is preferable to remove them by filtration in the measurement of the kinematic viscosity and the water retention rate.
<試験例1>
 以下に、本試験例で用いられた血液滑性付与剤を列挙する。
[(a1)鎖状炭化水素テトラオールと少なくとも1の脂肪酸とのエステル]
・ユニスター H-408BRS,日油株式会社製
 テトラ2-エチルヘキサン酸ペンタエリトリトール,重量平均分子量:約640
・ユニスター H-2408BRS-22,日油株式会社製
 テトラ2-エチルヘキサン酸ペンタエリトリトールと、ジ2-エチルヘキサン酸ネオペンチルグリコールとの混合物(58:42、重量比),重量平均分子量:約520
<Test Example 1>
The blood slipping agents used in this test example are listed below.
[Ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid]
-Unistar H-408 BRS, manufactured by NOF Corporation, pentaerythritol tetra 2-ethylhexanoate, weight average molecular weight: about 640
Unister H-2408 BRS-22, a mixture of NOF Corporation pentaerythritol tetra 2-ethylhexanoate and neopentyl glycol di-2-ethylhexanoate (58: 42, weight ratio), weight average molecular weight: about 520
[(a2)鎖状炭化水素トリオールと少なくとも1の脂肪酸とのエステル]
・Cetiol SB45DEO,コグニスジャパン株式会社製
 脂肪酸が、オレイン酸又はステアリル酸である、グリセリンと脂肪酸とのトリエステル
・SOY42,日油株式会社製
 C14の脂肪酸:C16の脂肪酸:C18の脂肪酸:C20の脂肪酸(飽和脂肪酸及び不飽和脂肪酸の両方を含む)がおおよそ0.2:11:88:0.8の質量比で含まれている、グリセリンと脂肪酸とのトリエステル,重量平均分子量:880
[Ester of (a 2 ) chain hydrocarbon triol and at least one fatty acid]
· Cetiol SB 45 DEO, manufactured by Cognis Japan Ltd. Triester of glycerin and fatty acid in which the fatty acid is oleic acid or stearyl acid · SOY 42 manufactured by NOF Corporation C 14 fatty acid: C 16 fatty acid: C 18 fatty acid: C 20 fatty acids (including both saturated and unsaturated fatty acids) is approximately 0.2: 11: 88: contains 0.8 weight ratio, triesters of glycerin and fatty acid, the weight average molecular weight: 880
・トリC2L油脂肪酸グリセリド,日油株式会社製
 C8の脂肪酸:C10の脂肪酸:C12の脂肪酸がおおよそ37:7:56の重量比で含まれている、グリセリンと脂肪酸とのトリエステル,重量平均分子量:約570
・トリCL油脂肪酸グリセリド,日油株式会社製
 C8の脂肪酸:C12の脂肪酸がおおよそ44:56の重量比で含まれている、グリセリンと脂肪酸とのトリエステル,重量平均分子量:約570
Tri C2 L oil fatty acid glyceride, manufactured by NOF Corporation C 8 fatty acid: C 10 fatty acid: C 12 fatty acid is contained in a weight ratio of approximately 37: 7: 56, triester of glycerin and fatty acid, Weight average molecular weight: about 570
Triethylene CL oil fatty acid glycerides, manufactured by NOF Corporation C 8 fatty acid: fatty acid of C 12 is approximately included in a weight ratio of 44:56, triesters of glycerin and fatty acid, the weight average molecular weight: about 570
・パナセート810s,日油株式会社製
 C8の脂肪酸:C10の脂肪酸がおおよそ85:15の重量比で含まれている、グリセリンと脂肪酸とのトリエステル,重量平均分子量:約480
・パナセート800,日油株式会社製
 脂肪酸が全てオクタン酸(C8)である、グリセリンと脂肪酸とのトリエステル,重量平均分子量:約470
Panaceto 810s, manufactured by NOF Corporation C 8 fatty acid: Triester of glycerin and fatty acid containing C 10 fatty acid at a weight ratio of approximately 85: 15, weight average molecular weight: about 480
-Panaceto 800, manufactured by NOF Corporation Triester of glycerin and fatty acid in which all fatty acids are octanoic acid (C 8 ), weight average molecular weight: about 470
・パナセート800B,日油株式会社製
 脂肪酸が全て2-エチルヘキサン酸(C8)である、グリセリンと脂肪酸とのトリエステル,重量平均分子量:約470
・NA36,日油株式会社製
 C16の脂肪酸:C18の脂肪酸:C20の脂肪酸(飽和脂肪酸及び不飽和脂肪酸の両方を含む)がおおよそ5:92:3の重量比で含まれている、グリセリンと脂肪酸とのトリエステル,重量平均分子量:約880
-Panaceto 800 B, manufactured by NOF Corporation Triester of glycerin and fatty acid in which all fatty acids are 2-ethylhexanoic acid (C 8 ), weight average molecular weight: about 470
NA36, manufactured by NOF Corporation C 16 fatty acids: C 18 fatty acids: C 20 fatty acids (including both saturated fatty acids and unsaturated fatty acids) in a weight ratio of approximately 5: 92: 3, Triester of glycerin and fatty acid, weight average molecular weight: about 880
・トリヤシ油脂肪酸グリセリド,日油株式会社製
 C8の脂肪酸:C10の脂肪酸:C12の脂肪酸:C14の脂肪酸:C16の脂肪酸(飽和脂肪酸及び不飽和脂肪酸の両方を含む)がおおよそ4:8:60:25:3の重量比で含まれている、グリセリンと脂肪酸とのトリエステル,重量平均分子量:670
・カプリル酸ジグリセリド,日油株式会社製
 脂肪酸がオクタン酸である、グリセリンと脂肪酸とのジエステル,重量平均分子量:340
· Tricot oil fatty acid glyceride, manufactured by NOF Corporation C 8 fatty acid: C 10 fatty acid: C 12 fatty acid: C 14 fatty acid: C 16 fatty acid (including both saturated fatty acid and unsaturated fatty acid) is approximately 4 Triester of glycerin and fatty acid, contained in a weight ratio of 8: 60: 25: 3, weight average molecular weight: 670
・ Caprylic diglyceride, manufactured by NOF Corporation Diester of glycerin and fatty acid wherein fatty acid is octanoic acid, weight average molecular weight: 340
[(a3)鎖状炭化水素ジオールと少なくとも1の脂肪酸とのエステル]
・ユニスター H-208BRS,日油株式会社製
 ジ2-エチルヘキサン酸ネオペンチルグリコール,重量平均分子量:約360
・コムポールBL,日油株式会社製
 ブチレングリコールのドデカン酸(C12)モノエステル,重量平均分子量:約270
・コムポールBS,日油株式会社製
 ブチレングリコールのオクタデカン酸(C18)モノエステル,重量平均分子量:約350
[Ester of (a 3 ) chain hydrocarbon diol and at least one fatty acid]
-Unistar H-208 BRS, manufactured by NOF Corporation Dipentyl 2-ethylhexanoate neopentyl glycol, weight average molecular weight: about 360
-Commol BL, manufactured by NOF Corporation, dodecanoic acid (C 12 ) monoester of butylene glycol, weight average molecular weight: about 270
・ Compol BS, manufactured by NOF Corporation Octadecanoic acid (C 18 ) monoester of butylene glycol, weight average molecular weight: about 350
[(c2)3個のカルボキシル基を有する鎖状炭化水素トリカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル]
・O-アセチルクエン酸トリブチル,東京化成工業株式会社製
 重量平均分子量:約400
・クエン酸トリブチル,東京化成工業株式会社製
 重量平均分子量:約360
[(C 2 ) Ester of linear hydrocarbon tricarboxylic acid having 3 carboxyl groups, hydroxy acid, alkoxy acid or oxo acid, and at least one aliphatic monohydric alcohol]
-Tributyl O-acetyl citrate, manufactured by Tokyo Chemical Industry Co., Ltd. Weight average molecular weight: about 400
Tributyl citrate, manufactured by Tokyo Chemical Industry Co., Ltd. Weight average molecular weight: about 360
[(c3)2個のカルボキシル基を有する鎖状炭化水素ジカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル]
・アジピン酸ジオクチル,和光純薬工業製
 重量平均分子量:約380
[(C 3 ) An ester of a linear hydrocarbon dicarboxylic acid having two carboxyl groups, a hydroxy acid, an alkoxy acid or an oxo acid, and at least one aliphatic monohydric alcohol]
・ Dioctyl adipate, manufactured by Wako Pure Chemical Industries, Ltd. Weight average molecular weight: about 380
[(d3)脂肪酸と脂肪族1価アルコールとのエステル]
・エレクトールWE20,日油株式会社製
 ドデカン酸(C12)と、ドデシルアルコール(C12)とのエステル,重量平均分子量:約360
・エレクトールWE40,日油株式会社製
 テトラデカン酸(C14)と、ドデシルアルコール(C12)とのエステル,重量平均分子量:約390
[(D 3 ) ester of fatty acid and aliphatic monohydric alcohol]
Electol WE20, an oil-in-oil company ester of dodecanoic acid (C 12 ) and dodecyl alcohol (C 12 ), weight average molecular weight: about 360
Electol WE40, an ester of tetradecanoic acid (C 14 ) manufactured by NOF Corporation, and dodecyl alcohol (C 12 ), weight average molecular weight: about 390
[(e1)ポリオキシC3~C6アルキレングリコール]
・ユニオールPB500,日油株式会社製
 ポリブチレングリコール,重量平均分子量:約500
・ユニオールPB700,日油株式会社製
 ポリオキシブチレンポリオキシプロピレングリコール,重量平均分子量:約700
[(E 1 ) polyoxy C 3 -C 6 alkylene glycol]
Uniol PB500, polybutylene glycol manufactured by NOF Corporation, weight average molecular weight: about 500
Uniol PB700, manufactured by NOF Corporation, polyoxybutylene polyoxypropylene glycol, weight average molecular weight: about 700
[(f1)鎖状アルカン]
・パールリーム6,日油株式会社製
 流動イソパラフィン、イソブテン及びn-ブテンを共重合し、次いで水素を付加することにより生成された分岐鎖炭化水素、重合度:約5~約10,重量平均分子量:約330
[(F 1 ) chain alkane]
Pearl Reem 6, manufactured by NOF Corporation, branched hydrocarbon produced by copolymerization of liquid isoparaffin, isobutene and n-butene and then adding hydrogen, degree of polymerization: about 5 to about 10, weight average molecular weight : About 330
[その他の材料]
・NA50,日油株式会社製
 NA36に水素を付加し、原料である不飽和脂肪酸に由来する二重結合の比率を下げたグリセリンと脂肪酸とのトリエステル,重量平均分子量:約880
・(カプリル酸/カプリン酸)モノグリセリド,日油株式会社製
 オクタン酸(C8)及びデカン酸(C10)がおおよそ85:15の重量比で含まれている、グリセリンと脂肪酸とのモノエステル,重量平均分子量:約220
・Monomuls 90-L2ラウリン酸モノグリセリド,コグニスジャパン株式会社製
[Other materials]
· NA50, a triester of glycerin and fatty acid in which hydrogen is added to NA36 manufactured by NOF Corporation and the ratio of double bonds derived from unsaturated fatty acid as a raw material is reduced, weight average molecular weight: about 880
(Caprylic acid / capric acid) monoglyceride, monoester of glycerin and fatty acid, which contains octanoic acid (C 8 ) and decanoic acid (C 10 ) manufactured by NOF Corporation at a weight ratio of about 85:15, Weight average molecular weight: about 220
Monomuls 90-L2 lauric acid monoglyceride, manufactured by Cognis Japan Ltd.
・クエン酸イソプロピル,東京化成工業株式会社製
 重量平均分子量:約230
・リンゴ酸ジイソステアリル
 重量平均分子量:約640
・ユニオールPB1000R,日油株式会社製
 ポリブチレングリコール,重量平均分子量:約1,000
・ユニオールD-250,日油株式会社製
 ポリプロピレングリコール,重量平均分子量:約250
Isopropyl citrate, manufactured by Tokyo Chemical Industry Co., Ltd. Weight average molecular weight: about 230
・ Diisostearyl malate Weight average molecular weight: about 640
Uniol PB 1000 R, polybutylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1,000
Uniol D-250, a polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 250
・ユニオールD-400,日油株式会社製
 ポリプロピレングリコール,重量平均分子量:約400
・ユニオールD-700,日油株式会社製
 ポリプロピレングリコール,重量平均分子量:約700
・ユニオールD-1000,日油株式会社製
 ポリプロピレングリコール,重量平均分子量:約1,000
・ユニオールD-1200,日油株式会社製
 ポリプロピレングリコール,重量平均分子量:約1,160
Uniol D-400, a polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 400
Uniol D-700, a polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 700
Uniol D-1000, a polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1,000
Uniol D-1200, polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1,160
・ユニオールD-2000,日油株式会社製
 ポリプロピレングリコール,重量平均分子量:約2,030
・ユニオールD-3000,日油株式会社製
 ポリプロピレングリコール,重量平均分子量:約3,000
・ユニオールD-4000,日油株式会社製
 ポリプロピレングリコール,重量平均分子量:約4,000
Uniol D-2000, a polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 2,030
Uniol D-3000, a polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 3,000
Uniol D-4000, polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 4,000
・PEG1500,日油株式会社製
 ポリエチレングリコール,重量平均分子量:約1,500~約1,600
・ウィルブライトcp9,日油株式会社製
 ポリブチレングリコールの両末端のOH基が、ヘキサデカン酸(C16)によりエステル化された化合物,重量平均分子量:約1,150
・ユニルーブMS-70K,日油株式会社製
 ポリプロピレングリコールのステアリルエーテル,約15の繰返し単位,重量平均分子量:約1,140
-PEG 1500, polyethylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1,500 to about 1,600
· Wilbright cp 9, a compound in which OH groups at both ends of polybutylene glycol manufactured by NOF Corporation were esterified with hexadecanoic acid (C 16 ), weight average molecular weight: about 1,150
・ Unileub MS-70K, stearyl ether of polypropylene glycol manufactured by NOF Corporation, about 15 repeating units, weight average molecular weight: about 1,140
・ノニオンS-6,日油株式会社製
 ポリオキシエチレンモノステアレート、約7の繰返し単位、重量平均分子量:約880
・ユニルーブ5TP-300KB
 ペンタエリトリトール1モルに、エチレンオキシド5モルと、プロピレンオキシド65モルとを付加させることにより生成した、ポリオキシエチレンポリオキシプロピレンペンタエリスリトールエーテル,重量平均分子量:4,130
Nonion S-6, manufactured by NOF Corporation, polyoxyethylene monostearate, repeating unit of about 7 weight average molecular weight: about 880
・ Unileve 5TP-300KB
Polyoxyethylene polyoxypropylene pentaerythritol ether, weight average molecular weight: 4,130, produced by adding 5 moles of ethylene oxide and 65 moles of propylene oxide to 1 mole of pentaerythritol.
・ウィルブライトs753,日油株式会社製
 ポリオキシエチレンポリオキシプロピレンポリオキシブチレングリセリン,重量平均分子量:約960
・ユニオール TG-330,日油株式会社製
 ポリプロピレングリコールのグリセリルエーテル,約6の繰返し単位,重量平均分子量:約330
Will Bright s 753, manufactured by NOF Corporation polyoxyethylene polyoxypropylene polyoxybutylene glycerin, weight average molecular weight: about 960
-Uniol TG-330, a glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 6 repeating units, weight average molecular weight: about 330
・ユニオール TG-1000,日油株式会社製
 ポリプロピレングリコールのグリセリルエーテル,約16の繰返し単位,重量平均分子量:約1,000
・ユニオール TG-3000,日油株式会社製
 ポリプロピレングリコールのグリセリルエーテル,約16の繰返し単位,重量平均分子量:約3,000
・ユニオール TG-4000,日油株式会社製
 ポリプロピレングリコールのグリセリルエーテル,約16の繰返し単位,重量平均分子量:約4,000
・ UNIOL TG-1000, glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 16 repeating units, weight average molecular weight: about 1,000
・ UNIOL TG-3000, glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 16 repeating units, weight average molecular weight: about 3,000
・ UNIOL TG-4000, glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 16 repeating units, weight average molecular weight: about 4,000
・ユニルーブ DGP-700,日油株式会社製
 ポリプロピレングリコールのジグリセリルエーテル,約9の繰返し単位,重量平均分子量:約700
・ユニオックスHC60,日油株式会社製
 ポリオキシエチレン硬化ヒマシ油,重量平均分子量:約3,570
・ワセリン,コグニスジャパン株式会社製
 石油に由来する炭化水素、半固形
・ Unirube DGP-700, a diglyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 9 repeating units, weight average molecular weight: about 700
-Uniox HC60, manufactured by NOF Co., Ltd. polyoxyethylene hydrogenated castor oil, weight average molecular weight: about 3,570
・ Vaseline, Cognis Japan Ltd. Petroleum derived hydrocarbon, semi-solid
<試験例2>
[大量の血液を吸収した際の経血の表面残存率A]
 生理用ナプキンが一度に大量の血液を吸収した場合の吸収性を評価する実験を行った。
 親水剤で処理されたエアスルー不織布(ポリエステル及びポリエチレンテレフタレートから成る複合繊維、坪量:35g/m2)から形成されたトップシートと、エアスルー不織布(ポリエステル及びポリエチレンテレフタレートから成る複合繊維、坪量:30g/m2)から形成されたセカンドシートと、パルプ(坪量:150~450g/m2、中央部ほど多い)、アクリル系高吸収ポリマー(坪量:15g/m2)及びコアラップとしてのティッシュを含む吸収体と、撥水剤処理されたサイドシートと、ポリエチレンフィルムから成るバックシートとを準備した。
Test Example 2
[Persistence rate of menstrual blood when absorbing a large amount of blood A]
An experiment was conducted to evaluate the absorbability when the sanitary napkin absorbs a large amount of blood at one time.
A top sheet formed of an air through non-woven fabric (composite fiber consisting of polyester and polyethylene terephthalate, basis weight: 35 g / m 2 ) treated with a hydrophilic agent, and an air through non-woven fabric (composite fiber consisting of polyester and polyethylene terephthalate, basis weight: 30 g) / M 2 ), pulp (basis weight: 150 to 450 g / m 2 , more in the central part), acrylic superabsorbent polymer (basis weight: 15 g / m 2 ) and tissue as core wrap An absorbent, a water repellent-treated side sheet, and a back sheet made of polyethylene film were prepared.
 上記トップシートは、特開2008-2034号公報に記載の方法に従って製造された、畝溝構造を有するトップシートであり、畝部の厚みが約1.5mmであり、溝部の厚みが約0.4mmであり、畝溝構造のピッチ(畝部の幅+溝部の幅)が約4mmであり、そして溝部には、開孔率約15%の開孔部が形成されていた。 The top sheet is a top sheet having a ridged groove structure manufactured according to the method described in Japanese Patent Application Laid-Open No. 2008-2034. The thickness of the ridge portion is about 1.5 mm, and the thickness of the groove portion is about 0. It had a diameter of 4 mm, a pitch of the weir structure (the width of the ridge + the width of the groove) of about 4 mm, and the groove had an opening with an opening ratio of about 15%.
 血液滑性付与剤として、ユニスター H-408BRS(日油株式会社製、ペンタエリトリトールと脂肪酸とのテトラエステル)を選択し、室温において、コントロールシームHMAガンから、上記トップシートの肌当接面(畝溝面)に、5.0g/m2の坪量で塗工した。電子顕微鏡で確認したところ、H-408BRSは、微粒子状で、繊維の表面に付着していた。
 次いで、バックシート、吸収体、セカンドシート、そして畝溝面を上にしてトップシートを順に重ね合わせることにより、生理用ナプキンNo.1-1を形成した。
Select Unister H-408 BRS (manufactured by NOF Corporation, tetraester of pentaerythritol and fatty acid) as a blood slipping agent, and at the room temperature, from the control seam HMA gun, the skin contact surface of the top sheet (シ ー トThe groove surface was coated at a basis weight of 5.0 g / m 2 . As confirmed by electron microscopy, H-408 BRS was in the form of fine particles and adhered to the surface of the fiber.
Next, the back sheet, the absorbent body, the second sheet, and the top sheet are sequentially stacked with the ridged surface up, sanitary napkin No. 1 It formed 1-1.
 血液滑性付与剤を、ユニスター H-408BRSから、表2に示されるものに変更して、生理用ナプキンNo.1-2~No.1-49を製造した。なお、血液滑性付与剤が室温で液体である場合には、そのまま、そして血液滑性付与剤が室温で固体である場合には、融点+20℃まで加熱し、次いで、コントロールシームHMAガンを用いて、血液滑性付与剤を微粒化し、トップシートの肌当接面に、坪量がおおよそ5g/m2となるように塗工した。
 また、血液滑性付与剤は、トップシートの肌当接面のほぼ全面に、そして畝部及び溝部の両方に塗工された。
The blood slipping agent was changed from Unistar H-408 BRS to that shown in Table 2, and sanitary napkin No. 1-2 to No. 1-49 were manufactured. If the blood slipping agent is liquid at room temperature, heat as it is, and if the blood slipping agent is solid at room temperature, heat to a melting point + 20 ° C, and then use a control seam HMA gun. The blood slipping agent was atomized and applied to the skin contact surface of the top sheet so that the basis weight was approximately 5 g / m 2 .
In addition, the blood slipping agent was applied to almost the entire surface of the skin contact surface of the top sheet, and to both the ridges and grooves.
[試験方法]
 トップシートの質量:W2(g)(試験前のトップシートの質量)を測定した後、吸収性物品の長手方向及び幅方向の中央部且つトップシートの上に、穴の開いたアクリル板(200mm×100mm,125g,中央に、40mm×10mmの穴が開いている)を置き、上記穴から、37±1℃のウマEDTA血(ウマの血液に、凝結防止のため、エチレンジアミン四酢酸(以下、「EDTA」と称する)が添加されたもの)4.0gを、ピペットを用いて滴下した。
[Test method]
Top sheet weight: After measuring W 2 (g) (weight of top sheet before test), an acrylic plate with holes opened on the center of the absorbent article in the longitudinal direction and width direction and on the top sheet ( Place a 200 mm × 100 mm, 125 g, 40 mm × 10 mm hole in the center, and from the above hole, equine EDTA blood at 37 ± 1 ° C. (to the blood of the horse, for prevention of coagulation ethylenediaminetetraacetic acid (In which "EDTA" was added) (4.0 g) was dropped using a pipette.
 ウマEDTA血の滴下後、直ちに上記アクリル板を外し、トップシートを取出し、その質量:W3(g)(試験後のトップシートの質量)を測定し、以下の式に従って、「表面残存率A(質量%)」を算出した。
 表面残存率A(質量%)
 =100×[W3(g)-W2(g)]/4.0(g)
Immediately after dropping the equine EDTA blood, remove the above-mentioned acrylic plate, take out the top sheet, and measure its weight: W 3 (g) (the weight of the top sheet after the test). (Mass%) was calculated.
Surface residual rate A (mass%)
= 100 × [W 3 (g ) -W 2 (g)] / 4.0 (g)
 また、トップシートの肌当接面のタック性を、以下の基準に従って35℃で測定した。
 ○:タック性なし
 △:若干のタック性有り
 ×:タック性有り
In addition, the tackiness of the skin contact surface of the top sheet was measured at 35 ° C. according to the following criteria.
○: no tackiness △: some tackiness ×: tackiness
 各吸収性物品の表面残存率A、及びタック性、並びに各血液滑性付与剤の特性を、以下の表2に示す。また、図6に、トップシートがトリC2L油脂肪酸グリセリドを含む生理用ナプキンにおける、トップシートの肌当接面の電子顕微鏡写真を示す。 The surface residual rate A of each absorbent article, and the tackiness, and the properties of each blood slipping agent are shown in Table 2 below. In addition, FIG. 6 shows an electron micrograph of the skin contact surface of the top sheet in the sanitary napkin in which the top sheet contains avian C2L oil fatty acid glyceride.
Figure JPOXMLDOC01-appb-T000011
Figure JPOXMLDOC01-appb-T000011
Figure JPOXMLDOC01-appb-T000012
Figure JPOXMLDOC01-appb-T000012
 血液滑性付与剤を有しない生理用ナプキンNo.1-49では、表面残存率Aが7.5質量%であったが、動粘度及び抱水率が所定の範囲内にある生理用ナプキンNo.1-1~No.1-21では、表面残存率Aが2.5質量%以下であった。 Sanitary napkin No. 1 having no blood slipping agent. In 1 to 49, although the surface residual rate A was 7.5% by mass, the sanitary napkin No. 1 in which the dynamic viscosity and the water retention rate fall within the predetermined ranges. 1-1 to No. In 1-21, the surface residual ratio A was 2.5 mass% or less.
 生理用ナプキンNo.1-1~No.1-21では、トップシートの畝部に滴下されたウマEDTA血が、畝部から溝部へと滑落し、溝部から吸収体内部に迅速に吸収される様子が観察された。一方、血液滑性付与剤を有しない生理用ナプキンNo.1-49では、滴下したウマEDTA血は、溝部に滑落するのではなく、溝部にゆっくりと垂れ落ち、その多くがトップシートの畝部に残存した。また、抱水率が高い吸収性物品、例えば、No.1-30では、トップシートの畝部に滴下されたウマEDTA血は、溝部に滑落するのではなく、トップシートに一部残存しながらゆっくりと垂れ落ち、そして一部が畝部に残存した。 Sanitary napkin No. 1-1 to No. In 1-21, it was observed that the horse EDTA blood dropped onto the hip of the top sheet slipped from the hip to the groove and was rapidly absorbed from the groove to the inside of the absorber. On the other hand, in the sanitary napkin No. 1-49 which does not have a blood slipping agent, the dripped equine EDTA blood does not slide down to the groove, but slowly drops down to the groove, many of which fall on the ridges of the top sheet Remained in In addition, in the absorbent article having a high water retention rate, for example, in No. 1-30, equine EDTA blood dropped on the buttocks of the top sheet does not slide down in the grooves but remains partially on the top sheet Gently dripped down and some remained in the buttocks.
 以上より、生理用ナプキンNo.1-1~No.1-21は、一度に大量の経血がトップシートに到達した際に、経血をトップシートから吸収体に迅速に移行させることができることが示唆される。 From the above, the sanitary napkin No. 1-1 to No. It is suggested that menstrual blood can be rapidly transferred from the top sheet to the absorber when a large amount of menstrual blood reaches the top sheet at one time.
 次に、No.1-1~1-49の生理用ナプキンを、複数のボランティアの被験者に着用してもらったところ、No.1-1~1-21の血液滑性付与剤を含む生理用ナプキンでは、経血を吸収した後であってもトップシートにべたつき感がなく、トップシートがサラサラしているとの回答が多かった。 Next, No. No. 1 to No. 1 to No. 1 to No. 1 to No. 1 to No. 1 to No. 1 to No. 1 to No. 1 to No. 1 to No. 1 to No. 1-1. In the sanitary napkin containing the blood slipping agent 1-1-1-21, there is no stickiness on the top sheet even after absorbing menstrual blood, and there are many responses that the top sheet is smooth. The
 本試験例では、特開2008-2034号公報に記載の方法に従って製造された畝溝構造を有するトップシートを使用したが、血液滑性付与剤は、別の方法で製造された畝溝構造を有するトップシートを使用する場合や、畝溝構造以外の凹凸構造を有するトップシートを使用する場合にも同様に血液滑落作用を発揮し、経血をトップシートから吸収体に迅速に移行させることができると考えられる。 In this test example, a top sheet having a ridge and groove structure manufactured according to the method described in Japanese Patent Application Laid-Open No. 2008-2034 was used, but the blood slip property imparting agent is a ridge and groove structure manufactured by another method. Also in the case of using a top sheet having the same or when using a top sheet having a concavo-convex structure other than the groin structure, the blood slipping action is similarly exhibited, and menstrual blood can be rapidly transferred from the top sheet to the absorber. It is considered possible.
<試験例3>
[少量の血液を吸収した際の経血の表面残存率B]
 生理用ナプキンが少量の血液を吸収した場合の吸収性を評価する実験を行った。
 親水剤で処理されたエアスルー不織布(ポリエステル及びポリエチレンテレフタレートから成る複合繊維、坪量:35g/m2)から形成されたトップシート(以下、「畝溝を有するトップシート」と称する場合がある)と、エアスルー不織布(ポリエステル及びポリエチレンテレフタレートから成る複合繊維、坪量:30g/m2)から形成されたセカンドシートと、パルプ(坪量:150~450g/m2、中央部ほど多い)、アクリル系高吸収ポリマー(坪量:15g/m2)及びコアラップとしてのティッシュを含む吸収体と、撥水剤処理されたサイドシートと、ポリエチレンフィルムから成るバックシートとを準備した。
<Test Example 3>
[Persistence rate of menstrual blood when absorbing a small amount of blood B]
An experiment was conducted to evaluate the absorbability when the sanitary napkin absorbs a small amount of blood.
A top sheet (hereinafter sometimes referred to as "the top sheet having ridges") formed of an air through non-woven fabric (composite fiber made of polyester and polyethylene terephthalate, basis weight: 35 g / m 2 ) treated with a hydrophilic agent A second sheet formed of an air through non-woven fabric (composite fiber made of polyester and polyethylene terephthalate, basis weight: 30 g / m 2 ), pulp (basis weight: 150 to 450 g / m 2 , more in the central part), acrylic type An absorbent containing an absorbent polymer (basis weight: 15 g / m 2 ) and a tissue as a core wrap, a water repellent-treated side sheet, and a back sheet comprising a polyethylene film were prepared.
 上記トップシートは、特開2008-2034号公報に記載の方法に従って製造された、畝溝構造を有するトップシートであり、畝部の厚みが約1.5mmであり、溝部の厚みが約0.4mmであり、畝溝構造のピッチ(畝部の幅+溝部の幅)が約4mmであり、そして溝部には、開孔率約15%の開孔部が形成されていた。 The top sheet is a top sheet having a ridged groove structure manufactured according to the method described in Japanese Patent Application Laid-Open No. 2008-2034. The thickness of the ridge portion is about 1.5 mm, and the thickness of the groove portion is about 0. It had a diameter of 4 mm, a pitch of the weir structure (the width of the ridge + the width of the groove) of about 4 mm, and the groove had an opening with an opening ratio of about 15%.
 血液滑性付与剤として、ユニスター H-408BRS(日油株式会社製、ペンタエリトリトールと脂肪酸とのテトラエステル)を選択し、室温において、コントロールシームHMAガンから、上記トップシートの肌当接面(畝溝面)に、5.0g/m2の坪量で塗工した。電子顕微鏡で確認したところ、H-408BRSは、微粒子状で、繊維の表面に付着していた。
 次いで、バックシート、吸収体、セカンドシート、そして畝溝面を上にしてトップシートを順に重ね合わせることにより、生理用ナプキンNo.2-1(i)を形成した。
Select Unister H-408 BRS (manufactured by NOF Corporation, tetraester of pentaerythritol and fatty acid) as a blood slipping agent, and at the room temperature, from the control seam HMA gun, the skin contact surface of the top sheet (シ ー トThe groove surface was coated at a basis weight of 5.0 g / m 2 . As confirmed by electron microscopy, H-408 BRS was in the form of fine particles and adhered to the surface of the fiber.
Next, the back sheet, the absorbent body, the second sheet, and the top sheet are sequentially stacked with the ridged surface up, sanitary napkin No. 1 Form 2-1 (i).
 トップシートを、畝溝構造を有しないフラットな、親水剤で処理されたエアスルー不織布(ポリエステル及びポリエチレンテレフタレートから成る複合繊維、坪量:35g/m2)から形成されたトップシート(以下、「フラットなトップシート」と称する場合がある)に変更した以外は、生理用ナプキンNo.2-1(i)と同様にして、生理用ナプキンNo.2-1(ii)を形成した。 Top sheet (hereinafter referred to as "flat") formed of a flat, hydrophilic agent-treated non-woven air-through non-woven fabric (composite fiber made of polyester and polyethylene terephthalate, basis weight: 35 g / m 2 ) having no ridge and groove structure (Sometimes referred to as “top sheet”) except for the sanitary napkin No. In the same manner as 2-1 (i), sanitary napkin No. Form 2-1 (ii).
 血液滑性付与剤を、ユニスター H-408BRSから、表3に示されるものに変更して、生理用ナプキンNo.2-2(i)~No.2-11(i)及びNo.2-2(ii)~No.2-11(ii)を製造した。なお、血液滑性付与剤が室温で液体である場合には、そのまま、そして血液滑性付与剤が室温で固体である場合には、融点+20℃まで加熱し、次いで、コントロールシームHMAガンを用いて、血液滑性付与剤を微粒化し、トップシートの肌当接面に、坪量がおおよそ5g/m2となるように塗工した。
 また、血液滑性付与剤は、トップシートの肌当接面のほぼ全面に、そして畝溝構造を有するトップシートでは、畝部及び溝部の両方に塗工された。
The blood slipping agent was changed from Unistar H-408 BRS to that shown in Table 3, and sanitary napkin No. 2-2 (i) to no. 2-11 (i) and no. 2-2 (ii) to no. 2-11 (ii) were manufactured. If the blood slipping agent is liquid at room temperature, heat as it is, and if the blood slipping agent is solid at room temperature, heat to a melting point + 20 ° C, and then use a control seam HMA gun. The blood slipping agent was atomized and applied to the skin contact surface of the top sheet so that the basis weight was approximately 5 g / m 2 .
In addition, the blood slipping agent was applied to almost the entire surface of the skin contact surface of the top sheet, and in the case of the top sheet having the furrow structure, on both the groin and the groove.
[試験方法]
 トップシートの質量:W4(g)(試験前のトップシートの質量)を測定した後、吸収性物品の長手方向及び幅方向の中央のトップシートの上に、37±1℃のウマEDTA血約0.25g(2滴)をピペットから滴下した。なお、畝溝を有するトップシートでは、畝部の頂部にウマEDTA血を滴下した。
[Test method]
Top sheet weight: After measuring W 4 (g) (the weight of the top sheet before testing), 37 ± 1 ° C. horse EDTA blood on the central top sheet in the longitudinal direction and width direction of the absorbent article About 0.25 g (2 drops) was dropped from the pipette. In the top sheet having a furrow, equine EDTA blood was dropped on the top of the buttocks.
 滴下から30秒後、トップシートを取出し、その質量:W5(g)(試験後のトップシートの質量)を測定し、以下の式に従って、「表面残存率B(質量%)」を算出した。
 表面残存率B(質量%)
 =100×(W5(g)-W4(g))/W6(g)
 なお、W6(g)は、滴下前後のピペットの質量から算出した、滴下されたウマEDTA血の質量である。
 結果を、下記表3に示す。
After 30 seconds from the dropping, the top sheet was taken out, its weight: W 5 (g) (the weight of the top sheet after the test) was measured, and the “surface residual ratio B (mass%)” was calculated according to the following formula .
Surface residual rate B (mass%)
= 100 x (W 5 (g)-W 4 (g)) / W 6 (g)
W 6 (g) is the mass of the dropped equine EDTA blood calculated from the mass of the pipette before and after the dropping.
The results are shown in Table 3 below.
Figure JPOXMLDOC01-appb-T000013
Figure JPOXMLDOC01-appb-T000013
 表3から、血液滑性付与剤がH-408BRS、パナセート810S、カプリン酸ジグリセリド、コムポールBL、O-アセチルクエン酸トリブチル、アジピン酸ジオクチル、エレクトールWE40、ユニオールPB500、及びパールリーム6である場合には、畝溝を有するトップシートにおいて、表面残存率Bが低いことがわかる。これは、所定の特性を有する血液滑性付与剤が、少量の血液を畝部から、溝部、及び吸収体に迅速に移行させたことを示唆していると思われる。 From Table 3, when the blood slipping agent is H-408 BRS, Panaceto 810S, capric acid diglyceride, Commopol BL, O-acetyl tributyl citrate, dioctyl adipate, Electol WE40, Uniol PB500, and Pearl Ream 6 It can be seen that the surface retention rate B is low in the top sheet having ridges. This seems to indicate that the blood slipping agent having the predetermined characteristics rapidly transferred a small amount of blood from the buttocks to the groove and the absorber.
 本試験例では、特開2008-2034号公報に記載の方法に従って製造された畝溝構造を有するトップシートを使用したが、血液滑性付与剤は、別の方法で製造された畝溝構造を有するトップシートを使用する場合や、畝溝構造以外の凹凸構造を有するトップシートを使用する場合にも同様に血液滑落作用を発揮し、経血をトップシートから吸収体に迅速に移行させることができると考えられる。 In this test example, a top sheet having a ridge and groove structure manufactured according to the method described in Japanese Patent Application Laid-Open No. 2008-2034 was used, but the blood slip property imparting agent is a ridge and groove structure manufactured by another method. Also in the case of using a top sheet having the same or when using a top sheet having a concavo-convex structure other than the groin structure, the blood slipping action is similarly exhibited, and menstrual blood can be rapidly transferred from the top sheet to the absorber. It is considered possible.
<試験例4>
[血液滑性付与剤を含む血液の粘性]
 血液滑性付与剤を含む血液の粘性を、Rheometric Expansion System ARES(Rheometric Scientific,Inc)を用いて測定した。ウマ脱繊維血に、パナセート810sを2質量%添加し、軽く撹拌して試料を形成し、直径50mmのパラレルプレートに試料を載せ、ギャップを100μmとし、37±0.5℃で粘度を測定した。パラレルプレートゆえ、試料に均一なせん断速度はかかっていないが、機器に表示された平均せん断速度は、10s-1であった。
<Test Example 4>
[Viscosity of blood containing blood slipping agent]
The viscosity of the blood containing the blood slipping agent was measured using Rheometric Expansion System ARES (Rheometric Scientific, Inc). 2% by weight of Panaceto 810s was added to equine defibrinated blood, the mixture was lightly stirred to form a sample, the sample was loaded on a parallel plate of 50 mm in diameter, the gap was made 100 μm, and the viscosity was measured at 37 ± 0.5 ° C. . Because of the parallel plate, the sample was not subjected to a uniform shear rate, but the average shear rate displayed on the instrument was 10 s −1 .
 パナセート810sを2質量%含むウマ脱繊維血の粘度は、5.9mPa・sであり、一方、血液滑性付与剤を含まないウマ脱繊維血の粘度は、50.4mPa・sであった。従って、パナセート810sを2質量%含むウマ脱繊維血は、血液滑性付与剤を含まない場合と比較して、約90%粘度を下げることが分かる。 The viscosity of equine defibrinated blood containing 2% by mass of Panaceto 810s was 5.9 mPa · s, while the viscosity of equine defibrillated blood containing no blood slipping agent was 50.4 mPa · s. Accordingly, it can be seen that equine defibrinated blood containing 2% by mass of Panaceto 810s reduces the viscosity by about 90% as compared to the case without the blood slipping agent.
 血液は、血球等の成分を含み、チキソトロピーの性質を有することが知られているが、本開示の血液滑性付与剤は、低粘度域で、経血等の血液の粘度を下げる作用をも有すると考えられる。血液の粘度を下げることにより、吸収した経血を、トップシートから吸収体に速やかに移行しやすくなると考えられる。 Blood contains components such as blood cells and is known to have thixotropy properties, but the blood slipping agent of the present disclosure also has the effect of lowering the viscosity of blood such as menstrual blood in a low viscosity region. It is considered to have. By reducing the viscosity of blood, it is considered that absorbed menstrual blood is likely to be rapidly transferred from the top sheet to the absorber.
<試験例5>
[血液滑性付与剤を含む血液の顕微鏡写真]
 健常ボランティアの経血を、食品保護用ラップフィルム上に採取し、その一部に、10倍の質量のリン酸緩衝生理食塩水中に分散されたパナセート810sを、パナセート810sの濃度が1質量%となるように添加した。経血を、スライドグラスに適下し、カバーグラスをかけ、光学顕微鏡にて、赤血球の状態を観察した。血液滑性付与剤を含まない経血の顕微鏡写真を図7(a)に、そしてパナセート810sを含む経血の顕微鏡写真を図7(b)に示す。
<Test Example 5>
[Micrograph of blood containing blood slipping agent]
A healthy volunteer's menstrual blood is collected on a food protection wrap film, and a portion of it is Panaceto 810s dispersed in 10 times the mass of phosphate buffered saline, and the concentration of Panaceto 810s is 1% by mass. It added so that it might become. The menstrual blood was applied to a slide glass, covered with a cover glass, and the condition of red blood cells was observed with a light microscope. A photomicrograph of menstrual blood containing no blood slipping agent is shown in FIG. 7 (a), and a photomicrograph of menstrual blood containing PANACET 810s is shown in FIG. 7 (b).
 図7から、血液滑性付与剤を含まない経血では、赤血球が連銭等の集合塊を形成しているが、パナセート810sを含む経血では、赤血球が、それぞれ、安定に分散していることが分かる。従って、血液滑性付与剤は、血液の中で、赤血球を安定化させる働きをも有することが示唆される。 From FIG. 7, in the menstrual blood which does not contain the blood slipping agent, red blood cells form a lump such as ritsusen, but in menstrual blood containing PANACET 810s, the red blood cells are dispersed stably. I understand that. Therefore, it is suggested that the blood slipping agent also has the function of stabilizing red blood cells in blood.
<試験例6>
[血液滑性付与剤を含む血液の表面張力]
 血液滑性付与剤を含む血液の表面張力を、協和界面科学社製接触角計 Drop Master500を用い、ペンダントドロップ法にて測定した。表面張力は、ヒツジ脱繊維血に、所定の量の血液滑性付与剤を添加し、十分振とうした後に測定した。
 測定は、機器が自動で行うが、表面張力γは、以下の式により求められる(図8を参照)。
Test Example 6
[Surface tension of blood containing blood slipping agent]
The surface tension of blood containing a blood slipping agent was measured by a pendant drop method using a contact angle meter Drop Master 500 manufactured by Kyowa Interface Science. The surface tension was measured after adding a predetermined amount of a blood slipping agent to sheep defibrinated blood and shaking sufficiently.
The measurement is automatically performed by the device, but the surface tension γ is obtained by the following equation (see FIG. 8).
 γ=g×ρ×(de)2×1/H
 g:重力定数
 1/H:ds/deから求められる補正項
 ρ:密度
 de:最大直径
 ds:滴下端よりdeだけ上がった位置での径
γ = g × ρ × (de) 2 × 1 / H
g: Gravitational constant 1 / H: correction term obtained from ds / de ρ: density de: maximum diameter ds: diameter at a position de up from the dropping end
 密度ρは、JIS K 2249-1995の「密度試験方法及び密度・質量・容量換算表」の5.振動式密度試験方法に準拠し、下記表4に示される温度で測定した。
 測定には、京都電子工業株式会社のDA-505を用いた。
 結果を、下記表4に示す。
The density ρ is 5 of “density test method and density / mass / volume conversion table” of JIS K 2249-1995. It was measured at the temperature shown in Table 4 below according to the vibrational density test method.
For measurement, DA-505 of Kyoto Electronics Industries Ltd. was used.
The results are shown in Table 4 below.
Figure JPOXMLDOC01-appb-T000014
Figure JPOXMLDOC01-appb-T000014
 表4から、血液滑性付与剤は、血液の表面張力を下げる作用をも有することが分かる。
 血液の表面張力を下げることにより、吸収した血液をトップシートの繊維間に保持せず、速やかに吸収体に移行させることができると考えられる。
It can be seen from Table 4 that the blood slipping agent also has the effect of lowering the surface tension of blood.
By lowering the surface tension of the blood, it is considered that the absorbed blood can be rapidly transferred to the absorber without being held between the fibers of the top sheet.
 1  生理用ナプキン(吸収性物品)
 2  トップシート(液透過性層)
 3  バックシート(液不透過性層)
 4  吸収体
 20  排泄口当接領域
 51  切断開口部
 52  吸収体凹部
 522  吸収体凹部の底部
1 Sanitary napkin (absorbent article)
2 Top sheet (liquid permeable layer)
3 Back sheet (liquid impermeable layer)
4 Absorber 20 Discharge port contact area 51 Cutting opening 52 Absorber recess 522 Bottom of absorber recess

Claims (14)

  1.  肌当接面を有する液透過性のトップシートと、非肌当接面を有する液不透過性のバックシートと、前記トップシート及び前記バックシートの間に設けられた吸収体とを備えた吸収性物品であって、
     前記トップシートが、前記肌当接面のうち少なくとも排泄口当接領域に、前記トップシートを貫通する複数の切断開口部を有し、
     前記吸収体が、前記複数の切断開口部のそれぞれに通じる吸収体凹部を有し、
     前記切断開口部の形成の際に生じたトップシート断片が、前記吸収体凹部の底部を被覆している、前記吸収性物品。
    A liquid-permeable top sheet having a skin-contacting surface, a liquid-impermeable back sheet having a non-skin-contacting surface, and an absorbent comprising an absorber provided between the top sheet and the back sheet Sexual goods,
    The top sheet has a plurality of cutting openings penetrating the top sheet at least in the excretory opening contact region of the skin contact surface,
    The absorber has an absorber recess leading to each of the plurality of cutting openings;
    The absorbent article, wherein the top sheet fragment generated in forming the cutting opening covers the bottom of the absorber recess.
  2.  前記トップシートのうち、前記切断開口部の周囲部分が高密度化している、請求項1に記載の吸収性物品。 The absorbent article according to claim 1, wherein a peripheral portion of the cutting opening in the top sheet is densified.
  3.  前記トップシートが複数の層からなり、前記複数の層が前記切断開口部の周囲部分で相互に圧着されている、請求項1又は2に記載の吸収性物品。 The absorbent article according to claim 1 or 2, wherein the top sheet is composed of a plurality of layers, and the plurality of layers are crimped to each other at a peripheral portion of the cutting opening.
  4.  前記吸収体に含有される吸収性材料が、前記吸収体凹部の側部から露出している、請求項1~3のいずれか1項に記載の吸収性物品。 The absorbent article according to any one of claims 1 to 3, wherein the absorbent material contained in the absorber is exposed from the side of the absorber recess.
  5.  前記トップシート断片が、前記吸収体凹部の底部と圧着している、請求項1~4のいずれか1項に記載の吸収性物品。 The absorbent article according to any one of claims 1 to 4, wherein the top sheet fragment is crimped to the bottom of the absorber recess.
  6.  前記排泄口当接領域のうち少なくとも前記切断開口部の周囲部分に、40℃における動粘度が0.01~80mm2/s、抱水率が0.01~4.0質量%、重量平均分子量が1,000未満である血液滑性付与剤が塗工されている、請求項1~5のいずれか1項に記載の吸収性物品。 The kinematic viscosity at 40 ° C. is 0.01 to 80 mm 2 / s, the water retention rate is 0.01 to 4.0 mass%, and the weight average molecular weight at least in the periphery of the cutting opening in the discharge port contact area The absorbent article according to any one of claims 1 to 5, wherein a blood slipping agent having a value of less than 1,000 is applied.
  7.  前記血液滑性付与剤のIOBが、0.00~0.60のIOBである、請求項6に記載の吸収性物品。 The absorbent article according to claim 6, wherein the blood slipping agent IOB is an IOB of 0.00 to 0.60.
  8.  前記血液滑性付与剤が、次の(i)~(iii):
     (i)炭化水素、
     (ii) (ii-1)炭化水素部分と、(ii-2)前記炭化水素部分のC-C単結合間に挿入された、カルボニル基(-CO-)及びオキシ基(-O-)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、及び
     (iii) (iii-1)炭化水素部分と、(iii-2)前記炭化水素部分のC-C単結合間に挿入された、カルボニル基(-CO-)及びオキシ基(-O-)から成る群から選択される、一又は複数の、同一又は異なる基と、(iii-3)前記炭化水素部分の水素原子を置換する、カルボキシル基(-COOH)及びヒドロキシル基(-OH)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、
     並びにそれらの任意の組み合わせから成る群から選択され、
     ここで、(ii)又は(iii)の化合物において、オキシ基が2つ以上挿入されている場合には、各オキシ基は隣接していない、
     請求項6又は7に記載の吸収性物品。
    The blood slipping agent may be any of the following (i) to (iii):
    (I) Hydrocarbons,
    (Ii) from a carbonyl group (-CO-) and an oxy group (-O-) inserted between (ii-1) a hydrocarbon moiety and (ii-2) a C-C single bond of the hydrocarbon moiety A compound having one or more same or different groups selected from the group consisting of: (iii) (iii-1) a hydrocarbon moiety, and (iii-2) a C—C single bond of the hydrocarbon moiety And one or more, same or different group (s) selected from the group consisting of carbonyl group (—CO—) and oxy group (—O—) inserted between (iii-3) A compound having one or more and the same or different groups selected from the group consisting of a carboxyl group (—COOH) and a hydroxyl group (—OH) which substitutes a hydrogen atom,
    And selected from the group consisting of any combination thereof,
    Here, in the compound (ii) or (iii), when two or more oxy groups are inserted, each oxy group is not adjacent,
    The absorbent article according to claim 6 or 7.
  9.  前記血液滑性付与剤が、次の(i’)~(iii’):
     (i’)炭化水素、
     (ii’) (ii’-1)炭化水素部分と、(ii’-2)前記炭化水素部分のC-C単結合間に挿入された、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)、及びエーテル結合(-O-)から成る群から選択される、一又は複数の、同一又は異なる結合とを有する化合物、及び
     (iii’) (iii’-1)炭化水素部分と、(iii’-2)前記炭化水素部分のC-C単結合間に挿入された、カルボニル結合(-CO-)、エステル結合(-COO-)、カーボネート結合(-OCOO-)、及びエーテル結合(-O-)から成る群から選択される、一又は複数の、同一又は異なる結合と、(iii’-3)前記炭化水素部分の水素原子を置換する、カルボキシル基(-COOH)及びヒドロキシル基(-OH)から成る群から選択される、一又は複数の、同一又は異なる基とを有する化合物、
     並びにそれらの任意の組み合わせから成る群から選択され、
     ここで、(ii’)又は(iii’)の化合物において、2以上の同一又は異なる結合が挿入されている場合には、各結合は隣接していない、
     請求項6~8のいずれか1項に記載の吸収性物品。
    The blood slipping agent may be any of the following (i ') to (iii'):
    (I ') hydrocarbons,
    (Ii ') (ii'-1) a hydrocarbon moiety, and (ii'-2) a carbonyl bond (-CO-), an ester bond (-COO) inserted between a C-C single bond of the hydrocarbon moiety -), A compound having one or more same or different bonds selected from the group consisting of carbonate bond (-OCOO-) and ether bond (-O-), and (iii ') (iii'-) 1) A carbonyl bond (-CO-), an ester bond (-COO-), a carbonate bond (-OCOO) inserted between a hydrocarbon moiety and (iii'-2) a C-C single bond of the hydrocarbon moiety -), And one or more same or different bonds selected from the group consisting of an ether bond (-O-) and (iii'-3) a carboxyl group replacing the hydrogen atom of the hydrocarbon moiety (iii'-3) -COOH) and hydroxyl A compound having one or more, same or different groups, selected from the group consisting of sil groups (—OH),
    And selected from the group consisting of any combination thereof,
    Here, in the compound (ii ') or (iii'), when two or more identical or different bonds are inserted, each bond is not adjacent,
    The absorbent article according to any one of claims 6 to 8.
  10.  前記血液滑性付与剤が、次の(A)~(F):
     (A) (A1)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(A2)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する1個のカルボキシル基とを有する化合物とのエステル、
     (B) (B1)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する2~4個のヒドロキシル基とを有する化合物と、(B2)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエーテル、
     (C) (C1)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する、2~4個のカルボキシル基とを含むカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、(C2)鎖状炭化水素部分と、前記鎖状炭化水素部分の水素原子を置換する1個のヒドロキシル基とを有する化合物とのエステル、
     (D)鎖状炭化水素部分と、前記鎖状炭化水素部分のC-C単結合間に挿入された、エーテル結合(-O-)、カルボニル結合(-CO-)、エステル結合(-COO-)、及びカーボネート結合(-OCOO-)から成る群から選択されるいずれか1つの結合とを有する化合物、
     (E)ポリオキシC3~C6アルキレングリコール、又はそのアルキルエステル若しくはアルキルエーテル、及び
     (F)鎖状炭化水素、
     並びにそれらの任意の組み合わせから成る群から選択される、請求項6~9のいずれか1項に記載の吸収性物品。
    The blood slipping agent may be any of the following (A) to (F):
    (A) A compound having (A1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms of the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and the chain Ester with a compound having one carboxyl group replacing the hydrogen atom of the cyclic hydrocarbon moiety,
    (B) a compound having (B1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the chain Ether with a compound having one hydroxyl group replacing the hydrogen atom of the cyclic hydrocarbon moiety,
    (C) a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing a (C1) linear hydrocarbon moiety and 2 to 4 carboxyl groups replacing the hydrogen atom of the linear hydrocarbon moiety; C2) an ester of a compound having a chain hydrocarbon moiety and one hydroxyl group replacing a hydrogen atom of the chain hydrocarbon moiety,
    (D) an ether bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO-) inserted between a chain hydrocarbon moiety and a C-C single bond of the chain hydrocarbon moiety ), And a compound having any one bond selected from the group consisting of carbonate bonds (—OCOO—),
    (E) Polyoxy C 3 -C 6 alkylene glycol, or an alkyl ester or alkyl ether thereof, and (F) a chain hydrocarbon,
    The absorbent article according to any one of claims 6 to 9, selected from the group consisting of and any combination thereof.
  11.  前記血液滑性付与剤が、(a1)鎖状炭化水素テトラオールと少なくとも1の脂肪酸とのエステル、(a2)鎖状炭化水素トリオールと少なくとも1の脂肪酸とのエステル、(a3)鎖状炭化水素ジオールと少なくとも1の脂肪酸とのエステル、(b1)鎖状炭化水素テトラオールと少なくとも1の脂肪族1価アルコールとのエーテル、(b2)鎖状炭化水素トリオールと少なくとも1の脂肪族1価アルコールとのエーテル、(b3)鎖状炭化水素ジオールと少なくとも1の脂肪族1価アルコールとのエーテル、(c1)4個のカルボキシル基を有する鎖状炭化水素テトラカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、(c2)3個のカルボキシル基を有する鎖状炭化水素トリカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、(c3)2個のカルボキシル基を有する鎖状炭化水素ジカルボン酸、ヒドロキシ酸、アルコキシ酸又はオキソ酸と、少なくとも1の脂肪族1価アルコールとのエステル、(d1)脂肪族1価アルコールと脂肪族1価アルコールとのエーテル、(d2)ジアルキルケトン、(d3)脂肪酸と脂肪族1価アルコールとのエステル、(d4)ジアルキルカーボネート、(e1)ポリオキシC3~C6アルキレングリコール、(e2)ポリオキシC3~C6アルキレングリコールと少なくとも1の脂肪酸とのエステル、(e3)ポリオキシC3~C6アルキレングリコールと少なくとも1の脂肪族1価アルコールとのエーテル、及び(f1)鎖状アルカン、並びにそれらの任意の組み合わせから成る群から選択される、請求項6~10のいずれか1項に記載の吸収性物品。 The blood slipping agent is an ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid, an ester of (a 2 ) chain hydrocarbon triol and at least one fatty acid, (a 3 ) chain Of a cyclic hydrocarbon diol and at least one fatty acid, an ether of (b 1 ) a linear hydrocarbon tetraol and at least one aliphatic monohydric alcohol, (b 2 ) a linear hydrocarbon triol and at least one fatty Ether with a monohydric monohydric alcohol, ether of (b 3 ) chain hydrocarbon diol and at least one aliphatic monohydric alcohol, chain hydrocarbon tetracarboxylic acid having (c 1 ) 4 carboxyl groups, hydroxy acid, alkoxy acid or an oxo acid, at least one ester of an aliphatic monohydric alcohol, (c 2) a chain hydrocarbon bets with 3 carboxyl groups Carboxylic acid, hydroxy acid, alkoxy acid or an oxo acid, at least one ester of an aliphatic monohydric alcohol, (c 3) a chain hydrocarbon dicarboxylic acids having two carboxyl groups, hydroxy acid, alkoxy acid or an oxo An ester of an acid and at least one aliphatic monohydric alcohol, (d 1 ) an ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol, (d 2 ) a dialkyl ketone, (d 3 ) a fatty acid and an aliphatic 1 Esters with dihydric alcohols, (d 4 ) dialkyl carbonates, (e 1 ) polyoxy C 3 -C 6 alkylene glycols, (e 2 ) esters of polyoxy C 3 -C 6 alkylene glycols with at least one fatty acid, (e 3 ) Ethers of polyoxy C 3 -C 6 alkylene glycol and at least one aliphatic monohydric alcohol, and (f 1 The absorbent article according to any one of claims 6 to 10, selected from the group consisting of chain alkanes, and any combination thereof.
  12.  前記血液滑性付与剤が、1気圧及び40℃において、0.00~0.01Paの蒸気圧を有する、請求項6~11のいずれか1項に記載の吸収性物品。 The absorbent article according to any one of claims 6 to 11, wherein the blood slipping agent has a vapor pressure of 0.00 to 0.01 Pa at 1 atm and 40 属 C.
  13.  トップシート及び吸収体の積層体をエンボス加工して、前記トップシートを貫通して前記吸収体に至る凹部を形成する工程を含む、吸収性物品の製造方法であって、
     前記エンボス加工が、前記トップシートに切断開口部を形成する段階と、前記切断開口部の形成の際に生じたトップシート断片を前記凹部の底部に圧着させる段階とを含む、前記製造方法。
    A method of manufacturing an absorbent article, comprising the steps of embossing a laminate of a top sheet and an absorbent to form a recess penetrating the top sheet to the absorbent.
    The manufacturing method, wherein the embossing includes forming a cutting opening in the top sheet, and pressing a top sheet fragment generated in forming the cutting opening onto a bottom of the recess.
  14.  前記エンボス加工に、複数の突起が設けられた外周面を有する突起ロールと、平滑な外周面を有するプレーンロールが使用され、前記積層体が前記突起ロールと前記プレーンロールとの間を通過する際、前記突起の剪断力によって前記トップシートに前記切断開口部が形成されるとともに、前記突起の前記吸収体への圧入によって前記凹部の底部に前記トップシート断片が圧着される、請求項13に記載の吸収性物品の製造方法。 In the embossing process, a projecting roll having an outer circumferential surface provided with a plurality of projections and a plain roll having a smooth outer circumferential surface are used, and the laminate passes between the projecting roll and the plain roll. The shear force of the protrusion forms the cutting opening in the top sheet, and the top sheet fragment is crimped to the bottom of the recess by press-fitting the protrusion into the absorber. Method of producing an absorbent article.
PCT/JP2013/072905 2012-09-30 2013-08-27 Absorbent article WO2014050412A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012-218982 2012-09-30
JP2012218982A JP5885633B2 (en) 2012-09-30 2012-09-30 Absorbent articles

Publications (1)

Publication Number Publication Date
WO2014050412A1 true WO2014050412A1 (en) 2014-04-03

Family

ID=50387821

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/072905 WO2014050412A1 (en) 2012-09-30 2013-08-27 Absorbent article

Country Status (2)

Country Link
JP (1) JP5885633B2 (en)
WO (1) WO2014050412A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110035731A (en) * 2016-11-30 2019-07-19 尤妮佳股份有限公司 Absorbent commodity

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01158953A (en) * 1987-12-16 1989-06-22 Kao Corp Surface material of sanitary article
JPH03186260A (en) * 1989-12-15 1991-08-14 Daiwabou Kurieito Kk Absorptive article
JPH0464356A (en) * 1990-07-04 1992-02-28 Daiwabo Create Kk Composite sheet for surface material for absorbing product
JPH04114647A (en) * 1990-09-06 1992-04-15 Kao Corp Surface material for sanitary product
JPH07506746A (en) * 1992-05-21 1995-07-27 メールンリユーケ アーベー Materials suitable for use as top sheets of disposable absorbent articles and methods for producing the same
JPH0871105A (en) * 1994-09-01 1996-03-19 Uni Charm Corp Absorber of sanitary goods
JP2003204993A (en) * 2002-01-16 2003-07-22 Kao Corp Absorbent body and method for manufacturing it
JP2010063921A (en) * 1994-11-28 2010-03-25 Procter & Gamble Co Absorption article with lotioned topsheet

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01158953A (en) * 1987-12-16 1989-06-22 Kao Corp Surface material of sanitary article
JPH03186260A (en) * 1989-12-15 1991-08-14 Daiwabou Kurieito Kk Absorptive article
JPH0464356A (en) * 1990-07-04 1992-02-28 Daiwabo Create Kk Composite sheet for surface material for absorbing product
JPH04114647A (en) * 1990-09-06 1992-04-15 Kao Corp Surface material for sanitary product
JPH07506746A (en) * 1992-05-21 1995-07-27 メールンリユーケ アーベー Materials suitable for use as top sheets of disposable absorbent articles and methods for producing the same
JPH0871105A (en) * 1994-09-01 1996-03-19 Uni Charm Corp Absorber of sanitary goods
JP2010063921A (en) * 1994-11-28 2010-03-25 Procter & Gamble Co Absorption article with lotioned topsheet
JP2003204993A (en) * 2002-01-16 2003-07-22 Kao Corp Absorbent body and method for manufacturing it

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110035731A (en) * 2016-11-30 2019-07-19 尤妮佳股份有限公司 Absorbent commodity
CN110035731B (en) * 2016-11-30 2020-10-27 尤妮佳股份有限公司 Absorbent article

Also Published As

Publication number Publication date
JP5885633B2 (en) 2016-03-15
JP2014068956A (en) 2014-04-21

Similar Documents

Publication Publication Date Title
JP6062199B2 (en) Absorbent articles
JP5925015B2 (en) Absorbent articles
JP6021567B2 (en) Absorbent articles
WO2013150921A1 (en) Absorbent article
JP6112816B2 (en) Absorbent articles
JP6004878B2 (en) Absorbent articles
EP2901983B1 (en) Absorbent article
JP6021565B2 (en) Absorbent articles
WO2014196670A1 (en) Absorbent article
KR101953428B1 (en) Absorbent article
WO2014200121A1 (en) Absorbent article
KR101953427B1 (en) Method for producing absorbent article
JP6041473B2 (en) Absorbent articles
JP6073101B2 (en) Absorbent articles
WO2014050412A1 (en) Absorbent article
JP5939949B2 (en) Absorbent articles
JP6041472B2 (en) Absorbent article, top sheet of absorbent article, and method for producing the top sheet

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13842501

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13842501

Country of ref document: EP

Kind code of ref document: A1